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l)ON THE ORIGIN AND DEVELOPMENT OF THE MEDICAL NUTRITION INDUSTRY
Product development in the health and life sciences is shifting from the development of
target-specific pharmaceutical products to multi-target therapies, including medical nutri -
tion. Medical nutrition consists of nutritional compositions, prescribed by medical profes -
sio nals for the nutritional support in the dietary management of diseases. The European
medical nutrition industry is rapidly maturing, driven by new knowledge on medical
nutrition effectiveness and increasing public awareness on its importance. Nevertheless,
there are still numerous unmet medical needs that can only be addressed through
innovation by the medical nutrition industry.
This dissertation describes the innovation dynamics within the European medical nutri -
tion industry, through exploring the origin and development of this industry and all
stakeholders involved. The research is multidisciplinary, encompassing scientific, industrial,
technological, economic and regulatory disciplines. Although the relatively new and
emerg ing medical nutrition industry offers innovation potential, the results show that a
lack of medical nutrition innovation may result in a gloomy future for the medical nutri -
tion industry. 
The dynamics of the medical nutrition innovation system induces the realization that
social well-being and economic growth is not only dependent on the innovation activity of
both the food and pharma industries but requires input from key opinion leaders in
academia; patients; regulatory and funding bodies.
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1 .1  SCOPE -  THE FOOD-PHARMA INTERFACE 
As the boundaries between many once-distinct industries are blurring and 
consequently combine, this process gives rise to new industries. This also holds true 
for the health and life science sector (4-6). In the past few years the gap between 
pharma and nutrition science is closing. One reason is the increasing scientific 
evidence regarding the potential of nutrition and the role in the prevention or 
treatment of diseases and/or risk factors for disease (7).  
 
As a result of the re-discovered medical application of nutrition, the traditional 
boundaries between the pharmaceutical and food industries are fading. It is at this 
interface where the ideal set of conditions/environment is provided for the 
development of a new industry segment: pharmanutrition. 
 
Convergence is taking place where (large) pharmaceutical, biotechnology and food 
companies are merging or forming strategic alliances to maintain long-term 
profitability (5, 6, 8). Consequently, the number of companies with multidisciplinary 
activities eligible to fall under the pharmanutrition industry has increased. Especially 
in an era where the pharmaceutical industry is facing both fewer product approvals in 
combination with block-buster patent expirations, such convergence trends offer 
profitable opportunities (8, 9). Food industry research programs slowly start 
resembling approaches used in the pharmaceutical world, while pharmaceutical 
companies realize the potential of nutrition slowing down disease progression or 
improving therapeutic outcome (7). 
 
The resulting new industries present companies with both threats and opportunities. 
On the one end, industry convergence increases the risks for developing new 
knowledge and technologies. Inventors leave the comfort zone of their mono-
disciplinary area of expertise to venture into unknown discipline-crossing activities. 
On the other hand, the early stages of industry convergence offer significant 
opportunities. One of them encompassing the first-mover advantage, and potentially 
setting the knowledge and technological industry standard in doing so (9). 
 
Compared to the food industry, the pharmaceutical industry is relatively young. Ever 
since the pharmaceutical industry has developed into a cluster of industries 
concentrating on developing commercial applications for global health care markets 
(10). 
 
Existing pharmaceutical and food companies realize that pharmanutrition is an area 
filled with opportunities for enhancing discovery, technological and development 
competencies. (8,11). Already during the past few decades, various boundary-
spanning innovative pharmanutritional products have been granted market approval. 
These, so-called, pharmanutrition products claim to provide a form of specific health 
benefits beyond basic nutrition. Examples of pharmanutrition products resulting from 
the convergence between the food- and pharmaceutical- industries are functional 
foods and medical nutrition (Figure 1.).  
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F igure  1 .  I ndus t r i es  s i t ua ted  i n  t he  hea l t h  and  l i f e  sc i ence  sec to r   
 
 
 
 
Nevertheless, both pharmaceutical and food companies also recognize the 
disadvantages in funding inventions that lead to the commercialization of boundary-
spanning products. Especially during the early stages of industry convergence, such 
products are perceived by the regulatory authorities and legal practices as entities 
with ambiguous identities. Consequently, the boundary-spanning product is generally 
misunderstood by the majority of risk-averse consumers and experienced as 
illegitimate. Additionally, the greatest distinction between food products and 
medicines is of great significance for legal practice, since medicines are more strictly 
regulated than foods (12). Therefore, carefully categorizing industries and identifying 
industry boundaries may lead to better consumer perception and higher market 
acceptance. 
 
Disadvantages of boundary spanning products are that having an unclear and 
ambiguous identity decreases the chances of receiving attention as well as not being 
perceived as legitimate and trustworthy (11).  
 
This introduction starts off by exploring the definitions and characteristics of the 
pharmanutrition industry in the European health and life science sector. At present, 
nonstandardized terminology describing pharmanutritional products is often 
perceived as confusing (7). The focus will be on defining the industry boundaries and 
illustrating industry convergence. By taking conventional foods at one end of the 
spectrum, and pharmaceutical products at the other, the pharmanutrition industry can 
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be split further into two categories falling within this spectrum: functional foods and 
medical nutrition. 
 
In order to understand the blurring of lines between the conventional foods; 
functional foods; medical nutrition; and pharmaceuticals industries, it is useful to 
review each industry.  
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1.1.1  Convent iona l  foods 
The conventional foods industry (Table 1.) encompasses a broad range of nutritional 
products for consumption, ranging from natural sources to genetically, biologically 
and/or chemically modified food substances. It is considered to be at the opposite 
end of the industry spectrum, unrelated to the pharmaceutical industry.  This product 
category is defined according to EU legislation as “any substance or product, 
whether processed, partially processed or unprocessed, intended to be, or 
reasonably expected to be ingested by humans. Foods include drinks, chewing gum 
and any substance, including water, intentionally incorporated into the food during 
its manufacture, preparation or treatment.” Food is consumed to provide nutritional 
support for the body. It is usually of plant or animal origin and contains essential 
nutrients, such as carbohydrates, fats proteins, vitamins or minerals (13). Foods do 
not include: live animals unless they are prepared for marketing for human 
consumption, plants prior to harvesting, medicinal products, tobacco and tobacco 
products, narcotic or psychotropic substances, and residues and contaminants. Both 
international trade and technological developments have contributed to a significant 
increase in the available foods and other edible ingredients. 
 
With the increasing pace of developments in the food industry, EU regulatory bodies 
realized the need for a formalized safety assessment of new foods In the EU (14), the 
general policy on food safety has been laid down in the EU White Paper on Food 
Safety (15). This document outlines a comprehensive range of actions required to 
complement and modernize existing European food legislation, which in turn led to 
the introduction of the General Food Law (Regulation (EC) 178/2001). This 
regulation formed the basis for the establishment of the independent European Food 
Safety Authority (EFSA) in 2002. In summary, these regulations are necessary to 
ensure EU unified food safety standards. 
 
Conventional foods are inherently linked to an individual’s health. As a result, 
conscious consumers seek out the health properties of natural food substances.   
1.1.2  Funct iona l  foods 
The term ‘‘functional food’’ was first introduced in Japan in the 1980’s as FOSHU 
(Food for Specified Health Uses) and has since developed into a successful and 
lucrative industry (16, 17). The Japanese interest in functional foods spread towards 
the Western world in the early 1990s. As a result, the Western functional food 
industry has evolved at the intersection of the pharmaceutical and food industries (9, 
17). This product category consists of food products with added health benefits when 
compared to the regular nutritional value of the traditional food product(18). To date, 
most countries do not have a formal and legislative definition of the term functional 
food. Even for experts, delineating the boundaries between food and functional foods 
is challenging (17). According to the EU-project Functional Food Science in Europe 
(FUFOSE), functional foods are defined as: ‘‘A food can be regarded as functional if 
it is satisfactorily demonstrated to affect beneficially one or more target functions in 
the body, beyond adequate nutritional effects...” (19). The functional food industry is 
seen to have evolved from the convergence of the food industry and health and life 
science sector. Comparable to the pharmaceutical industry, which is based on 
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traditional healing experiences such as willow bark (aspirin), functional foods are 
based on traditional nutrition folklore such as fatty fish, at present often 
supplemented as a refined omega fatty acid.  
 
As awareness and trust concerning food related health benefits is growing among the 
general public, consumer demands are changing. They collectively seek foods with 
added health benefits, which include functional foods. Most early developments of 
functional foods were food products enriched with vitamins and/or minerals. Soon, 
foods fortified with various essential micronutrients - such as phytosterol and soluble 
fiber - became more popular (20, 21).  
 
Through functional foods, consumers aim to prevent diseases and improve their 
physical and mental well-being (22). The majority of functional food products are 
aimed at; optimizing health by increasing energy-levels, by boosting the immune 
system or through the prevention of chronic illnesses (including cancer, 
cardiovascular disease, Alzheimer’s disease and osteoporosis) (18). Especially in the 
Western World, any innovation targeting those disease areas are considered valuable. 
combination of the following reasons; healthcare costs are increasing; people 
demand an improved quality of life; and there is a steady increase in life expectancy. 
Combined with the general saying that “an ounce prevention is worth a pound of 
cure”, consumers are more actively pursuing healthy lifestyle and dietary choices.   
 
Consumer perception of functional foods is strengthened by means of nutrition 
and/or health claims. A claim is defined by the Codex Alimentarius, as “any 
representation which states, suggests or implies that a food has particular 
characteristics relating to its origin, nutritional properties, nature, production, 
processing, composition or any other quality” (23). To ensure that claims on foods 
and food constituents are scientifically justified, the European Union published 
Regulation No 1924/2006 on nutrition and health claims made on foods (24). This 
regulation distinguishes two categories of claims on foods: health claims and 
nutritional claims. Nevertheless, functional foods are not regulated in the same way 
as pharma (EMA or FDA). According to functional food legislation, health claims 
state, suggest or imply, a relationship between food and health. Such claims include 
reduction of risk of disease claims, function claims, or claims referring to the growth 
and development of a child. 
 
Nutrition claims state, suggest or imply that a food has particular beneficial 
nutritional properties due to the energy it provides or the nutrients it contains. 
Examples hereof are content claims or comparative claims, e.g. ‘‘this product 
contains calcium” or ‘‘this product is low in sugar”. Explicit conditions are provided 
in EU legislation for claims such as ‘‘source of”, ‘‘rich in”, ‘‘reduced”, ‘‘fat-free” 
(23). The European Food Safety Authority (EFSA) carries out the scientific 
assessments of these claims in Europe. The final approval is provided by the 
European Commission and member states but is strongly based on the scientific 
opinions of EFSA as to whether the claim is sufficiently substantiated (25, 26). 
 
Since many applicants have encountered difficulties in submitting EFSA acceptable 
scientific evidence to be granted a health claim, they published in July 2007 its 
“scientific and technical guidance for the preparation and presentation of the 
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application for authorization of a health claim”. This publication is pursuant to 
Article 14 of Regulation 1924/2006 in order to assist the applicant with submitting 
health and nutritional claims. As may be expected, the reactions from various 
stakeholders regarding this EFSA document differ considerably (27). Some 
stakeholders have brought up the issue that the current EFSA approach may hamper 
innovation. Others state that in the long term, Regulation 1924/2006 will improve the 
reliability and credibility of health claims on foods. According to yet other experts, 
this regulation will not empty the functional food shelves but solely change the look 
of those shelves.  
1.1.3  Medica l  nut r i t ion 
Medical nutrition is perhaps the most confusing category, subject to different 
interpretations between, as well as within, geographical regions. Terms include; 
medical nutrition, clinical nutrition, medical foods, enteral nutrition, foods for special 
medical purposes, and dietary supplements (7, 12, 28, 29). 
 
In Europe, medical nutrition is not regulated by the EMA (European Medicines 
Agency) but is governed by the Foods for Special Medical Purposes (FSMP) 
Directive. The design and production of medical nutrition is predominantly based on 
scientific knowledge. In this Directive, medical nutrition is defined as: “foods that 
meet the particular nutritional requirements of persons affected by or who are 
malnourished because of a specific disease, disorder or medical condition” (30). 
This category includes oral nutritional supplements as well as tube feeding, of which 
the latter is administered via nasogastric, nasoenteric or percutaneous tubes. There 
are three categories in medical nutrition: nutritionally complete foods that can serve 
as the sole source of nutrition for a patient; nutritionally complete foods with an 
adapted nutrient formulation which can also serve as the sole source of nutrition for a 
patient; nutritionally incomplete foods which are not suitable as the sole source of a 
patient’s nourishment (30).  
 
As a result of the patient specific needs, medical nutrition is often personalized in 
order to optimize the health-benefit effect. The European Union provided 
manufacturers with basic rules concerning the vitamin and mineral substances that 
are needed for covering particular requirements of intended users (30). The 
legislation of medical nutrition is harmonized on EU level, but in case of the 
Directives it is implemented in the individual Member States.  
 
Medical nutrition spans both conventional food and pharmaceutical categories. 
Nevertheless, medical nutritional products are intended for patients suffering from a 
disease and are predominantly prescribed by a medical professional. Therefore, 
medical nutrition products are perceived to be more related to the latter category. As 
a consequence of this industry convergence, it is confusing for the regulatory 
authorities, medical nutrition companies and market, how to validate the safety, 
efficacy and quality of a medical nutritional product for example. In the 
pharmaceutical industry, clinical trials are an essential aspect in new product 
development. For the medical nutrition industry in Europe, clinical trials are 
optional. Companies may choose to carry out clinical trials to obtain sufficient 
evidence on the efficacy of a product to be able to substantiate a product claim. 
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These product claims are often important in the process of applying for 
reimbursement. The requirements for reimbursement are dependent on the health 
care system of the particular country and the reimbursement decision rests with the 
respective countries’ advisory committees (31, 32). 
 
Already in the last few decades, pharma-like clinical evidence concerning the 
effectiveness of medical nutrition has significantly enhanced its credibility (33). 
Medical nutrition is becoming a well-accepted form of nutritional support for 
patients suffering from disease-related malnutrition. Disease-related malnutrition is a 
highly underestimated condition, prevalent  throughout hospitals, community health 
care centres (outpatients, care homes, general practice) and other community settings 
(34). Malnutrition is defined as “a state of nutrition in which a deficiency, excess (or 
imbalance) of energy, protein and other essential nutrients causes measurable 
adverse effects on tissue/body form (body shape, size and composition) and function, 
and clinical outcome” (35). There are many causal factors leading to disease-related 
malnutrition, yet in general; it is the underlying medical condition that affects the 
intake of essential micronutrients.  
1.1.4  Pharmaceut ica ls  
The pharmaceutical industry represents the other end of the health & life science 
sector spectrum, and in turn is highly unrelated to the conventional foods industry. 
During the 1980s, the pharmaceutical industry experienced an exponential growth-
spurt, leading to the highest product turn-over and market approvals of new chemical 
entities (NCEs) known to history. Nevertheless, this growth has significantly slowed 
down at the start of the millennium, due to a number of reasons including, but not 
limited to; rising development costs; enhanced best-standard of care, blockbusters 
patent expiry and intensified global competition (36, 37). Pharmaceutical new 
chemical entities are defined by the EU legislation as: “any substance or 
combination of substances presented for treating or preventing disease in human 
beings. Any substance or combination of substances which may be administered to 
human beings with a view to making a medical diagnosis or to restoring, correcting 
or modifying physiological functions in human beings is likewise considered as a 
pharmaceutical product” (38) 
 
Pharmaceutical new chemical entities are considered prescription medicines, used for 
therapeutic treatment or prophylaxis of a chronic or acute disease. They can only be 
obtained at a pharmacy with a prescription from a physician. The drug development 
value chain is considered as one of the most (inter-) nationally regulated processes, 
whereby the NCE has to demonstrate specific safety, efficacy, quality and ethical 
standards throughout the discovery, pre-clinical, clinical and market phases. As a 
result, the average clinical development phase of the value chain takes over 12 years, 
and requires an investment close to €0.6 Billion (39). Since 1995, the European 
medicines Agency (EMA) is responsible for the scientific evaluation and monitoring 
of the safety and efficacy of pharmaceutical products in Europe.  
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1 .2  OBJECTIVES AND OUTLINE 
The European medical nutrition industry is relatively new within the historical scope 
of the health and life sciences and represents one of the fastest growing segments 
within this sector. This industry finds itself on the interface between the food and 
pharmaceutical industry with its own Foods for Special Medical Purposes (FSMPs) 
regulations. Medical nutrition products are prescribed food compositions that consist 
of targeted nutritional compositions for intervention in disease progression and 
symptom alleviation. The European medical nutrition industry is dominated by 5 
companies: Abbott Nutrition, B Braun, Danone (Nutricia), Fresenius Kabi and 
Nestle. This industry is perceived as an industry in an early development stage 
offering ample innovation opportunities. Its growth is most likely attributable to an 
increase in scientific advances and societal awareness on the functional health 
benefits of nutrition.  
 
Medical nutrition affects multiple societal levels, making innovations within this 
field particularly valuable (Figure 2). The primary goal of medical nutrition is to 
fulfill the unmet patient needs of malnourished patients, representing the onion core. 
The second inner layer is represented by the health care professionals who prescribe 
medical nutrition products to their patients to provide nutritional support. At the 
industry level, successful medical nutrition innovation is considered the primary 
driver for economic development. The outer onion layer represents the policy level, 
medical nutrition products can enhance public health; thereby significantly reducing 
healthcare related costs. Therefore, by staying innovative, medical nutrition 
companies will be able to maintain their competitive niche and continue to 
accommodate the unmet medical needs of malnourished patients.  
 
In this dissertation we tackle research topics addressing all societal levels, thereby 
stimulating the adoption of a holistic approach in developing medical nutrition 
products. This in turns may contribute to an innovation boost for the benefit of public 
health, academia and industry. Figure 2. depicts the outline of this dissertation 
according to the different societal levels. 
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F igure  2 .  Ou t l i ne  o f  d i sse r t a t i on  acco rd ing  t o  d i f f e ren t  soc ie ta l  l eve l s   
 

 
 
 
 
Medical nutrition innovation takes place within a so-called technological innovation 
system, which is a concept developed to explain the nature and rate of technological 
change. It can be defined as a set of actors and rules that influence the speed and 
direction of technological change in a specific technological area (40) Since we are 
dealing with a relatively new industry, academic insights into medical nutrition 
innovation are lacking. Motivated by the multi-leveled societal importance of 
medical nutrition, this PhD dissertation aims to advance the understanding of the 
innovation dynamics of the European medical nutrition industry. It starts off by (1) 
delineating the boundaries of medical nutrition; (2) followed by an analysis of the 
medical nutrition innovation system and (3) concluding by proposing possible 
medical nutrition industry future scenarios.  
 
(1) Delineating the boundaries of medical nutrition (Chapters 1, 2 & 3) 
 The concept of medical nutrition lacks universal coherence and therefore Chapter 1 
sets out to put clarity and continuity to the use of terms and definitions concerning 
the medical nutrition product category. Chapter 2 describes the emergence and 
boundaries of the medical nutrition industry as a result of food-pharma convergence 
focusing on knowledge diffusion and consolidation. Through patent analysis we 
visualized and measured which distinct industry domains have converged to result in 
the medical nutrition industry as it is today. 




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(2) The medical nutrition innovation system (Chapters 2, 3, 4, 5 & 6 & 7) 
Chapters 3, 4, 5 and 6 focus on analyzing the technological medical nutrition 
innovation system. The purpose of analyzing a sectoral innovation system is to study 
and evaluate the development of a particular technological field in terms of the 
structures and processes that support or hamper it.  
 
Innovation is a necessity for survival in dynamic and complex industries such as the 
medical nutrition industry. Nevertheless, innovation is a difficult undertaking and 
companies must first overcome numerous barriers inhibiting innovation. Chapter 3 
sets out to qualitatively and quantitatively explore the barriers inhibiting medical 
nutrition innovation. Studying these barriers provides insight into the dynamics of 
innovation, which simultaneously is a first step in the process of overcoming them. 
Subsequently, Chapter 4 analyzes medical nutrition market development and the 
innovation activities of the five players of the European medical nutrition industry by 
means of patent data analysis.  
 
Since innovation does not only rely on the development of ideas but also on the 
ability to protect these ideas, Chapters 4 & 5 evaluate intellectual property protection 
strategies within the medical nutrition industry. Chapter 5 concludes with an 
intellectual property decision framework supporting both medical nutrition 
companies and academic research and development departments in their intellectual 
property strategy decision processes. Ultimately, Chapter 6 evaluates the current 
involvement of key opinion leaders in the medical nutrition innovation process and 
provides a prioritization overview of unmet patient needs and innovation 
opportunities in the medical nutrition market.  

(3) Medical nutrition industry future scenarios (Chapters 8 & 9) 
Based on the results from the previous chapters, Chapter 8 consists of a medical 
nutrition industry development forecast analysis proposing four different possible 
future scenarios for the development of the medical nutrition industry. Chapter 9 
concludes this dissertation by summarizing the key findings and implications of this 
research, and provides directions for future research. 
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1.3  GLOSSARY OF TERMS 
Clinical trial / research Any investigation in human subjects intended to discover or verify the clinical safety and efficacy of a health 
product and its effect on humans. 
Incremental innovation  Incremental inventions consist of minor improvements or 
adjustments to existing inventions or technologies. 
Industry convergence The blurring of boundaries between distinct industries. 
Innovation  The process of turning opportunity into new ideas and of 
putting these into widely used practice. 
Inorganic growth  A growth in the operations of a business that arises from 
mergers or acquisitions, rather than an increase in the 
companies own business activity. 
 
Intellectual property Intellectual Property (IP) refers to the protection of creations of the mind, which have both a moral and a 
commercial value. IP law typically grants the author of an 
intellectual creation exclusive rights for exploiting and 
benefiting from their creation. Internationally recognized 
IP rights for protecting inventions include: trade secrets, 
copyrights, brands/trademarks, and patents. 
 
Malnutrition A state of nutrition in which a deficiency, excess (or imbalance) of energy, protein and other essential 
nutrients causes measurable adverse effects on 
tissue/body form (body shape, size and composition) and 
function, and clinical outcome. 
Medical nutrition Due to journal requirements, throughout this dissertation different terms for medical nutrition are used: 
 
Chapters Term Nutrition type 
1, 2.2, 3, 4, 
5, 7, 8 
Medical 
nutrition 
Oral nutrition & Tube 
feeding 
2.1 Medical nutrition 
Oral nutrition, Tube 
feeding & Intravenous 
nutrition 
6 Enteral nutrition 
Oral nutrition & Tube 
feeding 
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Medical nutrition is defined as a specially formulated 
nutritional composition for the dietary management of 
patients with diseases, disorders or medical conditions 
that cause distinct nutritional requirements. It may consist 
of partial or exclusive feeding by means of oral intake, 
tube feeding and/or parenteral administration under 
healthcare professional supervision. 
Organic growth Organic growth represents the true growth from the core 
of the company. 
Patent  A patent gives the inventor the right to exclude others 
from producing, using, selling, offering to sell, or 
importing the invention without permission and has a 
statutory duration of 20 years. 
Radical innovation Exhibits key characteristics that are inherently different 
from existing innovations or technologies and is 
considered to form a crucial basis from which subsequent 
incremental developments may evolve. 
Technology S-curve Describes successful industry development as an S-curve 
proceeding from the emerging, to the growth, to the 
saturation phase. 
  


 
  
 15 
CHAPTER 2  
A CRITICAL LOOK AT MEDICAL NUTRITION 
TERMINOLOGY AND DEFINITIONS: A 
LITERATURE REVIEW 
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
ABSTRACT  
 
A plethora of terms and definitions for medical nutrition has resulted in an ambiguity 
in the way “medical nutrition” is termed and defined across various societal levels. 
The terms medical nutrition, clinical nutrition, enteral nutrition, parenteral 
nutrition, oral nutritional supplements, medical foods, foods for special medical 
purposes, nutritional support, nutritional intervention and nutritional therapy are 
used interchangeably. To date consistent terminology/nomenclature and definitions 
have not emerged from the US and European medical nutrition community. The 
current absence of clear medical nutrition product category boundaries makes it 
necessary to introduce medical nutrition terminology conformance in order to reduce 
widespread confusion at policy; industry; healthcare; and patient level. In order to 
end discussion, this literature review attempts to put quantitative and qualitative 
clarity and continuity to the use of these terms and definitions by: (1) addressing the 
terminology used;  (2) discussing the distinguishing features of medical nutrition in 
various definitions and (3) proposing a single medical nutrition term and a clear 
pragmatic operational definition. A scientific literature-based comparison was 
conducted resulting in the selection of 22 publications, describing 8 different terms 
with 19 definitions.  
 
Based on the terminology found in literature, the following medical nutrition 
terminology is proposed: medical nutrition comprises both parenteral (intravenous) 
as well as enteral nutrition (tube feeding and oral nutrition), which may be given via 
the oral route or via a tube into the gastrointestinal tract. The features found to be 
most important in describing medical nutrition are: route of administration; disease; 
supervision; composition and support/management. These features have been 
integrated into one operational clinical definition and resulted in the following 
definition: MEDICAL NUTRITION: specially formulated nutritional composition 
for the dietary management of patients with diseases, disorders or medical conditions 
that cause distinct nutritional requirements. It may consist of partial or exclusive 
feeding by means of oral intake, tube feeding and/or parenteral administration under 
healthcare professional supervision.  
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2 .1  INTRODUCTION 
Nutrition is moving towards more health-oriented innovation thereby creating a 
“food-pharma” interface of products with an emphasis on the interaction between 
pharmacology and nutrition science (Figure 1) (7, 12). Drawing boundaries between 
the different food-pharma markets is challenging for those not actively involved in 
the nutrition market since there are few legislative term definitions for nutrition. 
During the last decade, the functional food (FF) industry is considered as an 
interesting area of research and innovation within the food industry (41). Adjacent to 
the functional foods industry, another food-pharma industry has emerged at this 
interface: the medical nutrition (MN) industry (42). The MN industry has been 
characterized as a growth industry with ample innovation opportunities. 
Nevertheless, newly emerging industries are often fragile and are prone to collapsing, 
possibly leading to the metaphorical innovation cliff (3, 43). Two key factors that 
may contribute to this phenomenon include a lack of regulatory transparency and 
reduced innovation adoption. These two factors are undeniably interlinked; clear 
regulatory frameworks often create pressure that motivates innovation and progress 
which in turn may enhance profits and competitiveness (44, 45). The emergence of 
new food-pharma industries such as the MN industry and the resulting absence of 
clear product category boundaries make it necessary to introduce MN terminology 
conformance in order to reduce widespread confusion. 
 
F igure  1 .  Food -Pha rma  I n te r f ace  –  F rom regu la r  f ood  t o  
pha rmaceu t i ca l s .  Adap ted  f r om (12)   
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Although previous research has shown that the MN industry originates from food-
pharma industry convergence, consensual product category boundaries have not been 
clearly delineated (46, 47). At the regulatory and clinical level, a plethora of MN 
terms are applied and used interchangeably. So far there is no unitary accepted 
terminology and definition for MN. Although this lack of conformance in defining 
MN has been recognized, there has been no embracement of a unitary accepted 
terminology and definition. A number of (inter)national authorities, academic bodies 
and the industry have proposed standardized terminology and definitions for aspects 
of medical nutrition. For example, in 2006, the European Society for Clinical 
Nutrition and Metabolism (ESPEN) attempted to implement a European terminology 
for this food type: “enteral nutrition: all forms of nutritional support that imply the 
use of ‘‘dietary foods for special medical purposes’’ as defined in the European 
legal regulation of the commission directive 1999/21/EC of 25 March 1999,1 
independent of the route of application. It includes oral nutritional supplements (oral 
nutrition) as well as tube feeding via nasogastric, nasoenteral or percutaneous 
tubes” (48). Nevertheless, this description of enteral nutrition only comprises a share 
of all types of medical nutrition products.  
 
Carefully categorizing MN product category boundaries can lead to an increase in 
healthcare professional awareness; resulting in higher patient acceptance and more 
targeted value-adding/safety-driven research and product development (3, 49-53). 
Currently, at the healthcare professional level, awareness concerning malnutrition 
and nutritional support is considered low (54). This directly influences patient 
awareness since patients are informed about nutritional support possibilities by their 
healthcare professional. Furthermore, reducing the uncertainty on product 
classification may also aid start-up enterprises at the front-end of the innovation 
process by enabling them to clearly define product innovation opportunities. At the 
public policy level, since MN is considered of high societal value, defining industry 
boundaries may have an indirect public health benefit thereby reducing healthcare 
costs (55). Agreement on terminology and definition for MN can therefore contribute 
to transparency at various societal levels (Figure 2). Such transparency can 
contribute to adopting a holistic approach in developing MN products. Creating 
holistic joined-up approaches across healthcare settings and communities may in turn 
stimulate innovation and prevent a possible MN innovation cliff (3, 54, 56). 
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F igure  2 .  D i f f e ren t  soc ie ta l  l eve l s  a f f ec ted  by  t r anspa ren t  MN 
te rm ino logy  and  de f i n i t i on   
 
 

 
 
 
The objective of this review in order to reduce terminology and definition confusion 
and to end discussion is therefore to: (1) address the terminology used;  (2) discuss 
the distinguishing features of MN in various definitions and (3) conclude with a 
proposition of consensual MN terminology and a pragmatic operational definition. A 
scientific literature-based comparison is presented, followed by a stepwise discussion 
on terminology and definitions.  
Overv iew 
Search terms 
Fifteen ESPEN faculty members whom are considered MN key opinion leaders 
(KOLs) (practicing MD; dieticians; nurses; researchers; professors; and consultants) 
were asked to list all terms used to describe MN so as to create an overview of search 
terms applied in the literature search. The following 11 terms were stated: medical 
nutrition (MN); clinical nutrition (CN); enteral nutrition (EN); parenteral nutrition 
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(PN); medical foods (MF); foods for special medical purposes (FSMP); oral 
nutritional supplements (ONS); tube feeding (TF); nutritional support ; nutritional 
intervention and nutritional therapy. 
Li tera ture search 
The literature search was conducted using a combination of Metapress, Pubmed, 
Google Scholar and Sciencedirect public search engines, applying relevant search 
terms on the theme, including the terms MN, CN, EN, PN, MF, FSMP, ONS, TF, 
nutritional support, nutritional intervention and nutritional therapy. The search was 
restricted to publications in English. We primarily focused on MN oriented scientific 
journals such as Clinical Nutrition; The American Journal of Clinical Nutrition; 
Nutrition in Clinical Practice; Journal of Parenteral and Enteral Nutrition; Journal 
of Human Nutrition and Dietetics; Journal of American Dietetic Association and 
Nutrition. Furthermore, the online publications of US and European regulations were 
used as sources. 
 
After reviewing 113 scientific publications from 1999 to 2013, 22 publications were 
selected on the basis of their representation of a definition of MN, describing 8 
different terms with 19 definitions (Table 1.). Surprisingly, the terms clinical 
nutrition, nutritional intervention and nutritional therapy are not defined as such in 
regulatory or scientific publications. All other terms as mentioned by the KOLs were 
found in literature. In addition, the definitions predominately originate from 
scientific papers published by either governmental bodies and/or nutrition oriented 
societies.  
 
The different MN terms are first discussed in a stepwise manner, followed by an 
analysis of the different MN definitions on the basis of distinguishing MN features. 
The definitions were analysed on the basis of the occurrence of six features: route of 
administration; disease; malnutrition; supervision; composition; support / 
management (Table 2.), and discussed below. 
 
Tab le  2 .  Fea tu res  de f i n i ng  MN men t i on ed  i n  l i t e ra tu re  (de f i n i t i on  
numbers  r e fe r  t o  t ab le  1 .   
 
Feature Definition Nr. 
Nutrition type All 
Disease 1,2,3,5,6,10,11 
Malnutrition 1 
Supervision 5,10,14 
Composition 3,12,13, 17 
Support / management 1,4,5,7, 8, 10,11, 18 
Region All 
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Termino logy 
Although the terms clinical nutrition, nutritional intervention and nutritional therapy 
are often used in the medical field, these terms are not defined in scientific literature. 
These terms may refer to the use of nutrition in clinical settings and not as a product 
category on its own. These terms may also include dietary changes for patients in 
clinical settings in contrast to MN, which is defined here as specially formulated 
nutritional compositions. This is confirmed by the definition of the European 
Journal of Clinical Nutrition: “…. an international journal providing essential 
scientific information on nutritional and metabolic care and the relationship between 
nutrition and disease both in the setting of basic science and clinical practice.”. 
Therefore, these terms are not discussed in this review. Furthermore, the term 
nutritional support was defined in the ESPEN guidelines on enteral nutrition. 
According to these guidelines, nutritional support encompasses oral nutrition 
products, tube feeding (TF) and food fortification. Since nutritional support is 
regarded as a generic way of applying MN to manage nutritional risk, it is further left 
out of scope in this review.  
 
Further complicating the terminology is that enteral nutrition (EN) is applied both to 
describe solely TF as well as both oral nutrition and TF (48). Since enteros means 
intestine, and both TF and oral nutrition utilise the gastro-intestinal tract, we propose 
that the term enteral nutrition encompasses both TF as well as oral nutrition. Also 
commonly perceived as MN but regulated within the pharmaceutical scope, lies the 
concept of intravenous nutrition, or parenteral nutrition (PN). Since the purpose of 
PN is to meet the patients’ special nutritional needs, similar to the other types of MN, 
PN is included in this MN terminology and definition review 
 
Geographic  reg ion –  Europe and US 
Both the United States (US) and European (EU) governments have mandated, 
through their regulatory bodies, that legislation be established to ensure the safety 
and truthful labelling of nutritional products (57). However, the regulatory 
approaches and terminology differ from each other. In the US, the oral and tube 
routes of administration of MN are regulated as a Medical Foods (MF), whereas in 
the EU, these are regulated as Foods for Special Medical Purposes (FSMPs). At 
present, regulatory changes are taking place within the European MN market with 
the goal to provide a better environment for businesses, better application of rules, 
better consumer protection on the content and marketing of MN and possibly 
inducing an innovation boost (46).. 
 
The US FDA regulations define MN as a medical food, therefore logically, this term 
is only found in the definitions of US origin. Similarly, the European regulatory term 
Foods for Special Medical Purposes is only found in the definitions originating from 
Europe. Parenteral nutrition is regulated both in Europe and the US under the 
pharmaceutical regulatory framework. All other terms (MN; EN; oral nutrition) are 
used interchangeably in terminology and definitions originate both from the US and 
Europe.  
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Medica l  nut r i t ion purposes 
Within the concept of MN we propose that at present two types of medical nutrition 
purposes exist: 
(1) Management of disease-related malnutrition: these are often high protein / high 
energy, multi-nutrient dense products intended to manage disease-related 
malnutrition in patients who are unable to consume sufficient normal foods to 
meet their nutritional requirements as a result of a disease, disorder or condition, 
or its associated treatment e.g. stroke, oncology, surgery or chemotherapy  
(2) Disease-specific dietary management: these products are intended for the dietary 
management of a particular disease state. They can be considered to manage 
nutritional risk by omitting specific ingredients or nutrients which would cause 
problems if consumed as part of a normal diet by patients with specific diseases, 
e.g. avoidance of cow’s milk protein in cow milk allergy, and avoidance of 
phenylalanine in phenylketonuria, or by providing nutrients in a specific amount 
or balance that might be difficult or impractical to achieve by means of normal 
foods, e.g. ketogenic diet for childhood epilepsy.     
 
Route o f  admin is t ra t ion 
Three routes of application for MN exist: Oral Route = orally; Tube Feeding (TF) = 
through a gastrointestinal tube; and Parenteral Nutrition (PN) = intravenously. The 
different routes of administration are described separately. 
Oral  Route 
Broadly, oral route products can be divided into two categories: (1) those intended 
for the dietary management of disease-related malnutrition, also known as oral 
nutritional supplements (ONS) and (2) specialised compositions designed to be used 
in a particular disease, termed here as disease-specific dietary management products. 
The first type, ONS products, may have a standard nutrient composition and are 
designed to be used to manage a state of malnutrition in a variety of different 
diseases. These are often high-protein / high-energy dense products containing 
macro- and micronutrients. Some ONS have a disease-specific composition, whereby 
the nutrient profile is adapted to make them particularly suitable for managing 
disease-related malnutrition in a certain disease, disorder or condition.  The second 
category consists of disease-specific dietary management products which are 
designed to be used in the dietary management of a particular disease state, but 
where disease-related malnutrition is not the primary concern. In all cases, these 
products should be used under healthcare professional supervision after an evaluation 
of individual circumstances, to ensure that the right type of product is used at the 
right time to meet predefined nutritional goals (56). 
 
Oral nutrition products are regulated as medical foods in the US, as part of the 
orphan drug act. In Europe, oral nutrition products are governed by the FSMP 
directive which is part of food legislation. These products are usually specifically 
designed for oral use and are generally only prescribed under supervision of a medial 
professional. These are not to be confused with food or dietary supplements in pill 
formats that solely provide vitamins, minerals, etc. and which can be purchased over 
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the counter / freely by consumers (56). Oral nutrition products are often used as a 
supplement to other food intake, but in many cases they are nutritionally complete 
and may be used as a sole source of nutrition (58). Oral nutrition products may be 
liquid, ready to use products, e.g. in a small bottle with a straw or may be available in 
powder form, to be added as a fortifier to other foods, or to be made up into a drink 
with water or milk. Some oral nutrition products are thickened for use in patient 
groups with swallowing difficulties (dysphagia).  
Tube feed ing (TF)  
When the administration of nutritional support via the oral route is not possible, 
provided that the gastrointestinal tract is at least partially functional, feeding via a 
tube may be advisable. Similar to oral nutrition, TF may be supplementary to oral 
intake or can be the sole source of nutrition (56). TF may be administered through a 
nasogastric, nasoenteral or percutaneous tube (56, 59). In the US and Europe, oral 
nutrition and TF are regulated similarly, either as MF (in the US) or as FSMPs  (in 
Europe).  
 
Similar to oral nutrition products, the desired impact/effect of TF can be divided into: 
(1) managing disease-related malnutrition; (2) disease-specific dietary management.   
Parentera l  nut r i t ion (PN)  
The term parenteral originates from the Greek para meaning “besides” and enteros 
meaning “intestine”, because it bypasses the intestines. PN thus refers to a means of 
bringing nutrition into the body other than through the gastrointestinal tract, in other 
words, intravenously (56). PN is administered when other nutritional routes (regular 
diet/oral nutrition/TF) are not efficacious or when it is unsafe to use those other 
routes (59). It is delivered via a catheter inserted into a peripheral or central vein 
(venous access), and depending on the patient’s clinical situation,  may be required 
as short-term nutritional support, for the longer term or even for life (56). The term 
total parenteral nutrition refers to the administration of nutrients and energy solely by 
the parenteral route, while supplemental parenteral nutrition complements either oral 
or TF supply (56).  The purpose of PN is to reduce a patient’s nutritional risk by 
managing disease-related malnutrition. PN is part of the pharmaceutical regulatory 
landscape (covered by the FDA in the US and EMA in the EU), and as such must 
follow a clearly defined clinical research process (56). 
  
 24 
2 .2   Def in i t ion:  d is t inguish ing features  
Disease 
The feature disease (or similarly: illness, (medical) condition or disorder) can be 
found in 39% of all the MN definitions presented in this review. Dorland’s Medical 
Dictionary for healthcare Consumers defines disease as: “a definite pathological 
process having a characteristic set of signs and symptoms. It may affect the whole 
body or any of its parts, and its etiology, pathology, and prognosis may be known or 
unknown” (60). In contrary to for example functional foods, which are 
predominantly intended for healthy consumers, MN is primarily intended for patients 
whose nutritional requirements cannot be met by normal foods, due to an underlying 
medical condition/disease/disorder or illness (61).  
Malnut r i t ion 
Even though malnutrition is often overheard in the context of MN, the concept itself 
can only be found in one of the MN definitions in this review (62). Malnutrition can 
be defined as “a state of nutrition in which a deficiency, excess or imbalance of 
energy, protein and other nutrients causes measurable adverse effects on tissue/body 
form (body shape, size and composition) and function, and clinical outcome” (63). 
Malnutrition thus often arises due to the consequences of disease. In this review, we 
will only refer to disease-related malnutrition. Disease can result in under-nutrition 
due to different effects: decreased dietary intakes; impaired gastrointestinal functions 
reducing digestion and absorption; and an altered metabolism. The prevalence of 
disease-related malnutrition is high in patients in hospitals, care homes and other 
institutions, and those living in their own homes in industrialized regions such as 
Europe and the US (MNI, 2012). Not all MN products are intended to manage 
disease-related malnutrition; some types   are intended for the disease-specific 
dietary management of patients (see section 1.2.2). 
Superv is ion 
Despite the fact that the term supervision is stated in both the US and European MN 
regulations, it remains poorly defined and under-debated in literature. The Miller-
Keane encyclopedia & dictionary of medicine, nursing & allied health defines 
healthcare supervision as: “the management of the treatment plan by a healthcare 
professional” (64). This in turn leads to the question, what is a healthcare 
professional? Dorland’s Medical Dictionary for Healthcare Consumers defines a 
healthcare professional as: “a person who by education, training, certification, or 
licensesure is qualified to and is engaged in providing healthcare” (60).  
 
In addition, in Directive 2011/24/EU on the application of patients' rights in cross-
border healthcare, the following definitions are laid out: “health professional: means 
a doctor of medicine, a nurse responsible for general care, a dental practitioner, a 
midwife or a pharmacist within the meaning of Directive 2005/36/EC, or another 
professional exercising activities in the healthcare sector which are restricted to a 
regulated profession as defined in Article 3(1)(a) of Directive 2005/36/EC, or a 
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person considered to be a health professional according to the legislation of the 
Member State of treatment” (65). 
 
Since MN is prescribed/recommended in clinical, dietetic and pharmacy settings, we 
propose to define physicians, dietitians, nurses and pharmacists as the supervising 
healthcare professionals. 
Composi t ion  
Overall, MN aims for an increased and/or adapted intake of macro- and 
micronutrients and even though each MN composition differs, the European 
regulations define minimum and maximum levels of vitamins, minerals and trace 
elements. The maximum levels in the European FSMP directive are based to some 
extent on existing MN compositions and safety data (66). Ingredients used in MN in 
the US must be approved with a Generally Recognized as Safe (GRAS) status. With 
respect to the concept composition, the MN definitions in this review refer to: micro- 
and/or macro nutrients; nutritional compositions; high energy and/or high protein 
intake.  
Suppor t  /  management  
Since the concepts support and management are found in 44% of all the MN 
definitions, they seem to be an important factor in defining MN. Despite the fact that 
the concepts support and/or management are stated in both the US and European 
MN regulations, it remains poorly defined. In 2009, Schrijvers proposed an overall 
definition for disease management: “Disease management consists of a group of 
coherent interventions designed to prevent or manage one or more chronic conditions 
using a systematic, multidisciplinary approach and potentially employi ng multiple 
treatment modalities. The goal of disease management is to identify persons at risk 
for one or more chronic conditions, to promote self management by patients and to 
address the illnesses or conditions with maximum clinical outcome, effectiveness 
and efficiency regardless of treatment setting(s) or typical reimbursement patterns” 
(67). In the case of MN, it is not only patients with chronic conditions who are 
prescribed MN; in some circumstances, e.g. after surgery, it may be a short-term 
solution to bridge a gap until a patient is able to resume normal food intake. 
Furthermore, MN is generally prescribed under supervision of a medical professional 
in contrary to the general definition of disease management which states: “to 
promote self management by patients”. 
 
One barrier that can be encountered in the development of TF and oral MN is that it 
cannot be claimed to treat or cure a disease since it is considered as a food. The 
recognized therapeutic mode of action of substances may be used as a cut-off point 
to differentiate between a food item and a pharmaceutical substance. Pharmaceutical 
legislation only applies to a product if it is capable of modifying human 
physiological functions by exerting a pharmacological, immunological or metabolic 
action (12, 68). Nevertheless, delineating the boundaries clinically between the 
concepts support/management and treat/cure remains difficult. Delineating these 
boundaries could lead to an increase in MN development costs if certain MN 
 26 
products would require more clinical research or follow pharmaceutical processes 
(54).  
 
With the exception of malnutrition, all concepts are present in three or more MN 
definitions. We therefore propose that the remaining concepts should all be present in 
a clear clinical definition of MN.   
2.3   Conclus ions:  operat ional  terminology and def in i t ion 
This literature review provides a qualitative and quantitative overview of MN 
terminology and definitions. It confirms that, comparable to previous research, 
market boundaries have not been clearly delineated (47). At present, a plethora of 
terms and definitions for MN are used interchangeably in the US and Europe. In 
practice, consistent terminology/nomenclature and definitions have not emerged 
from the US and European MN communities resulting in an ambiguity in the 
consensus on MN terminology and the absence of a pragmatic operational definition. 
Agreement on terminology and definition for MN can therefore contribute to 
transparency at various societal levels thereby increasing MN awareness and 
fostering innovative MN development. Faced with a potential innovation cliff, 
transparent terminology and a clear definition can hopefully stimulate development 
and contribute to an innovation boost in a market with such public health benefit. 
 
In this review we have discussed two elements to foster this discussion: the first 
addressed the terminology used; the second dealt with the features considered in the 
definition. To conclude we would like to propose consensual terminology followed 
by a pragmatic operational definition.  
Termino logy 
The terms medical nutrition, clinical nutrition, enteral nutrition, parenteral 
nutrition, oral nutritional supplements, medical foods and foods for special medical 
purposes are used interchangeably. Eight out of eleven terms are defined in the 
literature, and although the term clinical nutrition is often used/heard in the 
professional field, this concept is not defined in scientific literature and therefore 
excluded from the consensual the proposed MN terminology. The term nutritional 
support is left out of scope of this review due to the generic use of this term. Based 
on how the terminology from scientific literature describes different types of 
nutritional support, encompassing both enteral nutrition and parenteral nutrition, we 
propose the following terminology for MN: medical nutrition comprises both 
parenteral as well as enteral nutrition, which in turn is divided into oral route 
products and tube feeding (Figure 3). Whereas EN is regulated as a food, PN is 
regulated as a pharmaceutical product.  
 
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
F igure  3 .  Ca tego r i za t i on  o f  t he  d i f f e ren t  t ypes  o f  med i ca l  nu t r i t i on  i n  
t he  US  and  Eu rope  
 
 
 
 
Def in i t ion 
The MN definitions from twenty-three selected and relevant literature sources were 
characterized by means of five distinguishing MN features. Due to the high 
prevalence of four of these features, we propose that the following four features 
should be included in a common and consensual clinical MN definition: disease; 
supervision; composition and support/management. These features are integrated 
into one operational clinical MN definition and presented in Box 1. 
 
 
 
  
MEDICAL NUTRITION 
ENTERAL NUTRITION PARENTERAL NUTRITION 
ORAL ROUTE TUBE FEEDING 
Regulatory Scope 
Regulated as “Food” Regulated as “Drug” 
Reduce patient’s nutritional risk 
•  Manage state of disease related malnutrition 
Dietary management of a disease 
Manage state of disease related malnutrition 
Route: 
Purpose: 
Purpose: 
BOX 1. MEDICAL NUTRITION: specially formulated nutritional composition for the dietary 
management of patients with diseases, disorders or medical conditions that cause distinct 
nutritional requirements. It may consist of partial or exclusive feeding by means of oral intake, 
tube feeding and/or parenteral administration under healthcare professional supervision.  
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CHAPTER 3  
FOOD-PHARMA CONVERGENCE IN MEDICAL 
NUTRITION – BEST OF BOTH WORLDS? 
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ABSTRACT  
 
At present, industries within the health and life science sector are moving towards 
one another resulting in new industries such as the medical nutrition industry. 
Medical nutrition products are specific nutritional compositions for intervention in 
disease progression and symptom alleviation. Industry convergence, described as the 
blurring of boundaries between industries, plays a crucial role in the shaping of new 
markets and industries.  Assuming that the medical nutrition industry has emerged 
from the convergence between the food and pharma industries, it is crucial to 
research how and which distinct industry domains have contributed to establish this 
relatively new industry.  
 
The first two stages of industry convergence (knowledge diffusion and 
consolidation) are measured by means of patent analysis. First, the extent of 
knowledge diffusion within the medical nutrition industry is graphed in a patent 
citation interrelations network. Subsequently the consolidation based on 
technological convergence is determined by means of patent co-classification. 
Furthermore, the medical nutrition core domain and technology interrelations are 
measured by means of a cross impact analysis. 
 
This study proves that the medical nutrition industry is a result of food and pharma 
convergence. It is therefore crucial for medical nutrition companies to effectively 
monitor technological developments within as well as across industry boundaries. 
This study further reveals that although the medical nutrition industry’s core 
technology domain is food, technological development is mainly driven by 
pharmaceutical/pharmacological technologies Additionally, the results indicate that 
the industry has surpassed the knowledge diffusion stage of convergence, and is 
currently in the consolidation phase of industry convergence. Nevertheless, while the 
medical nutrition can be classified as an industry in an advanced phase of 
convergence, one cannot predict that the pharma and food industry segments will 
completely converge or whether the medical industry will become an individual 
successful industry.  
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3 .1  INTRODUCTION 
The Health & Life Sciences sector is currently undergoing significant change across 
all its industries. Boundary-crossing developments are occurring, especially between 
the food and pharmaceutical industries. The emergence of innovation at this 
intersection is blurring the clear boundaries between these two industries (69). Such 
boundary-blurring innovation leads to industry convergence, which in turn results in 
the emergence of new industries. Food-pharma products resulting from this 
convergence are known as Nutritional Supplements (NS), Functional Foods (FF), 
and Medical Nutrition (MN). NS include vitamins, minerals, herbs, amino acids, and 
other related products intended to supplement the nutritional content of the diet in 
tablet/capsule dosage (70). FF are conventional foods with added nutrients that claim 
to improve health beyond the basic nutritional functions (3, 71-75). MN products are 
specific nutritional compositions for disease intervention that effectively contribute 
to the therapeutic regimen by improving a patient’s general condition (42, 76). MN 
can be divided into tube feeding and oral nutritional supplements (e.g. Nutridrink; 
Ensure; and Resource) and are primarily prescribed by healthcare professionals. NS, 
FF, and MN are food substances that are considered to improve health, and exist 
between conventional foods and pharmaceuticals at the so-called food-pharma 
interface (Figure 1) (77). Nevertheless, the individual pharmaceutical and food 
companies recognize the risks in developing food-pharma inventions(76, 78). They 
fear that the commercialization of boundary-spanning products (3) could result in a 
lower customer acceptance due to the ambiguous identity of the product (3).  

F igure  1 .  I ndus t r i es  s i t ua ted  a t  t he  f ood= -pha rma  i n te r f ace .  Adap ted  
f r om  (3)  


 


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The present study focuses on the emerging MN industry, where industry boundaries 
are still relatively undefined. This is reflected by the terminology used to describe 
this product category, which is most often perceived as confusing. MN is just one 
term among many others to indicate the same product category (e.g. oral nutritional 
supplement, medical food, clinical nutrition, enteral nutrition). 
The European (EU) MN industry comprises 5 leading companies and currently finds 
itself in the growth phase of the industry lifecycle (3, 79). It is difficult to predict the 
prerequisites for determining the future success of an emerging industry such as the 
MN industry, nonetheless: carefully categorizing industries and identifying industry 
boundaries is crucial and can lead to better consumer perception and higher market 
acceptance (3, 49-53).  In the view that millions of patients are suffering from 
disease-related malnutrition, including a surprisingly high proportion living in the 
developed countries/high income economies (3, 58, 76) and many studies have 
proven that nutritional interventions prevent and/or support the development of 
disease-related malnutrition (58, 76), MN is considered of high societal value. 
Therefore, defining industry boundaries may also have an indirect societal impact. 
The first step in identifying industry boundaries is by determining the status of 
industry convergence and thereby investigating how and which distinct industry 
domains have contributed to establish an industry.  
In this research the concept of MN industrial convergence is based upon the 
assumption that the phenomenon of industry convergence proceeds along an 
evolutionary trajectory consisting of four phases: Initialization; Knowledge 
Diffusion; Consolidation; and Maturation (Figure 2) (80-82). Such industry 
convergence has been observed in many industries such as telecommunications, 
computing and consumer electronics or cosmetics and pharmaceuticals (83-86). In 
the initial stage, R&D of two or more distinct industries segments remains 
independent. It is during the knowledge diffusion stage where cross-disciplinary 
citations may eventually result into joint research collaborations (consolidation 
stage). As the metaphorical distance between the two knowledge areas decreases, 
technology development follows, which in turn leads to technology convergence 
(82). It is believed that market convergence is also a consequence of the new 
technological combinations. Ultimately, sectors begin to merge with one another, 
completing the industrial convergence process. 
 
This study shows how and which distinct industry domains have contributed to 
establish the MN industry. First we determine the extent of knowledge diffusion 
within the MN industry, subsequently we define the consolidation into the MN 
industry on the basis of technological convergence (Fig. 2), and eventually we 
identify the MN core domains and chart the technology interrelation and its influence 
on the MN industry development. Both knowledge diffusion and technological 
convergence are two important drivers of innovation and recognized as crucial 
components for industry growth (86, 87). Specifically within the health and life 
science sector, both drivers contribute to the evolution of young and emerging 
industries such as the MN industry (88). Moreover, scientific advancements are the 
key ingredient in stimulating both knowledge diffusion and technological 
convergence. The former - knowledge diffusion - is defined as the process through 
which knowledge is spread along a specific path in a social system (89). 
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Technological convergence implies a technological change where inventions emerge 
at the intersection of established and clearly defined industry boundaries (90). The 
cumulative effect of both drivers ultimately leads to industry convergence (91).  
 
The quantitative diffusion and consolidation results from this study will contribute to 
detailed insights in MN industry development and can help industry players to 
address specific innovation strategies for the future. 
 
Patents have been proven to be a valuable source of information in mapping MN 
industry development (92, 93), they contain about 80% of all technological 
knowledge and are generally regarded as precursors of technological developments 
(82, 94). In addition, they can be independently accessed and analyzed through 
various types of comprehensive and open databases (95). Finally, in contrary to other 
knowledge sources, such as scientific literature, patents are categorized according to 
multiple technology classes according to their technological characteristics. This 
allows for accurate co-classification analyses to identify the interrelation between 
technologies (96). Therefore, in this study, patent data was used to identify the 
evolutionary (technological) development of the MN industry.

F igure  2 .  Linear model of convergence adapted from (80-82, 97) Linear model of 
convergence adapted from (80-82, 97) 


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3 .2  METHODOLOGY 
The methods applied in this study are based on research methods by Karvonen, 
Tseng, and Choi (90, 98, 99) and adapted to fit our research objective. To determine 
the stage of convergence in the MN industry, this study is divided into Knowledge 
Diffusion and Consolidation. Furthermore, the consolidation is divided into 
technological convergence, and CIA (Figure 3). Data on patents concerning MN was 
extracted from the Derwent Innovations IndexSM and Espacenet pertaining to the 
European published patent applications. In total, 274 patent applications were filed 
by the 5 leading EU MN companies from 1984 up to 2013 (so-called; main patents).  
 
F igure  3 .  Resea rch  F ramework   

 
 
 
3.2.1  Knowledge d i f fus ion 
Since knowledge convergence is the first stage of convergence, the analysis of 
knowledge flow within the MN industry is an appropriate method for identifying 
possible current and future convergence between knowledge disciplines originating 
from different industries (100). Patent citation data is considered an important 
information source for analyzing science-based knowledge flows. Patent citations 
within the MN industry are indicative for the technological relationship between 
patents in the MN industry (101-105). Patent citations refer to the number of cited 
patents within the original patent application as an indicator of prior art. Such an 
analysis provides information of inter- industry competition and knowledge 
spillovers (90, 106).  
 
In order to identify the knowledge diffusion within the MN industry, the backward 
citations of all main patents were extracted. Subsequently, we constructed an 
affiliation network visualizing the interrelations of all main patents of the European 
MN companies. This method is a powerful tool to analyze knowledge flows and 
within-industry competition (98). The mutual linkage between the main MN patents 
were explored and visualized using the statistical software programs Ucinet and 
Medical Nutrition 
Convergence 
 DIFFUSION Knowledge Diffusion  
Affiliation Network 
(Backward citation) 
Linkage Between Main 
MN Patents 
CONSOLIDATION 
Technology domain 
convergence CPC Domain Pairs 
Interaction & Impact 
between technologies 
Cross Impact Analysis 
(CIA) 
- Bidirectional Impact 
- Unidirectional Impact 
- Non impact           
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NetDraw (107). This network represents the knowledge flows between the European 
MN companies  (anonymous) and gives an indication of within industry competition.  
 
3.2.2  Technolog ica l  convergence 
In general, patents have multiple technology classifications depending on their 
claims. Since patents are classified into certain technological classes according to 
their technological characteristics, co-classification analysis identifies the 
interrelation between technologies (96). The co-classification analysis measures the 
frequency by which two classification codes are jointly assigned to a patent and can 
be interpreted as an indication of the strength of the technological relationships. 
Ultimately, this allows for calculating technological convergence (95, 108). The co-
classification in this study is based on the Cooperative Patent Classification (CPC) 
codes (109). Since the MN industry is not yet assigned to one specific classification 
category, the co-classification of different technologies currently delineates this 
industry. This is in accordance with the fact that the MN industry is still in growth 
phase as described earlier (3).  
 
The expert designated CPC codes from each patent were extracted to analyze 
science-based technological convergence within the MN industry. CPC is an 
extension of the International Patent Classification (IPC) and is a joint endeavor of 
the European Patent Office (EPO) and the United States Patent and Trademark 
Office (USPTO) to harmonize the classification systems into a single system. This 
jointly developed classification system is much more granulated than the IPC system. 
 
The CPCs were extracted from the patent search and analysis software ACCLAIMiP 
and the Espacenet portal. Since patents can be classified into several CPC groups, the 
co-classification provides information concerning technological convergence. In 
order to reveal the technological convergence domains within the MN industry, the 
first two (converging) CPC codes were extracted from all main patents and grouped 
into various domain combinations (90, 110, 111). CPC codes are a hierarchical way 
of assigning the category to which every patent belongs (112). The MN patents are 
categorized into classes, which are divided into sub-classes, main groups and sub-
groups. The main groups are merged into domain combinations as illustrated in 
Table 1. In this study we make no difference between the orders of category 
combinations (e.g. no difference between 1-2 and 2-1). Subsequently, the number of 
patents per domain combination was divided in time blocks of 5 years, showing the 
evolutionary development of the emerging MN industry. 
 
There is a predicted lag in the convergent domains since patent applications are 
available in the public domain only 18 months after filing. As a result, the dataset is 
accurate to January 2012 and therefore by definition no 2013 patent applications 
could be included. 
 



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Tab le  1 .  Predom inan t  CPC g roups  i n  MN pa ten t  l i t e ra tu re   
 
Nr. CPC Code Groups 
1 A23K1 Animal feeding-stuffs 
2 A23G1 Cocoa; Cocoa products 
3 A23F5 Coffee; Coffee substitutes; Preparations thereof 
4 A61K8 Cosmetic or similar toilet preparations 
5 F24D19 Details 
6 A23D7 Edible oil or fat compositions containing an aqueous phase 
7 Y02B30 Energy efficient heating, ventilation or air conditioning 
8 A61J15 Feeding-tubes for therapeutic purposes  
9 A23V2002 Food compositions, function of food ingredients or processes for food or foodstuffs 
10 A23L1 Foods or foodstuffs  
11 C07K16 Immunoglobulins 
12 A61K9 Medicinal preparations characterized by special physical form 
13 A61K45 Medicinal preparations containing active ingredients 
14 A61K2039 Medicinal preparations containing antigens or antibodies 
15 A61K33 Medicinal preparations containing inorganic active ingredients 
16 A61K35 Medicinal preparations containing materials or reaction products thereof with undetermined constitution 
17 A61K31 Medicinal preparations containing organic active ingredients 
18 A61K38 Medicinal preparations containing peptides 
19 A61K36 Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof 
20 A23C9 Milk preparations; Milk powder or milk powder preparations 
21 A23C11 Milk substitutes 
22 A61K2300 Mixtures or combinations of active ingredients 
23 A23L2 Non-alcoholic beverages; Dry compositions or concentrates thereof 
24 A23J1 Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites 
25 A23D9 Other edible oils or fats 
26 C07K14 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof 
27 A23J7 Phosphatide compositions for foodstuffs 
28 C12P19 Preparation of compounds containing saccharide radicals 
29 C12P17 Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms 
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30 A61Q19 Preparations for care of the skin 
31 A23L3 Preservation of foods or foodstuffs, in general 
32 C12R1 Processes using micro-organisms 
33 A23G3 Sweetmeats; Confectionery; Marzipan; Coated or filled products 
34 A23F3 Tea; Tea substitutes; Preparations thereof 
35 A23C21 Whey; Whey preparations 
36 A23J3 Working-up of proteins for foodstuffs 

 

3.2.3  Cross impact  ana lys is  
The identification of the overall structure of technologies and interaction among 
them is essential to recognize the maturity of technological trends and discover 
technological possibilities through convergence between various fields of 
technologies (113). Cross Impact Analysis (CIA) is considered a reliable quantitative 
methodology to identify the core technologies and interrelations between technology 
domains (114-116) based on patent classification data (99). In our study, the 
technology impact between various MN technology domains is analyzed based on 
patent co-classification data as described in technological convergence section. The 
impact between technologies can be derived from the CPC codes of the patent. 
Moreover, the impact of (A, B) can be defined as conditional probabilities between 
two technologies (99). This means that the cross impact of technology A on 
technology B can be defined as follows:   
 
Impact (A, B) = P (B|A) = (N (A ∩ B)) / (N (A)) 
 
In this equation, N (A) refers to the total number of patents included in domain A, 
and N (A∩B) indicates the number of patents, which include both domain A and 
domain B. The patent-based cross impact between domains can be analyzed by 
calculating the conditional probability with the number of patents in the patent 
classes. The score of index ranges from 0 to 1. If the score is close to 1, then 
technology domain A has a high impact on technology domain B and when the score 
is approaching the 0, the impact is considered lower.  
Technology pairs based on the cross impact scores can be classified into three 
groups. In case 1, the so-called bidirectional impact, most of the patents in 
technologies A and B overlap; hence, both Impact (A, B) and Impact (B, A) are high. 
Consequently, conditional probabilities are relatively high and the impacts of one 
technology on the other technology are both high. 
In case 2, called one directional impact, a high number of patents in technology A is 
also included in technology B, however, the portion of patents in technology B that is 
also included in technology A is relatively small. This means that Impact (A, B) is 
high, but Impact (B, A) is low. In this case, the impact between technologies A and B 
is unidirectional. 
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In case 3, called nonimpact, technologies A and B are almost exclusive and there is 
little interaction between them. Basically, these two technologies can be said to be 
almost independent. 
Moreover, the individual impacts between the domains are visualized by means of 
network analysis depicting the type of interaction (arrow) between the domains 
(node). The direction of the arrow indicates the direction of impact between two 
domains. It visualizes whether technologies are equally influencing one another 
(bidirectional) or whether the impact of the first technology on the second is different 
from the impact of the second technology on the first (unidirectional) (99, 117).  
Patent data is a valuable source of information and is useful in the study of 
technological convergence and diffusion as well as in technology interrelation and 
development. Nonetheless, not all inventions are patented and changes in patent law 
over the years make it difficult to analyze trends over time (118). Since the 
protection afforded to patentees worldwide has been improved, the companies are 
more inclined to file for a patent than before (118). Additionally, since CPC is a joint 
endeavor of the EPO and USPTO, this classification system is more detailed, up to 
date, and dynamic (112).  Subsequently, we have applied the quantitative patent-
based CIA method of Choi (99) as opposed to the more conventional qualitative 
(CIA) approach, by means of literature surveys and expert interviews, aiming to 
overcome inconsistent outcomes. Furthermore, the citations lag between the 
application or grant year of the citing patent and that of the cited patents make it 
impossible to assemble all the main patents within the MN industry up until present 
time (119). To address this limitation, a prediction line was drawn (result section 
CIA).  
3.3   RESULTS 
In total, 274 patent applications were filed by the 5 leading European MN companies 
between 1984 and 2013. The MN patents can be assigned to 5 classes which are 
subsequently divided into 7 sub-classes, 37 main groups and 151 sub-groups. 
 
3.3.1  Knowledge Di f fus ion 
The knowledge diffusion network shows that most patents (78%) are not interrelated 
within the MN industry by means of patent citations. Interestingly, figure 4 shows 
that the remaining 22% of the patents lead back to two patent precursors and the 
CPCs of the precursors indicate convergence between the Food – Food 
Compositions and the Food – Pharmaceutical Organic Active Ingredients industrial 
domain combinations (Figure 4). The remaining 78% of the main patents are not 
linked to patents within the MN industry domain and are therefore linked to patents 
from other industrial domains. The high occurrence of patent linkage beyond the 
industrial domain indicates boundary-spanning convergence is taking place in MN 
development.  
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3.3.2  Technolog ica l  convergence 
Figure 5 illustrates that between 1989 and 2013, 84% of all MN main patents show 
convergence between different industrial domains indicating technological 
convergence. Furthermore, figure 5 demonstrates that convergence of industry 
domains have played an essential role in the MN industry development since 1989, 
nevertheless, the importance of specific domain combinations varies over the course 
of time (Figure 6).  

F igure  5 .  Evo lu t i on  o f  s i ng le  doma ins  ve rsus  d i f f e ren t  doma in  
conve rgence  i n  MN –  MN canno t  be  c l ass i f i ed  as  a  s i ng le  doma in  bu t  
p redom inan t l y  as  a  conve r gence  be tween  d i f f e ren t  doma ins .  

 

Further sub-categorization of the MN domains, indicating domain convergence, 
reveals the 5 most prevalent sub-groups: Food – Medicinal preparations containing 
organic active ingredients; Food – Medicinal preparations containing peptides; 
Food – Food Compositions; Food – Medicinal preparations containing 
combinations of active ingredients (MPOAI); and Food – Materials/Reaction 
Products (Figure 6).  
 
Figure 6 shows that from 1989 until now Organic Active Ingredients, Food 
Compositions, and Peptide Compositions have played an essential role in the 
development of MN industry. In 1994 a new domain combination emerged: Food – 
Materials/Reaction Product. Since 1999, another new domain combination emerged: 
Food – Medicinal preparations containing peptides.  
 
The principal domain convergence has occurred between the Food domain and 
MPOAI domain. Examples of MPOAI are: carbohydrates; sugars; carboxylic acids; 
hydrocarbons; amino acids; vitamins; and medicinal plant derivatives. 
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
F igure  6 .  Food -Pha rma  dom ina tes  t he  doma in  conve rgence  i n  MN –  
Se lec t i on  o f  t op  5  conve rg i ng  dom a ins  f r om  1989  t o  2013  i n  MN  

 
 
3.3.3  CIA 
The cross impact scores help classify each technology pair into three groups: 
Bidirectional, Unidirectional, and Non-impact. The CIA network illustrates that 22 
out of 47 technology pairs can be classified as bidirectional- or unidirectional impact 
(Figure 7). 
Furthermore, the bottom-right quadrant of figure 7 illustrates a network graph of the 
relationships between technology domains within the MN industry. Each node 
represents a technology domain and the color of the node indicates its corresponding 
score that classifies the impact between two technology domains. The bidirectional 
impact technology pairs are expressed as blue nodes and the unidirectional impact 
technology pairs as red nodes. Furthermore, the direction of the arrows indicates the 
direction of impact. The network graph helps us identify the influencing- and 
influenced technology domains. 
The network graph indicates that 11 technology domains directly influence the food 
domain. Eight of the eleven influencing domains originate from food (8, 9, 20, 23, 
28, 31, 35 and 39) whilst three domains (15, 16 and 17) originate from pharma. The 
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domains impacting the food domain (10) that originate from pharma account for 138 
patents, while the domains originating from food account for 57 patents.  
 
The central positioning of Food (10) in the network graph shows that this technology 
domain can be considered as the core MN domain. Additionally, technological 
development from the pharmaceutical domain, especially medicinal preparations 
containing: inorganic active ingredients, organic active ingredients and materials or 
reaction products thereof with undetermined constitution, influence the core MN 
domain.

 
 

 
 
3 .4  DISCUSSION & IMPLICATIONS 
This study proves that the MN industry is a result of a bona fide food-pharma 
convergence. Additionally, the results indicate that the industry has surpassed the 
knowledge diffusion stage of convergence, and is currently in the consolidation 
phase of industry convergence. Nevertheless, while the medical nutrition can be 
classified as an industry in an advanced phase of convergence, one cannot predict 
F igure  7 .  G roup ing  o f  t he  t echno logy  pa i r s  i n  t he  MN i ndus t r y .  Ne two rk  
g raph  o f  b i d i r ec t i ona l  and  un id i r ec t i ona l  impac t  w i t h i n  t he  MN i ndus t r y  
( 1984 -2013 )   
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that the pharma and food industry segments will completely converge or whether the 
MN industry will reach a state of maturation and become an individual successful 
industry. This confirms previous research which revealed the MN industry to be in 
the relatively early development stage of the technology life cycle (42). The 
knowledge flows and subsequently trans-disciplinary technological convergence 
between the food-pharma technology domains have fine-tuned the MN industry as it 
is today. This study further reveals that although the MN industry’s core technology 
domain is food, the technological development is mainly driven by pharmaceutical 
technologies.  
 
Although not scientifically proven, in the past few years literature has stated that the 
gap between pharmacology and nutrition science has been narrowing, a development 
stimulated by both disciplines (76). The increase in technological convergence 
between food and MPOAI confirms this observation, which previously has been 
termed as “pharmaconutrition”. Although in the past only drugs were considered 
pharmacologically active substances, this new treatment paradigm embraces the fact 
that nutrients can have profound effects on immunological, metabolic and other 
pathophysiological processes of diseased patients (76, 120).  
 
Our results show that there are currently five different CPC combinations required to 
define MN in patent literature. This emphasizes the necessity for a specific CPC code 
to clearly categorize MN, which may contribute to clearly delineating MN industry 
boundaries. Having its own identity may lead to better consumer perception and 
higher market acceptance thereby stimulating MN market growth.  
 
Considering that convergence drastically alters industry structures, companies should 
consider evaluating whether their activities may be affected by trends of convergence 
(121). By monitoring convergence trends, companies can benefit by commercializing 
on trans-disciplinary opportunities.  The MN industry can be characterized as a 
convergent/converging area at the food-pharma interface and it is therefore crucial 
for MN companies to effectively monitor developments within as well as across 
industry boundaries. Both in the food- and pharmaceutical industry trends should be 
monitored, as our results indicate that critical knowledge is also developed in those 
fields (121). Especially the technological development within the pharmaceutical 
industry is essential since our CIA results shows that pharmaceutical technologies 
have the greatest impact on MN development. 
 
The knowledge diffusion results indicate a high occurrence of patent linkage beyond 
the MN industrial domain implying that the first step in boundary-spanning industry 
convergence: knowledge diffusion, is taking place in MN development. Our 
empirical analysis further reveals both knowledge and technological convergence 
between the food-pharma technological domains, thereby showing the first three 
phases of convergence of the linear model of convergence in the MN industry.  
 
Nevertheless, it is often argued that factors other than technology are involved in the 
process of industry convergence. Weaver (2007) and Karvonen & Kassi (2013) 
believe that technology and industry convergence are often intrinsically linked, yet 
these two concepts are causally and conceptually distinct (90, 122). Examples of 
those factors include: regulation, quality standards, business model innovation, 
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changing customer requirements and industry channel structure. The process of food-
pharma convergence is nurtured by the trend of regulatory convergence with respect 
to costly clinical research increasingly required for MN. These factors can be divided 
into supply (science, technology) and demand (consumer needs) factors.  
 
The absence of competencies in either supply or demand understanding may lead to 
considerable problems at the front end of innovation (idea generation, evaluation and 
selection) (86). Our results indicate that the front end of MN innovation is affected 
by convergence (Figure 8). Especially as the process of innovation requires the 
combination of new knowledge and competencies owned by different industries 
domains (86). Perhaps this is one of the reasons that the MN industry may currently 
be facing an innovation cliff (3, 42, 54). We would argue that in the MN industry, 
front-end innovation challenges are related to the converging industries. For 
example; the food industry counterparts of the trans-disciplinary venture might 
experience challenges on the technological/supply aspect of the convergence (e.g. 
clinical trials (endpoints, quality standards, pharmacokinetics and pharmacodynamics 
(76)) whereas the pharmaceutical participant may find the consumer/demand 
experience (e.g. taste, texture, tolerance, smell) a particular bottleneck (Figure 8). 
Successful convergence would therefore require awareness on matching skills, 
experience and resources that would complement the, otherwise lacking, absorptive 
capacity (86). Innovation managers must be aware of competence gaps on the supply 
and/or demand side. One way to bridge this gap is to identify external partners, 
already at the idea generation phase, with the additional competences to account for 
the missing absorptive capacity (86). Such innovation strategies by means of 
acquisition and consolidation are already occurring in the MN industry and may 
contribute to progressing to the final stage of convergence: maturation (3). 
 
 
We argue that the result of food-pharma convergence into the MN industry is both 
supply (technology) and demand (consumer) driven. For example, technology has 
made it possible to reduce the volume of high-protein oral nutritional supplements  
(ONS) while simultaneously, due to a higher awareness of MN effectiveness, the 
demand for low-volume high-protein ONS is rising. Due to convergence of the 
supply (pharma) and demand (food) sides, a new MN value chain emerges. Value 
chain reconfiguration as a result of industry convergence may lead to the elimination 
of entire value chain steps or activities while other, value-added value chain activities 
may be introduced (122, 123). 









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F igure  8 .  F ron t  end  o f  i nnova t i on  ac t i v i t i e s  i n  conve rg ing  i ndus t r i es .  
Adap ted  f r om  (86)   

 

 

In addition to diagnosing the MN industry to be in stage three of the industry 
convergence life cycle, the process of convergence in itself comes in two varieties; 
substitutive and complementary. Such a classification allows for characterization of 
the convergent industry. In the case of substitutive convergence, innovation leads to 
a phasing out of the two formerly discrete operating industries. Consequently; the 
added value of the complementary products combined is higher when compared to 
the individual components, thereby resulting in technological substitution from a 
consumer perspective (1+1=1). Complementary convergence is the process whereby 
previously unrelated products are bundled together to form a new combined and 
integrated class of product with added value for end-users (1+1=3) (122, 123). In this 
case, the convergence between technologies results from technology fusion or  by 
bundling exemplify complementarities (124). The MN industry belongs to the 
second category in the view that MN replaces neither conventional foods nor 
pharmaceutical products (Figure 9).  







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F igure  9 .  Ca tego r i za t i on  o f  MN i ndus t r y  conve rgence ,  adap ted  f r om  
(124)  
 
 
 
Ultimately, additional research is required to understand the full impact of the MN 
industry within the context of the individual food and pharmaceutical industries. 
While this study focused on the use of patents to identify the stages of industry 
convergence, future research could focus on complementary data and methods for 
mapping the convergence process. One option may be to look at clinical research 
data by assessing to what extent these studies meet pharma industry standards. The 
MN industry offers a unique dataset for studying industry convergence and 
experimenting with tools on how this is best accomplished.  
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ABSTRACT  
 
Innovation is a necessity for survival in dynamic and complex industries such as the 
medical nutrition industry. To remain competitive, medical nutrition companies must 
embrace innovation activities that improve productivity. Nevertheless, innovation is 
a difficult undertaking and companies must first overcome numerous barriers 
inhibiting innovation. Studying these barriers provides insight into the dynamics of 
innovation, which simultaneously is a first step in the process of overcoming them. 
This study investigates the exogenous barriers that inhibit medical nutrition 
innovation.  
 
Primary data was collected by qualitative interviews from 17 medical nutrition key 
opinion leaders (KOLs) through and quantitative data by means of a questionnaire 
from 77 KOLs. Medical nutrition innovation barriers were identified and ranked 
according to importance. 
 
This study shows that barriers impact all steps of the medical nutrition value chain. 
Nine main innovation barriers emerged from the research. The most significant 
barriers are associated with financial aspects and clinical research, whereas the least 
significant are associated with product barriers. Medical nutrition companies must 
realize that investment in innovation is and remains crucial within this industry. 

 
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4 .1 .  INTRODUCTION 
The health industry is acknowledging that most low-hanging fruits have been picked 
in the pharmaceutical sector and that the industry provides fewer successes than it 
did in the past (7, 8). During the last decades of the 20th century the potential of 
nutrition for the prevention or treatment of diseases or risk factors for disease was 
rediscovered (7, 12). Therefore, product development in the health and life sciences 
is experiencing a shift from the development of specific-target pharmaceutical 
products to multi-target nutritional therapy products. The European medical nutrition 
(EU MN) market is a fast-growing nutrition market, driven by new knowledge on 
MN effectiveness. MN consists of targeted nutritional compositions for intervention 
in disease progression and symptom alleviation. We found that the EU MN is 
currently in the growth phase of the technological life cycle (10). This phase is 
characterized by the highest rate of technological developments yielding the most 
innovations when compared to the other phases (10, 79). An industry’s capacity to 
innovate is considered the primary driver for economic development, which in turn is 
seen as a predictor of future growth. Nevertheless, innovation is a difficult and non-
trivial undertaking. Innovation is a necessity for survival in dynamic and complex 
industries (125) such as the MN industry, yet not all innovations contribute to 
commercial success. To remain competitive, MN companies must embrace 
innovation activities that improve productivity and fulfill the patients’ unmet needs. 
Only a small number of MN companies manage to leverage their knowledge and 
maximize their innovation capability (126). However, innovation corresponds with 
high (financial) risks and uncertainties. This creates a catch-22 situation, whereby 
innovation is necessary in order to stimulate industry growth. This shows us that 
there is an obvious need to systematically assess what inhibits the flow of innovation 
from existing players and prevents new players from entering the market. 
 
Earlier research on the topic of industry innovation predominantly focused on 
success factors stimulating innovation, often disregarding obstacles (126, 127). An 
opposite approach is the barriers approach to innovation (128, 129). The aim of the 
barriers approach is initially to explore the nature, origin, and importance of the 
barriers, in order to identify their impact on the value chain.  Studying barriers to 
innovation provides insight into the dynamics of innovation, which simultaneously is 
a first step in the process of overcoming them (128). Better understanding of barriers 
to innovation can assist companies to foster the development of an environment that 
supports innovation (130, 131). Companies can identify the right approach for 
innovation by analyzing the innovation barriers, and adapting their business 
strategies accordingly.  
 
Even though innovation is considered the key driver in advancing the MN industry 
through the technological life cycle, a surprisingly limited amount of research is 
dedicated to the topic of innovation barriers. Our research aims to identify the main 
barriers, as experienced by key opinion leaders (KOLs) in the MN innovation 
process. The current study focuses specifically on the relation between innovation 
barriers and the underlying causes. KOLs were interviewed on the topic of 
innovation barriers, and were asked to rank them in terms of importance. This study 
provides novel insights into the topic of innovation barriers in the MN industry. 
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Innovat ion & the va lue cha in 
Innovation has always been at the heart of technological progress but more than ever 
it has become a fundamental strategy of companies. The effect of globalization on 
business activities forces companies to constantly adapt and develop new products 
and technologies resulting in intense competition. The race ends for those who do not 
innovate (132). Definitions of innovation vary widely, yet in a broad sense, can be 
defined as: “the process of turning opportunity into new ideas and of putting these 
into widely used practice”(125). This paper focuses on technological innovation 
which concerns translational application of innovative knowledge in new processes 
and products (127). 
 
Technological innovation is the result of a company’s process or product idea 
successfully passing through the value chain (133). The medical nutrition value chain 
can be broken down into six sequential steps: (1) Translational science; (2) Product 
development; (3) Clinical research; (4) Product notification (5) Reimbursement 
granting and (6) Product marketing. By managing the value chain, companies drive 
ideas from the concept phase to the end of the product lifecycle (134). This approach 
requires the translation of nutrition science through food and ingredient technology 
to generate innovative impactful products of high quality, stability, safety and value 
for consumers (135).  
The barr iers  approach to  innovat ion  
Innovation is a complex phenomenon and thus needs a multilevel model of analysis. 
A barrier to innovation is any factor that negatively influences the innovation 
process. Barriers are also known as obstacles, constraints and inhibitors that prevent 
an innovation from commercial exploitation. Although subtle differences exist 
between these terms, they are used as synonyms here.  
 
Barriers to innovation are grouped relative to their relationship with the company, 
resulting in the dichotomous categories; endogenous to the firm and those exogenous 
to the firm (130, 131). Endogenous barriers may arise for example due to 
organizational routines, lack of technical expertise, resource related or human nature 
related e.g. risk-adverse top managers (128, 130). Exogenous barriers may include 
financial barriers e.g. reluctance of investors, governmental barriers e.g. policies and 
regulations and collaboration barriers e.g. differences in objectives between players 
(128, 130, 136). Barriers can further be classified into general/relative barriers. 
General barriers are barriers affecting all types of companies, while relative barriers 
selectively affect companies in specific sectors (128).  
 
The focus of the present research lies on the relative exogenous barriers, since this 
results in a cross-industry perspective. It is believed that barriers may act on one or 
more points of the value chain. Consequently, by aligning the barriers along the 
value chain; a barrier can have a different effect during the various stages (130). 
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4 .2 .  METHODOLOGY 
The methodology of this research is build-up into three individual data collection 
moments. First by determining and visualizing the innovation barriers and their 
underlying causes by means of qualitative root cause analysis (137, 138). Next, the 
innovation barriers are quantitatively ranked by the KOLs in the questionnaire by 
means of priority ranking. Finally, the first two steps are integrated to generate a top-
down view of what is inhibiting innovation in the medical nutrition industry (Table 
1).   
Par t ic ipants  
Thirty faculty members of the European Society for Clinical Nutrition (ESPEN) 
(practicing MD, dieticians, nurses, researchers, academics, and consultants) were 
selected to participate in the semi-structured interviews. Selection was based on their 
experience in the field of MN.  
Exploratory  In terv iews 
The selected participants were first contacted and informed of the nature of the study 
and invited to take part. A structured format was used for the interview schedule 
where each participant was taken through a standardized set of questions asked in a 
similar way1. By means of theme coding, the barriers were first categorized into 
general innovation barriers and subsequently into several barrier categories (139). 
The results from the interviews were used as input for the subsequent innovation 
barrier prioritization process questionnaire.  
Quest ionnai re  
 The aim of the survey was to prioritize the main inhibiting MN innovation barriers 
as identified during the interviews. 220 questionnaire participants were selected from 
the ESPEN faculty members. Selection was based on active KOL members with 
extensive MN knowledge. The anonymous online questionnaire was created and 
distributed through the online web survey program SurveyMonkey. KOLs that did 
not respond to the initial survey received a follow up letter 1.5 week later to increase 
response rates.  
Study des ign 
A Root Cause Analysis (RCA), also known as causal tree analysis or argumentation 
tree analysis is used for visualizing associations between arguments (137, 138, 140). 
This method provides a structured and process-focused framework with which to 
approach the underlying causes of events, in this case of the MN innovation barriers. 
Understanding the cause of such a barrier is the key for companies to develop 
effective strategies to overcome these challenges. Semi-structured qualitative 
interviews serve as a data collection tool for the purpose of the RCA (139). In this 
research RCA is applied top-down to identify the main barriers of innovation in the 
MN industry.  

1 Interview format available upon request 
2 It should be noted that since conventional patents are usually classified and published within 
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The prioritization process was based on previously published prioritization methods 
(141, 142) and adapted to fit MN, the goal and subject of our research. The results 
from the RCA and the prioritization process are combined to create a top-down view 
of the innovation barriers, their relative importance and the underlying causes. These 
results are combined to create an RCA tree visualizing all three aspects.  

Tab le  1 .  Study  des ign   
 
Step 1: Root cause analysis (137, 138, 140) 
1.1 Data collection: establishment of the barriers and causes through semi-structured 
interviews.  
1.2 Data analysis: an iterative process categorizing and visualizing the barriers with its 
underlying causes: 
a. The identified barriers are classified into main categories by means of data 
labeling; 
b. The barriers and causes are visualized in a causal tree showing the 
interrelations of the causes of the innovation barriers.   
Step 2: Innovation barrier prioritization (141, 142) 
2.1 Data collection: a survey is sent to 220 KOLs in which the previously main identified 
innovation barriers are stated. The KOLs were asked to prioritize the 3 most important 
innovation barriers ranging 1-3 (1 being highest priority, presents a weight of 3).  
2.2 Data analysis: Each score was multiplied by the weight for the respective criterion. The 
sum of these weighted scores reflects the total weighted score of the innovation barrier. 
The total weighted scores were finally re-scaled to a range from 1-100 in order to 
facilitate final interpretation.  
 
WR = Weighted ranking            
n = number of times 
IB = Innovation barrier   
R 1/2/3 = rank 1/2/3 
HRB = Highest rated barrier 
 
Step 3: Result Integration (139) 
3.1 The results of the main innovation barrier prioritization are integrated and subsequently 
visualized in an RCA tree. 
3.2 The point of impact in the value chain of each innovation barrier is identified and 
visualized. 

 
4 .3 .  RESULTS 
Saturation of innovation barriers mentioned by the KOLs during the qualitative 
interviews was reached after 12 interviews (fig. 1). Seventy-seven KOLs completed 
the online questionnaire. The demographic characteristics of the respondents were as 
follows: 7.8% was aged between 25-40yrs, 45.5% between 40-55yrs and 46.8% 
 55 
≥55yrs. The majority of participants fulfilled a position as practicing MD (40.7%), 
followed by academics (31.6%) and consultants (10.5%).  

F igure  1 .  Sa tu ra t i on  o f  i nnova t i on  ba r r i e r s  men t i oned  du r i ng  KOL  
i n te r v i ew s   
 
 








 
 
Eight main barriers were identified and ranked from analysis of the exploratory 
interviews. Table 2 shows the weighted rankings of the importance of exogenous 
factors negatively influencing the adoption of innovation. Only one barrier (clinical 
trial research) has a weighted ranking above 50 indicating the severe importance of 
this barrier. The second and third barriers are directly related to financial barriers. 
The main barriers were classified and ranked according to importance into the 
following categories: financial barriers (119); clinical trial barriers (100); knowledge 
barriers (76); collaboration barriers (35); and product barriers (11). Each category is 
described below with its respective underlying causes.  
 
Tab le  2 .  Rank ing  o f  impo r tance  o f  med i ca l  nu t r i t i on  i nnova t i on  ba r r i e r s   
 
Rank Innovation Barrier Weighted ranking  
Barrier 
category 
 
1 
 
Difficulty to carry out randomized controlled clinical 
trials 
 
100 
 
Clinical 
research 
2 Difficult to obtain reimbursement 44 Financial 
3 Low return on investment 42 Financial 
4 Lack of awareness among governments 
concerning MN 
38 Knowledge 
5 Lack of awareness among medical staff concerning 
MN 
38 Knowledge 
6 Collaboration barrier between industry and 
academia 
35 Collaborati
on 
7 Lack of funds from state / government 33 Financial 
8 Consumer acceptance of product characteristics 11 Product 

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4.3.1 .  Descr ip t ive  resu l ts  
F inanc ia l   
Financial barriers may also vary during the different phases of the business cycle of 
the economy due to the differentiated availability of resources and the investment 
climate (128). The current economic downfall (2008-2012) has proven an underlying 
cause of MN financial barriers. The lack of financial resources and difficulty in 
obtaining national reimbursement and ROI are all related to the current economy. 
The economy also negatively contributed to the decline in governmental grants. 
 
Second; medical nutrition reimbursement. Globally, healthcare costs are growing and 
healthcare systems are being reformed (31). One of the results is the decline in 
reimbursement of medical products, including MN products. The decrease of 
reimbursed MN products which in turn will lead to a stifling of innovation as 
companies are hesitant to develop unreimbursed products (29, 31). In addition to 
that, despite the unified EU directive concerning MN, reimbursement policies differ 
among EU countries. Although clinical evidence concerning MN effectiveness is 
generally required, precise country-specific reimbursement guidelines are lacking. 
This further complicates the process of acquiring reimbursement for companies 
developing MN. 
 
Third; return on investment (ROI). Similar to other industries (143), difficulties in 
predicting a monetary return on investments, especially in radical innovation poses a 
barrier in the MN industry. Especially with the threat of decline in MN 
reimbursement, forecasting a MN product’s ROI is considered a significant financial 
barrier.   
Cl in ica l  research  
The development of MN is relatively young (10), regulatory frameworks or 
guidelines have not been well established for all stages of medical nutrition 
development (144). The execution of clinical trials has proven to be the most 
significant constraining factor in the development of medical nutrition. This situation 
arises due to several underlying factors, including: high clinical research costs; 
difficulty to blind the studies; size of the patient groups/power of the study and; 
regulatory interpretations of MN clinical studies at EU level. The difficulty to blind 
studies results from limitations specific to nutrition support. For example; highly 
malnourished patients, seriously in need of nutritional support, cannot be randomized 
to a no-feeding group and are therefore excluded from participation in clinical 
research (145).  
Knowledge  
The European Nutrition for Health Alliance (ENHA) was established in 2005 to raise 
awareness concerning the relevance and urgency of malnutrition. Their mission was 
to ensure that the issue of malnutrition was included in policy discussions about 
nutrition and that appropriate actions are being taken by policymakers and 
stakeholders at the EU and member state levels (146). Nonetheless, awareness 
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concerning MN effectiveness among both governments and medical professionals is 
at present still perceived as an innovation barrier. Especially since the issue of 
malnutrition is of high societal importance with significant economic consequences, 
its under-recognition, under-detection and under-management is alarming (146). This 
issue ought to be prioritized, especially with the knowledge that malnutrition costs 
EUR 12 billion/year in the UK alone (146).        
Col laborat ion  
Typically, academia and industry collaboration is initiated during the early stages of 
the MN value chain, translational science and clinical research. Despite the benefits 
that result from collaboration, it is well-known that companies and academia lack a 
systematic approach for capturing the full potential of such relationships (147, 148). 
According to the MN KOLs, collaboration between academia and industry is 
inhibiting MN innovation. This barrier may be due to the differences in objectives 
between academia and industry. Exaggerated; academia mainly focuses on scientific 
research whereas the industry focus lies primarily on economic benefit created by 
scientific research.  
Product   
Each firm may independently encounter various endogenous product barriers, due to 
for example technological difficulties. Since our focus lies on the exogenous barriers 
to innovation, endogenous barriers are not taken into account. Nevertheless, product 
barriers also arise at the exogenous level. In MN, consumer acceptance is perceived 
as such a product barrier.  
4.3.2 .  Data in tegrat ion 
Integrating the results from the RCA with the ranking, results in a causal tree (fig. 2). 
This tree visualizes which main barriers are impacting innovation and which causes 
underlie these barriers. Since barriers usually mutually reinforce their impact, the 
identification of the root causes of the innovation barriers may assist in their 
elimination or reduction. The causal tree, from left to right, starts with the innovation 
barrier categories, followed by the main innovation barriers and ends with the 
underlying causes.  
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F igure  2 .  I n t eg ra t i on  o f  RCA and  im po r tance  rank ing  o f  med i ca l  
nu t r i t i on  i nnova t i on  ba r r i e r s   

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Figure 3. depicts the point of impact of the innovation barriers on the medical 
nutrition value chain. This gives an indication on the complexity of the impact of the 
barriers to the innovation process, the actors involved, and the barrier interaction. 
Barriers may act one or more stages of the value chain, and their impact may be 
different at their various points of action (128). Of particular interest is the role of 
barriers during the initial stages of the value chain, since inability of an actor to 
overcome them leads to a passive attitude and avoidance of innovation (128). 
Numerical, most barriers have an impact at the final marketing stage of the MN value 
chain. Financial and collaboration barriers exist on three out of six stages of the value 
chain (translational science, product development and clinical research). 






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

F igure  3 .  Po in t  o f  impac t  o f  med i ca l  nu t r i t i on  i nnova t i on  ba r r i e r s  a l ong  
t he  va l ue  cha in   
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
 
4.4.  DISCUSSION 
Our analysis reveals that nine exogenous innovation barriers have the potential to 
interrupt all steps of the MN value chain (fig 3.). These barriers are grouped into five 
categories (ranked according to importance): financial; clinical research; knowledge, 
collaboration and; product related. Industry success and survival is dependent on the 
degree companies incorporate innovation into their organizational strategy. MN 
companies that successfully embrace innovation in their strategy increase their 
chances for company growth and commercial survival. The first step is to 
acknowledge the presence of barriers hindering innovation, followed by 
understanding how to overcome them in order to effectively implement innovation 
practices. Since barriers may be industry-specific, it is important to identify 
innovation barriers specific to the MN industry. In this paper we set out to explore 
the factors that inhibit innovation in the medical nutrition value chain.  
 
During this study we found that the likelihood of translational application of 
innovative knowledge very much depends on a company’s capability of overcoming 
innovation barriers. Academia and industry struggle in collaborating during the early 
stages of the value chain and a lack of financial resources further complicates this. 
Often, challenging and costly clinical research needs to be performed to evaluate 
effectiveness and safety. The ROI of MN products is highly dependent on the 
possibility of obtaining reimbursement for that particular product. This consequently 
depends on the regulatory standards of that particular nation. Deploying public 
affairs for better regulatory guidelines at both clinical research and reimbursement 
level remains challenging considering the un-standardized regulatory practices in the 
EU-region alone. Additionally, a low awareness on the issue of malnutrition and MN 
effectiveness still exists at state/governmental level, limiting reimbursement 
opportunities. Response of both consumers and health care professionals are of 
particular importance at the marketing level. Low awareness here inhibits the 
adoption of innovation.  
 
The present RCA suggests that clinical trial and financial barriers are interrelated. 
We can assume that by solving the root causes of these two barriers, both may be 
solved. The fact that financial barriers are the highest rated barrier is consistent with 
literature (149, 150). However, barriers in carrying out clinical research are MN 
industry specific. MN innovation is predominantly constrained by difficulties 
encountered in practical aspects of clinical research e.g. double blinding and the size 
of patient populations versus the statistical power of the study. 
 
Literature has widely acknowledged that creating a tight network of collaboration 
between industry and academia is an unavoidable part of any innovation strategy 
(151, 152). Although efforts are being made to stimulate collaboration between 
academia and the MN industry (144, 153) this factor remains to be an important 
barrier inhibiting innovation. Much of the tension between industry and academia 
arises from the conflicting desire of academia to perform perfect research, and the 
desire of industry to quickly bring new reliable products to the market (148). One 
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solution is for both industry and academia to remain focused on the needs of the 
consumer as the target for both research and sales. 
 
Consumers and healthcare professionals are commonly rightfully skeptical of 
information coming from industry, a source that stands mainly to make a profit 
(148). This reinforces the importance of collaboration with- and the role for 
academia in providing independent scientific advice and education to healthcare 
professionals and consumers. Consequently, this will lead to a higher awareness 
among healthcare professionals and consumers concerning MN effectiveness. 
 
 Although exogenous barriers cannot be easily influenced at the short-term (128), the 
company can adjust their organizational strategy in such a way so as to overcome 
them. If companies are able to adapt their organizational strategies in such a way, 
they transform these barriers into positive opportunities and develop a unique 
competitive advantage. Organizational strategies to overcome exogenous MN 
innovation barriers could involve: 
 
• Adopting (orphan drug) pharmaceutical-oriented clinical research with 
clear end-points and cost-effectiveness methodologies to set a golden 
medical nutrition clinical research standard thereby also facilitating the 
reimbursement procedure; 
• Higher involvement of academic research institutions to facilitate 
collaboration and reduce investment; 
• Initiating education programs and/or conferences to increase awareness 
among medical staff and government. 
 
Since this study only focused on exogenous innovation barriers from a top-down 
viewpoint, future research should further investigate which endogenous barriers are 
experienced by MN companies. In combination with results from this study this will 
provide a complete overview of all barriers.  
 
As a final note, transparent regulatory legislation at EU level would most likely 
benefit MN innovation. Even though this is challenging to accomplish on the short-
term, the aim of regulatory bodies should be to protect the consumers without 
discouraging innovation. Especially legislation concerning clinical research and 
reimbursement are essential and will most likely eradicate numerous MN innovation 
barriers currently experienced within the industry. However, new regulations will 
most likely also create significant new barriers. By establishing MN clinical 
guidelines, all MN products have to comply to the same set of (compositional) 
guidelines, even though the products target patients with very specific and deviating 
nutritional needs. This may force industry to deliver the cheapest possible product 
complying with guidelines instead of a radical innovation. Apart from non-technical 
factors such as market and economic forces, food sciences and nutritional 
technologies are also considered primary drivers of the food industry. Challenging 
external environments offer opportunity but also require firms to become more 
innovative to succeed. MN companies must therefore realize that investment in 
innovation is and remains crucial. 
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Our results provide insights for existing but also starting MN companies attempting 
to innovate. Understanding these MN innovation barriers can aid the innovation 
process and development of firm strategies and government policies that contribute 
to economic growth, job creation and increased wealth. Especially in an industry 
with such high social values, innovation benefits everyone: from economic value for 
industry and government to social value to patients. 
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PATENTING IN THE EUROPEAN MEDICAL 
NUTRITION INDUSTRY: TRENDS, 
OPPORTUNITIES AND STRATEGIES 
 
 




















Published as: 
Weenen TC, Pronker ES, Commandeur HR, Claassen E (2013) Patenting in the 
European medical nutrition industry: Trends, opportunities and strategies. 
PharmaNutrition 1: 13-21. 
 66 
ABSTRACT  
 
Medical nutrition products are specific nutritional compositions for intervention in 
disease progression and symptom alleviation. This industry finds itself on the 
interface between the food and pharmaceutical industry and even though it represents 
one of the fastest growing segments within the health and life sciences, it is still a 
relatively unknown industry. At present, insights concerning industry development 
and patenting in the European medical nutrition industry are limited. This research 
presents a systematic patent portfolio analysis of the industrial patenting trends and 
patenting strategy categorization of the 5 leading companies.  
 
Focusing on EU patent applications, we calculated company specific patent-, 
product- and market shares and average forward- and backward- citations. These 
indicators were combined to illustrate the European medical nutrition industry trends 
and company specific patent- and innovation- strategies. We found 222 European 
medical nutrition patent applications between 1990 up to 2010 with company 
specific patent shares ranging from 1-58%.  
 
The analysis of the industry trends shows that the industry currently resides in the 
growth phase and is estimated to reach the stage of maturation within two years with 
approximately 400 patents. Predominantly neurological diseases, cancer and diabetes 
show opportunity for future MN innovations while gastrointestinal and infection 
related diseases may have already reached a market saturation stage. Only three 
distinct patent strategies can be distinguished within this industry: the Prospector; the 
Analyzer; and the Reactor. 

 
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5 .1 .  INTRODUCTION  
Knowledge is the key ingredient in every innovation-driven industry. Knowledge 
and innovation are clearly imperative for creating a sustainable competitive 
advantage (154). At the start of the invention process, novelty and creativity lead to a 
product innovation (155, 156). It is crucial for companies to protect new assets in 
order to remain competitive and valuable in the competitive market environment. 
 
There are various legal intellectual property instruments aimed at excluding the 
competition for a specified period of time. Such measures are perceived as rewarding 
for the inventor for developing new knowledge, while additionally providing the 
opportunity to commercially exploit it. By strategically combining various 
Intellectual Property (IP) methods, optimal protection of the innovation can be 
achieved (157). 
 
In the health and life science industry, patents are considered valuable instruments 
for protecting innovations. Although a costly endeavor, patenting is considered 
essential because of a twenty-year exclusivity period (158, 159). During this time, 
the applicant may recover the high investments incurred during research and 
development through premium product pricing or receiving royalties. The (financial) 
benefits of patenting are optimally exploited before expiration, after which the 
market value of the innovation decreases. As a result, companies adopt numerous 
other strategies for extending the protection life-time of an innovation.  Nevertheless, 
the decision to patent remains complex (160). 
 
The European (EU) Medical Nutrition (MN) industry is relatively new within the 
historical scope of the health and life sciences and represents one of the fastest 
growing segments within this sector. This industry finds itself on the interface 
between the food and pharmaceutical industry with its own Foods for Special 
Medical Purposes (FSMPs) regulations (161). MN products are prescribed food 
compositions that consist of targeted nutritional compositions for intervention in 
disease progression and symptom alleviation. The EU MN industry is led by 5 
companies: Abbott Nutrition, B Braun, Danone (Nutricia), Fresenius Kabi and 
Nestle. This industry is perceived as an industry in an early development stage. In the 
case of the MN industry, its growth is most likely attributable to an increase in 
societal awareness on the functional health benefits of nutrition. 
 
Thus, the growth is driven by an expanding body of knowledge which demonstrates 
the benefits of nutritional intervention on improving and supporting an individual’s 
health status (58). Since the EU MN industry is a relatively new industry, academic 
insights into the industry development and innovation protection strategies are 
lacking. This paper presents MN industry trends, innovation opportunities and patent 
strategies thereby aiding both industry as well as academia in their search for new 
research and business opportunities. By completing a patent analysis at an industry 
and company level for the EU MN industry, we aim to: 
 
1. At industry level: analyze and compare patents applied for by the main 
competitive MN companies, thereby providing an industry patent landscape. We 
look at the stage of maturity the industry finds itself in within the technological 
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life cycle and at disease areas that offer possible product innovation 
opportunities. 
2. At company level: evaluate company specific patent indicators with which to 
categorize the MN companies’ patenting strategies. 
Background in format ion 
As an industry emerges, IP protection mechanisms are yet undefined. However, 
companies may have different motives to patent and therefore may employ diverse 
patenting strategies (160). The decision to apply for a patent can be influenced by the 
degree of technology or knowledge innovation, ranging from incremental, to radical. 
Incremental inventions consist of minor improvements or adjustments to existing 
inventions or technologies. Radical inventions exhibit key characteristics that are 
inherently different from existing inventions or technologies. The latter type is 
considered to form a crucial basis from which subsequent incremental developments 
may evolve (162, 163).  
Patent applications describe in detail the date and nature of the invention, inventor, 
the applicant, and are categorized according to a complex system of international 
patent codes (IPCs). Data is readily available, organized in discrete categories and 
can be disaggregated to specific technological areas recognized through the IPCs 
(110). This research is based on patent applications; whether or not a patent is truly 
granted is a process that will take several years. 
 
Moreover, patents can be analyzed based on citations. Citations of the patent are 
allocated by the examiner in the patent application file, and indicate the history of 
related inventions. These patent citations are often used in patent analyses. Two 
types of citations exist: backward and forward citations. The former refers to the 
number of previous patents as an indicator of related preceding knowledge on which 
the new patent is based. The average number of backward citations in a patent has 
proven to be related to how radical or incremental an invention is. For example, 
patents with lower numbers of backward citations are considered to refer to radical 
inventions. Forward citations indicate the frequency of a newer patent application 
citing the original patent application. It serves as an indicator for the economic value 
of the patent and the technological importance of the invention  (98, 102, 164). In the 
European Patent Office (EPO) system, the patent applicant may include citations to 
prior patents, but ultimately it is the patent office examiner who determines which 
citations are included in a patent. Therefore, the patent citations are considered to be 
unbiased and trustworthy patent indicators (165). 
To perform this study, different patent indicators and company specific 
characteristics such as market- and product share, are combined. By using this 
information in a patent portfolio analysis, one can identify industrial developmental 
trends and patent strategies on industry level as well as at the company level (166-
169). This study combines different types of publicly available information to look at 
the EU MN industrial trends and the companies’ patenting strategies through a patent 
portfolio analysis.   
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5 .2 .  MATERIALS AND METHODS 
The method of this patent portfolio analysis is based on methods by Chen, Ernst and 
Tseng (79, 98, 169) . The patent portfolio analysis (Fig. 1) is based on the five 
leading companies according to market shares of the EU MN industry: Abbott 
Nutrition, B Braun, Danone (Nutricia), Fresenius Kabi and Nestle. The analysis is 
divided into two parts; starting off with analyzing the industry-level development 
trends. The industry is evaluated based on the timeline of patent applications and the 
disease areas the patent targets. Subsequently, patent strategies at company-level are 
defined. Data on company characterization (patent-, product-, and market share) and 
company-level citations (forward- and backward-citations) is collected in order to 
systematically categorize the company strategies. 
 

F igure  1 .  Resea rch  f r am ework  o f  t he  pa ten t  po r t f o l i o  ana l ys i s  i n  t he  
Eu ropean  MN i ndus t r y :  1 .  Company - Leve l  Pa ten t  S t ra teg ies  2 .  
I ndus t r y -Leve l  T rends .   


 

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Patent  Search 
Data on patent indicators was retrieved from the Derwent Inovations Index. 
pertaining to the European published patent applications (EP) between 1995 and 
20102. Furthermore, two different search fields were combined: assignee (patent 
applicant) and international patent code (IPC). The former search field refers to the 
five selected companies. Correct IPCs were obtained from the classification database 
at the Espacenet portal3: A23L0014 in combination with A61K031/035/0455. Only 
compositional patents, publishing nutritional compositions of MN: tube feeding (TF) 
and oral nutritional supplement (ONS) were selected, as based on the definition 
provided by the ESPEN Guidelines on MN (28). We did not filter between pending, 
granted and rejected patents. 
 
Indust ry- leve l  Data 
The first step in revealing the industry-level developmental trends in the MN 
industry was to create a patent application timeline. According to Ernst, 
technological change within an industry follows a certain pattern with different 
development stages (79). Logically, four stages within the technological life cycle 
are identified, those being; Emerging, Growth, Maturity and Saturation (Fig 2). For 
the MN industry we created such a timeline of cumulative patent applications 
between 1995 and 2010. 
 
To complete the characterization, the marketed products, patent application and 
prevalence of malnutrition were segregated into 9 different disease areas: cancer, 
gastrointestinal, infection, neurological, respiratory, dementia, heart and coronary, 
genitourinary and renal, and diabetes (28). 
 
Recent large-scale multi-center surveys consistently show that malnutrition risk is 
common across many disease areas in hospitals. These studies indicate the 
prevalence of malnutrition among patients with a wide variety of diseases (55, 58, 
170). The division of these disease areas is also applied to the EU MN industry 
products and patent applications. These marketed European MN products were 
extracted from the MN company websites. Different flavors were not taken into 
account as separate products. 
 
Company- leve l  Data 
To compare the patent indicators to specific company characteristics: patent shares, 
product shares and market shares were calculated (Table 1). The product shares were 
calculated with data from company websites on product information. Market shares 
are determined based on revenue information from the companies’ annual reports 

2 It should be noted that since conventional patents are usually classified and published within 
eighteen months after filing, the patent record set covering 1990 - present might not be complete.  
3 http://v3.espacenet.com/eclasrch?locale=nl_NL&classification=ecla 
4 A23L001: foods or foodstuffs; the preparation or treatment. 
5 A61K031/035/045: pharmaceuticals. 
 71 
and were later confirmed by the companies. Market shares are solely based on the 
companies’ revenue figures of MN products in Europe in 2009. By plotting the 
different company characteristics in a 3-dimensional graph, the MN companies were 
classified based on three dimensions: patent share, product share and market share. 
The dependent variable in the determination of the companies’ patenting strategies 
was patent share, and the independent variables were the average backward citations 
and average forward citations, while the control variables were the product share and 
market share. By combining the patent indicators, company characteristics, we were 
able to define the MN companies’ patent strategies.   
 
This study took all European filed patent applications into account that met the 
search criteria, even though not all patent applications end up as an actual granted 
patent. As this fell beyond the scope of the research objective, we did not analyze 
this criterion. 
 

  
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5 .3 .  RESULTS 
The patent search revealed 222 eligible patent applications. 
5.3.1 .  Indust ry  Leve l  Deve lopment  Trends 
We assumed that the MN industry, just like any other industry (79), follows a certain 
technological development pattern. Figure 2 illustrates this development of 
cumulative patent applications and confirms that the MN industry does indeed follow 
the standard development pattern and currently resides in the growth phase.  
 

F igure  2 .  Cumu la t i ve  i ndus t r y  l i f e  cyc l e  deve lopmen t  ( adap ted  f r om:  
E rns t  1997 ) .  Wh i t e  c i r c l es  i nd i ca te  t he  t echno log i ca l  deve lopmen t  o f  
t he  EU  EN i ndus t r y  be tween  1995  and  2009   
 
 
 
 
 
 
Number of patents, products and the prevalence of malnutrition were calculated 
across 9 different disease areas. We classified the disease areas into 4 groups (A-D) 
according to prevalence of malnutrition, number of patents and number of products. 
These 4 groups characterize EU MN industry niches that reside in different stages of 
innovation development (Table 2, Fig 3). 



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Tab le  2 .  Disease  g roup  c l ass i f i ca t i on   
 
Group Malnutrition Patents Products 
A High Intermediate Intermediate 
B High Intermediate High 
C Intermediate High High 
D Low/Intermediate Low  Intermediate 

 


F igure  3 .  Unme t  needs  and  i nnova t i on  oppo r t un i t i e s  i n  t he  EU  MN 
i ndus t r y  –  Pa ten t  vs  P roduc t  vs  P rev a lence  o f  Ma lnu t r i t i on  –  t he  bubb le  
s i ze  i nd i ca tes  t he  p reva lence  o f  ma lnu t r i t i on  acco rd i ng  t o  d i sease  a rea  
i n  hosp i t a l s  (MNI ,  2010 )   
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Group A – “Oppor tun i ty  N iche”  
This market niche can be defined as a niche with a high unmet medical need due to a 
high prevalence of malnutrition, and an intermediate number of patents and products. 
Therefore the disease area “cancer” may offer future innovation opportunities for 
MN companies developing MN products. 
 
Group B – “Low Hanging Fru i ts ”  
With a very high prevalence of malnutrition among patients in this disease area and 
many products for these patients, this market niche seems quite saturated. 
Additionally, an intermediate number of patented inventions can be observed 
possibly indicating that MN compositions in this niche are either difficult to be 
patented or unnecessary since the compositions are not unique. This is an easy-to-
access niche where patenting is not necessary and with a high patient need. However, 
competition is also fierce in this niche.  
 
Group C – “Future  Defense”  
This seems to be a relatively saturated market niche with a high number of patients 
suffering from malnutrition but also with a high number of patented inventions and a 
high number of marketed products. 
 
Group D – “Latent  Oppor tun i ty  Segment”  
Although the prevalence of malnutrition and thus medical need of most disease areas, 
except neurological diseases, in this group is relatively low compared to the other 
disease areas, the number of patents and products are correspondingly low. This 
results in an opportunity niche which offers MN companies some innovation 
opportunity. Especially for new Small and Medium Sized Enterprises (SMEs) these 
disease areas may be of opportunity interest since there are few patents and marketed 
products and thus a low level of competition with the big nutritional companies.  
 
Overall these results show that there are many niches which yield innovative 
capacity in the emerging EU MN industry both to the larger nutritional companies as 
well as to the new SMEs. 
 
5.3.2 .  Company Leve l  Patent  St ra teg ies 
The number of patent applications differs substantially between the 5 leading 
companies, ranging from a patent share of 1-58% (Table 3).  




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Tab le  3 .  Company  spec i f i c  desc r i p t i ve  pa ten t  ana l ys i s  r esu l t s   
 
 Type 1 Type 2 Type 3 
 Company A Company B Company C Company D Company E 
Patent Indicators 
Patent Share (%) 58 22 17 2 1 
Average Backward 
Citations  
(Radical < Incremental) 
16 31 27 13 11 
Average Forward Citations  
(Low value < High value) 
5 20 12 5 11 
Company Characteristics 
Product Share  (%) 59 13 10 15 3 
Market Share  (%) 45 17 37 8 1 

 

Even though empirical evidence suggests that 66-87% of firms’ inventions are 
patented (171) this has not been observed in our data set describing the MN industry. 
Our results show that patent strategies for the five leading companies differ 
extremely (Table 3).  
 
When evaluating the company-level patent strategies, the data reveals three distinct 
company behaviors. Figure 2 depicts the company classification by means of a 3-
dimensional graph based on three dimensions: patent share, product share and market 
share. The X-axis of the classification in this study shows the patent share, the Y-axis 
the product share and the Z-axis the market share. The characteristics of company 
Type 1 include: high patent share, high product share and a high market share, 
describing only company A. Type 2 company characteristics display an intermediate 
patent share, intermediate product share and an intermediate market share, including 
companies B and C. The characteristics of Type 3 companies are: a very low patent 
share, a low product share and a low market share, describing companies D and E.  
 
 
 
 
 
 
 
 
 
 
 
 
 

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F igure  4 .  Company  c l ass i f i ca t i on  acco rd ing  t o  t he i r  pa ten t - ,  p roduc t - ,  
and  marke t  sha res .  Th ree  t ypes  o f  compan ies  can  be  d i s t i ngu i shed :  
T ype  1 ,  T ype  2  and  T ype3 .   

 
 
To further characterize the companies, average backward citations and average 
forward citations are taken into consideration and the 5 companies are plotted in 
Figure 5.  
 
• The X-axis of the patent strategy classification displays the patent shares of 
the EUMN companies. 
• The Y-axis in this figure is the average backward citations of each company’s 
patents. The company specific average backward citations are an indication 
of how radical a company’s inventions are. The lower the number of 
average backward citations, the more radical the inventions are considered 
to be. 
• The Z-axis is the market share of the companies, indicating the market share 
the company holds in the EU MN industry.  
 
The cube graph is divided into 8 spaces in Figure 3. The 5 EU MN companies fall 
within only 3 quadrants and are divided into category 1, 2 and 3. In Figure 5, 
identical company clusters are exhibited as in Figure 4, thus displaying three 
different patent strategies across the same clusters. The average forward citations are 
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not displayed in the figure but are also taken into consideration. The different 
clusters are described and further elaborated on. 
Type 1  
This cluster is characterized by the highest patent, product and market shares 
indicating a dominant position in the EU MN industry (Fig 5c). Furthermore, 
company A has relatively low average backward citation counts, meaning its 
inventions are radical, and low average forward citation counts, indicating low values 
of its inventions. There are two explanations for these observations. First; the 
company patents all of its radical inventions. Since the citation results indicate that 
many of its inventions appear to be radical but may turn out to be of an overall low 
value. Overall, radical inventions are of high risk and therefore may turn out to be of 
low value thus explaining this pattern. Second, the company could be applying an 
“offensive blocking” patent strategy. This entails the building of a wall of patents 
surrounding the few crucial core patents, keeping the competition at a distance (157). 
Since some patented MN compositions may be difficult to protect from competition, 
this may be applied by Type 1 company within the MN industry. 
Type 2  
The Type 2 EU MN companies (Fig 5d) are characterized by intermediate patent-, 
product- and market shares indicating a stable position within the industry. The 
inventions patented by these companies are typically incremental with high value as 
observed in companies B and C in Table 2. This is an indication that in the EU MN 
industry, incremental inventions can be of high value and therefore also worth 
protecting and commercializing. Reasoning behind this strategy is most probably a 
“defensive blockade” to prevent the competition from imitating the invention (157). 
Type 3  
The final cluster of companies, Type 3 (Fig 5e), exhibit low patent, product and 
market shares in the MN industry. Their citation patterns indicate their patents to be 
radical but of low value. Although this citation pattern is similar to the Type 1 
citation pattern, the Type 3 companies have very different company classification 
indicators and therefore a different explanation exists for their citation pattern. It is 
assumed the combination of company characteristics with citations data indicate 
these radical patents may be used as a marketing tool.  
 
While using the EPO database we encountered one inherent problem. This has to do 
with the number of forward citations received by a patent. Older patents have a 
higher chance of receiving forward citations, simply because the period over which 
the citations are counted is longer compared to younger patents (162). 
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
Figure 5. Patent strategy classification according to patent share, average 
backward citations and market share. Figure 5a shows where the 5 largest EU EN 
companies (A,B,C,D and E) are plotted in the cube graph. Three distinct patent 
strategy clusters can be identified. Figure 5c: Group 1. Figure 5d: Group 2. Figure 
5E: Group 3. 

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5 .4 .  DISCUSSION & CONCLUSIONS 
Conclus ions 
The company specific patenting strategies show that while some EUMN companies 
use patenting for its original function to protect the company’s inventions, others 
patent to block competition or even deploy this IP method as a marketing tool. These 
observed patenting differences might be explained by the original roots of the 
EUMN companies. Some EU MN companies originate from the food industry while 
others originate from the pharmaceutical industry. The patenting trends in these two 
industries differ tremendously and therefore most probably influence the patent 
strategy choice within the EUMN industry. The growth rate of MN patents is the 
same as for other industrial life cycles and will lead to maturity in 2-3 years. 
 
The results of the industry development trends suggest that the MN industry shows a 
growth rate in the quantity and type of patent applications, implicating sufficient 
innovation opportunities. Based on our patent analysis, the MN industry is best 
described as being in start-up growth phase. The industry is forecasted to reach the 
stage of maturation by 2014 with approximately 400 patents (Fig 2). Nevertheless, 
while certain disease areas show growth opportunity for future MN innovations (e.g. 
cancer, diabetes and neurological diseases), others may have already reached a stage 
of market saturation (e.g. gastrointestinal and infection related diseases). 
 
Discuss ion 
Even though patenting is seen as an important tool in the technological strategies, in 
the EU MN industry patenting has proven to be of variable importance to the five 
key players. The dataset reveals incoherent patenting behavior across industry-level, 
whereby certain companies seem to simply patent all their inventions while others 
only patent their (rare) radical inventions. Previous research confirms this irregular 
patenting behavior in other life sciences industries where it was observed that 
patenting was proven to be an ineffective intellectual property protection strategy 
(172, 173). Therefore, if a company is willing to forgo patenting for mere freedom to 
operate, other IP methods may also be effective.  
 
The high frequency of incremental inventions in the MN industry appears to be a 
similar trend as what has been demonstrated in the pharmaceutical industry where on 
average more than half (51%) of all FDA approved drugs are incremental 
innovations (174). Although beyond the scope of this research, we expect this to be 
similar in the MN industry with more introductions of incremental than of radical 
innovations. Another similarity between these two industries is the high value of 
incremental inventions within the MN industry just as in the pharmaceutical industry 
(174). The low value of many radical MN inventions, a result of this research, may 
be explained because radical inventions are often high risk and only a few will result 
in a marketed product and yield a profit while the rest fails.  
 
At company-level, the three patenting behaviors conform to the business strategy 
typology framework as published by Miles et al. (1978) (175).  This analysis 
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framework can be applied to organizations as an integrated and dynamic whole. This 
framework essentially defines four strategic types of organizations: Defenders, 
Analyzers, Prospectors and Reactors. Each type has its own unique strategy. Three of 
the typologies fit our observations of the EU MN companies: the Prospector; the 
Analyzer; and the Reactor. 
TYPE 1 –  The Prospector  
MN companies classified under type 1 are best describes as prospector companies. 
The Prospector’s leading capability is that of finding and exploiting new product and 
market opportunities. This type of company’s priority lies in maintaining a reputation 
as an innovator in product development. Company type 1 clearly exhibits a very low 
average number of backward citations as an indicator of radical innovativeness. For 
the prospector, maintaining a reputation as an innovator in product and market 
development may be as important as high profitability. Due to the inevitable “failure 
rate” associated with radical innovations, it may be difficult to attain high 
profitability on all the innovative products [29]. This may be the explanation of the 
low value of patents in Company Type 1; as a result of the high attrition rates, such 
patents are regarded as less valuable to competitors 
 
As a result, the prospector can resort to an offensive patent strategy. By building a 
wall of patents around the core-innovation, the prospector intends to fully benefit 
from market exclusivity. Especially in the MN industry it may be difficult to protect 
a proprietary MN composition and it may therefore be advisable to build such a 
protective wall of similar patents around the main valuable patent to prevent 
imitation from competitors. 
TYPE 2 –  The Analyzer  
Type 2 MN companies display the characteristics of “The Analyzer”. An analyzer 
company moves toward new products or new markets but only after viability has 
been demonstrated. This may be accomplished through imitation or incremental 
innovation – only the most successful product innovations developed by other 
companies are adopted. At the same time, the majority of the Analyzer’s revenue is 
generated by a fairly stable set of products and customer groups. This type of 
organization must learn how to achieve and protect an equilibrium between 
conflicting demands for technological flexibility and for technological stability 
(Miles et al. 1978) [29].  
 
Results show that incremental inventions in the MN industry are generally of higher 
value than the radical inventions. This proves that patenting incremental inventions 
with this company-level strategy may result in a high return on investment (ROI).  
TYPE 3 –  The Reactor  
The final type of organization exhibits a pattern which usually consists of responding 
inappropriately to environment change and uncertainty. As a consequence companies 
within this group exist in a state of almost continuous instability. This type of 
strategy usually arises when one of the other three strategies is improperly applied. A 
reason for developing such a strategy may be that management does not fully shape 
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the organization’s structure and processes to fit a chosen strategy. Another reason 
may be the tendency of a company’s management to maintain the organization’s 
current strategy-structure relationship despite overwhelming changes in 
environmental conditions. Unless a company operates in a monopolistic industry, it 
cannot continue to behave as a Reactor indefinitely. Since the EU MN industry can 
be defined as an oligopolistic market and not a monopolistic market, this inclines that 
the type 3 companies will have to alter their strategy to a more stable strategy to stay 
profitable.  
 
For this type of company it also appears that they apply the strategy of using its 
patents as a marketing tool, a novel approach applied in several industries. It entails 
that companies use their patents to promote their novel and radical inventions to set 
the product apart from other products in the market (176). In the MN industry case, 
this marketing technique will be targeted at the medical professionals prescribing the 
MN to the patients. A patent may provide the customer with the confirmation of the 
effectiveness of the MN product especially if this product is based on a radical and 
therefore relatively unknown invention. In the case of the MN industry, companies 
may use the term “proprietary composition” or the patent number to convince 
medical professionals to prescribe their products to patients.  
This research is based on  “composition of matter” patents. A suggestion for future 
research is to also take into account the “technological” patents. This is because 
“technology” patents are often applicable in different industries and therefore not 
specific for the MN industry. Additionally, there is no standardized IPC code for 
MN. Since the MN industry is a fast-growing industry it would therefore be 
advisable to the European Patent Office to create such a code. 
 
Overall, this study illustrates the EU MN industry can be characterized as an 
inventive and fast developing market dominated by 5 large nutritional companies 
with 3 different patent strategies. With such optimistic future prospects, 
understanding of the most applicable methods for protecting IP would aid both the 
academic as well as the industrial sector. This paper presents the first systematic 
analysis of industry trends and patenting activities in the EU MN industry in order to 
provide both academia as well as industry with an overview of this emerging 
inventive market. 
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CHAPTER 6   
A DECISION FRAMEWORK TO EVALUATE 
INTELLECTUAL PROPERTY STRATEGIES IN THE 
MEDICAL NUTRITION MARKET 
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
ABSTRACT  
 
In the medical nutrition (MN) market, insights into the motives driving intellectual 
property (IP) protection strategies remain unclear. This emerging market has 
expressed the pressing need for clarity on the subject of applicable IP methods. The 
aim of this study is therefore to evaluate the role of patents and alternative IP 
instruments for the protection of innovations in the MN market, and to construct an 
IP decision framework facilitating IP selection. Data collection consists of a 
literature study on the topic of IP strategies, combined with a supplementary 
questionnaire sent out to MN companies.  
 
Although there are many different strategic motives to apply for a patent in the MN 
market, the classic protective motives prove to be most important. While our findings 
acknowledge that patenting is of paramount importance to this industry, different 
scenarios call for combining the various IP methods for the optimal protection of the 
MN innovation. One must therefore always carefully consider additional IP rights. 
Our IP decision framework provides both MN companies and academic R&D 
departments with a tool to assess the best applicable IP strategy for the protection of 
MN inventions.  
 
 
  
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6 .1 .  INTRODUCTION 
To protect an invention, one must consider employing different types of available 
intellectual property (IP) methods. The type of IP that has received the most attention 
and has been subjected to vigorous study is the patent. A patent protects new and 
useful inventions and provides the applicant with a granted 20-year period of 
exclusivity in return for complete disclosure of the invention (160, 177-181). 
In the health and life sciences sector, patents are considered essential instruments for 
protecting innovations. A relatively new and emerging industry within this sector is 
concerned with medical nutrition (MN) (182). MN deals with the prevention and 
treatment of malnutrition related disorders that arise due to either inadequate or 
improper diet, or underlying diseases whereby the body is unable to handle certain 
essential nutrients (7). MN counteracts this nutrient imbalance either through tube 
feeding or through the administration of oral nutritional supplements. MN products 
are perceived as “borderline-products” on the interface of the food- and the 
pharmaceutical- industry but with their own Foods for Special Medical Purposes 
(FSMPs) guidelines (7).  
Within the European MN industry, patenting has proven to be important. Previous 
research has demonstrated that MN companies adopt different patenting strategies 
with knowledge concerning the driving forces and motives to patent in the MN 
market still lacking (182). There is also an explicit need expressed by the MN market 
for clarity in their search for suitable IP methods in this industry [interviews with 
KOLs].   
The present paper adds to the existing body of knowledge on patenting and other IP 
methods by investigating IP strategies and motives to patent specific to the MN 
market. Through questionnaire analysis, the factors that are considered to be 
important in the decision to patent in the MN market are revealed. This knowledge is 
then combined with results from a literature study to construct an IP decision 
framework supporting MN companies but also R&D departments in their IP strategy 
decision processes. The framework is meant to serve as a helpful tool, which can 
assist MN companies and R&D departments in shifting from unclear IP situations to 
clear cut decisions regarding the strategy of choice. The objective of the study is to 
provide smaller and larger MN companies and R&D departments with a decision 
framework to assess the best applicable IP strategy to protect their market position. 
This framework assists both industry and R&D departments involved in MN R&D 
by protecting their inventions and evaluating project-licensing possibilities. 
Background in format ion 
In te l lec tua l  Proper ty  Rights 
Internationally recognized IP rights for protecting inventions include: trade secrets, 
copyrights, brands/trademarks, and patents (Table 1) (157). Despite their 
commonalities, each IP has its own rules and standards which differ between 
countries, based on the international standards published in the TRIPS agreement 
(183). Trade secrets are regarded as valuable information that is kept secret within a 
company because it provides an economic advantage over other companies. 
Obviously, the length of a trade secret’s lifespan is equal to the duration to which the 
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information is kept hidden from the competition, but the costs of keeping the secret 
can be very high (184). 

Tab le  1 .  Summary  o f  t he  d i f f e ren t  ava i l ab l e  IP  me thods  and  t he  use  
t he reo f  (157, 185) 
 
 
 

 
IP Method Protection Subject of 
protection 
Scope of rights Duration Costs 
 
Trade 
secret 
 
Information 
that has 
commercial 
value to 
protect 
secrecy  
 
 
Product formulas, 
chemical 
compounds, 
blueprints, 
dimensions, 
tolerances, 
customer lists, 
suppliers, financial 
information  
 
 
Prevents disclosure 
or acquisition by 
dishonest means, or 
use of the secret 
information without 
permission 
 
As long as 
information 
remains 
secret 
 
None 
Trademark Identifying 
signs and 
symbols 
Words, personal 
names, letters, 
numerals, 
figurative, 
elements, and 
combinations of 
colors, symbols or 
other devices used 
to distinguish 
goods or services 
 
Excludes others from 
using the mark 
Generally 
10 years 
from 
registration, 
renewable 
indefinitely 
for 
additional 
10 year 
terms 
 
Low 
Copyright Original 
expressions  
of 
authorship 
Works of 
authorship, 
including writings, 
books, papers, 
photographs, 
music, art, 
recording, 
software 
Prevents others from 
reproducing or 
distributing copies; 
preparing derivative 
works; performing or 
displaying the work 
publicly; and 
transmitting sound 
recordings 
 
At least 50 
years from 
publication 
in US 
None 
Patent Useful, new 
and non-
obvious 
processes 
and 
products 
Machines, articles 
of manufacture, 
and composition of 
matter, chemical 
compound, 
processes 
Excludes others from 
making, using, 
selling, offering to 
sell, or importing the 
patented invention, 
as defined in claims 
issued in a particular 
country 
 
20 years 
from filing of 
the patent 
application. 
High 
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Copyright (©) protects work of authorship. These innovations are generally 
expressed in a tangible medium and can remain in the copyright domain for at least 
50 years from publication. Trademarks (™) give the right to identify goods or 
services using that trademark and to exclude others from using it. A trademark lasts 
10 years from registration and can be renewed for an additional 10 years (157). 
Lastly, a patent gives the inventor the right to exclude others from producing, using, 
selling, offering to sell, or importing the invention without permission and has a 
statutory duration of 20 years (157, 186). Within industrial patent strategies, an 
increasing event is the patent (application) lapse. The lapse of a patent right occurs 
when an official deadline has been missed (187, 188).  When a patent (application) 
has lapsed, other companies are no longer able to apply for a similar patent since 
prior art has been created. Thus, a company may strategically apply the patent lapse 
to prevent competition from patenting the same invention. 
 
Patents are not always effective and a number of studies have shown cases where 
patenting is ineffective (172, 173, 179). Therefore, if a company is willing to forgo 
patenting for mere freedom to operate, using copyright as defensive publishing is 
more attractive. More specifically, defensive publishing is the publication of an 
invention with the purpose of creating prior art. Thereby, preventing patents being 
granted for this specific invention (189). 
Patent  mot ives  
The initial purpose of a patent is to provide companies with the exclusive right to 
commercialize a patented invention. However, in addition to their initial purpose to 
protect, patents can be employed in various other ways of which some are considered 
as strategic motives (160, 190, 191) (Table 2). These strategic motives are more 
important with respect to patenting-products than for -processes. Patent strategies 
can be categorized into two main types; offensive- and defensive blockage. 
Companies patent offensively to prevent other companies from using their inventions 
in the same, similar or related fields of application. As a result walls of patents can 
be built around the invention, not intended to be used, only to protect the actual 
invention also known as a patent thicket (160). Defensive blocking is patenting an 
invention to prevent other companies from patenting their inventions and suing it for 
infringement. Even if the company doesn’t need the patent on this invention to 
receive a return for profit (191).  In addition to these two motives, studies have 
demonstrated that additional strategic motives exist, including: to reward R&D 
personnel, generation of licensing income, to exchange potential (in,-out,- cross-
licensing), international market extension, improve company value and image, and to 
prevent infringement lawsuits (173, 178). Over recent years, the patent has 
developed another important economic potential that is to use it as a marketing tool. 
Nowadays patents are being deployed as convincing devices for communicating a 
unique product innovation, setting it apart from other products in the market. Patents 
as a marketing tool are first and foremost used in patent product advertising, where 
patent numbers or claims such as “proprietary product” are used in a product 
advertisement (192). 
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A recent questionnaire by Blind et al. (160) analyzed the motives to patent and 
grouped the various motives in different clusters: 1. Protective motives: protection 
from imitation and safeguarding markets, 2. Blocking motives: blocking competitors 
defensively and offensively, 3. Reputation motives: improvement of technological 
image and increase in company value, 4. Exchange motives improved access to the 
capital market, exchange potential and licensing income and 5. Incentive motive: 
motivation of staff and internal performance indicator. More research on motives to 
patent has been conducted by the PatVal EU project on European inventors (193). 
This study shows that smaller companies more often license their patents to third 
parties, when compared to larger companies.  
Mot ives not  to  patent  
Some inventors regard their inventions as not patentable and there are several 
reasons that may lead companies to forgo patent protection. These motives are: 
Patent provides weak protection for that specific case; Product does not meet patent 
requirements; High costs of acquiring and enforcing a patent and fear of disclosing 
valuable trade secrets (181). Currently it remains unclear what the value of patenting 
holds for the MN market. 
IP  dec is ion f ramework 
In 2002, Daizadeh et al. propose a user-friendly approach for assessing the best 
overall legal and business strategy to protect a company’s invention (194). This IP 
decision framework is tailored to companies operating within the biotechnology 
industry. Biotechnology also falls within the scope of the health and life sciences 
sector, but possesses other characteristics to those of the MN industry. An example is 
that the development of a product in the biotechnology industry usually revolves 
around a single-compound with a specific target whilst MN products are multi-target 
nutritional therapy products. Other differences are the lower profit margins in the 
MN industry and the mandatory clinical trials in biotechnology but not in MN 
product development. These differences all influence a lower applicability of 
Daizadeh’s IP decision framework in the MN industry. In addition, Daizadeh et al. 
only take three possible IP methods into account: patent, trade secret and defensive 
publication. This framework excludes the possibility to utilize a trademark and patent 
lapse as an IP method. Therefore this IP decision framework can be used as a 
foundation for a MN specific IP decision framework and additional information 
gathered through extensive questionnaires will complete the framework. 
6.2.  MATERIALS AND METHODS 
6.2.1 .  Quest ionnai re  
Admin is t ra t ion o f  the quest ionnai re  
In this descriptive quantitative research, data was collected through an email 
questionnaire. Respondents were selected based on their employment position within 
the MN companies based in the EU and US. Ultimately, questionnaires were sent out 
industry wide to 14 relevant professionals working in a research and development, 
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intellectual property or management position. The questionnaire was created and 
distributed through the online web questionnaire program, SurveyMonkey. Follow-
up emails and phone calls were used to increase response rates.  
Quest ionnai re  Des ign 6  
Taken that a firm’s patent strategy is sensitive information, therefore data was 
collected through an anonymous online questionnaire. The questionnaire consisted of 
both open and closed questions. The questionnaire was built up of three parts. First, 
general questions concerning the use of IP methods within the MN industry were 
asked (3.1), then the motives to patent were examined (3.2&3.3), followed by 
questions concerning important factors in the decision to patent (3.4). The 
respondents were asked to provide information regarding their employing company’s 
patenting strategies: the company’s motives to patent (or not) and the relative 
importance of different IP methods. In the research by Blind et al. (160), the motives 
to patent were divided into various groups: protecting motives, blocking motives, 
reputation motives, exchange motives and incentive motives. 11 different motives to 
patent and 7 motives not to patent were introduced to the respondent in the 
questionnaire. For these questions, respondents were asked to rank the importance of 
these motives on a 5-point Likert scale (not relevant, to very important). A few 
questions required yes/no answers or percentages. For the majority of the questions, 
the respondents were asked to explain their answers in more detail. Table 3 
summarizes the types of questions that were included in the questionnaire.  
Analys is  
By means of weighted ranking, the importance of the IP methods, motives to patent 
and motives not to patent are calculated (141). Each score was multiplied by the 
weight for the respective criterion (Very important = 5, Important, Not relevant = 1). 
The sum of these weighted scores divided by the number of respondents reflects the 
average weighted score. Since there are only a limited number of active MN 
companies, statistical analysis could not be performed to seek out any differences 
between SMEs and large MN companies. The results of this questionnaire therefore 
are a valid representation of the current MN market and are meant to provide an 
overview of the current situation. 
IP  dec is ion f ramework 
A MN industry specific IP decision framework was created by combining the 
questionnaire results and the existing general IP decision framework created by 
Daizadeh et al. (194).This MN industry specific IP strategy recommendation 
framework was developed with a 7-step approach. The most important factors 
according to the different MN companies derived from the questionnaire involved in 
their decisions to patent were included in the IP decision framework. 
 

6 Sample questionnaire available upon request 
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6 .3 .  RESULTS 
The questionnaire generated a response rate of 71%. The final dataset consists of 10 
MN companies, with 3 large companies and 7 small and medium enterprises (SMEs). 
The participating companies combined are responsible for the greatest share of the 
development and production of MN in Europe and the United States.  
6.3.1 .  IP  R ights  
Results from the questionnaire indicate that 70% of all respondents believe patenting 
to be a necessary IP measure to protect a MN invention. In addition, 80% of the 
respondents have observed a dramatic increase in the importance of patenting in the 
MN industry in the past 10 years. This is confirmed by previous research 
demonstrating an increase in the number of patent applications in the EU MN 
industry (182). The respondents explain this increase in importance with a number of 
reasons. The main reason mentioned concerns the advances in knowledge that 
nutrients may even support the treatment of diseases in addition to only improving a 
patient’s nutritional status. This enables the MN developer to file a patent for a 
nutritional composition in combination with a disease application. One of the 
respondents mentioned the following:  
 
“The combination of specific nutrients with a disease application allow for IP filing 
and this is needed to protect products coming out the complex, time consuming 
and very costly R&D”.  
 
In addition to the importance of patenting for the MN companies, other IP rights are 
also considered to be of great value. By means of weighted ranking, the importance 
of each IP method is calculated. Each score was multiplied by the weight for the 
respective criterion. The sum of these weighted scores reflects the total weighted 
score of the IP method. In consecutive order: Trademark (average sum of ranks: 4,3), 
Trade secret (4,1) and Copyright (3,6) were ranked from most important to least 
important (Fig. 1). By means of a trademark, a product can be visually differentiated 
from the competitor to the consumer and is assessed as most important by the 
respondents. Trade secrets are employed by companies when a process or 
composition is difficult to be reverse engineered by the competition and thus can be 
kept a secret within the company. This is also perceived as an important IP method in 
the MN market. Copyright is perceived as the least relevant IP method in the MN 
market with only 20% of the respondents ranking it as very important. 
 
 







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F igure  1 .  The  impo r tance  o f  app l i cab le  IP  r i gh t s  i n  t he  MN i ndus t r y  ( 5 -
po in t  L i ke r t  s ca le :  Ve r y  impo r tan t  –  No t  r e l evan t )   

 

6.3.2 .  Mot ives to  patent  
7 different groups of motives to patent were introduced to the respondents and were 
asked to rate the importance of each motive for their company.  
The two motives that are considered to be most important according to the MN 
companies are the prevention of imitation (Fig. 2) and the securing of international 
markets. These are both protective motives. Besides this intentional motivation of 
patent protection, further motives emerged to be of great importance; reputation and 
the blocking of competition were ranked as third and fourth most important. Motives 
considered to be less important in the decision to patent are: Granting for product 
reimbursement; Exchange motives and Incentives for employees.  

F igure  2 .  Rank ing  o f  impo r tance  o f  mo t i ves  t o  pa ten t  i n  t he  med i ca l  
nu t r i t i on  marke t .  X -ax i s  dep i c t s  t he  ave rage  we igh ted  sco re  pe r  
mo t i ve .   
 
 
 
0 0,5 1 1,5 2 2,5 3 3,5 4 4,5 5 
Incentives for employees 
Exchange [licensing] 
Product reimbursement 
Blocking 
Reputation 
Securing markets 
Preventing imitation 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
Trade Secret 
Trademark 
Copyright 
Very Important Important Neutral Slightly Important Not relevant 
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6.3.3 .  Mot ives not  to  patent  
There are also reasons to decide to forgo patenting and the MN companies were 
asked about their preference among a number of motives not to patent. The two most 
important reasons to forgo patenting for MN companies are that a product is not 
patentable and secondly that companies are reluctant to disclose information required 
for patenting (Fig. 3). These motives are closely followed by the motive that 
competitors could easily invent around a patent, the costs of enforcing and acquiring 
a patent. Motives considered to be less important in the decision to patent are: did not 
want to become subject to legal restrictions on licensing and already cooperation 
with competitors. Interesting to notice, mainly for SMEs the costs of acquiring and 
enforcing a patent is important compared to the large companies.  

F igure  3 .  Rank ing  o f  impo r tance  o f  mo t i ves  no t  t o  pa ten t  i n  t he  
med i ca l  nu t r i t i on  marke t .  X -ax i s  dep i c t s  t he  ave rage  we igh ted  sco re  
pe r  mo t i ve   
 
 

 

6.3.4 .  Factors  invo lved in  IP dec is ion  
Several factors (A-D) resulted from the questionnaire to be important in the MN 
companies’ decision to patent and are discussed separately. These factors are 
integrated in the MN specific IP decision framework described in the final results 
section (3.5). The following factors are discussed due to data significance or 
surprising findings: A. clinical trials; B. return on investment (ROI); C. radical 
versus incremental inventions and D. patent type. 
A. C l in ica l  Tr ia ls   
Since clinical trials are resource intensive, a company may choose to protect an 
invention with a higher investment by means of a patent (195). 80% of the MN 
companies agreed that clinical trials are important in their decision process whether 
0,0 0,5 1,0 1,5 2,0 2,5 3,0 3,5 
Already cooperation with competitors 
Legal restrictions on licensing 
Circumvention 
Costs of acquiring patent 
Costs of enforcing patent 
Reluctant to disclose information 
Product not patentable 
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to patent a MN invention. The reasons were related to validation and efficacy of the 
product.  
B.  Return on investment  
Innovations in the health and life sciences are lengthy and costly with almost 60% of 
patent life expired before market introduction. Therefore, knowledge of R&D and 
patent costs, and the expected revenue of the invention are important for analyzing 
the return on investment (ROI), a performance measure used to evaluate the 
efficiency of an investment (195). Resulting from the questionnaire, according to 
80% of the MN companies, ROI is regarded as an important factor in the decision 
whether to patent or not. 
C. Radica l  versus Incrementa l  invent ion 
Radical innovations are crucial in the development of a market but barely provide 
benefits if competitors are able to copy it with little or no extra cost. Radical 
innovation may be easier to protect from imitation than incremental innovation for 
the same reasons as a stand-alone innovation might be easier to protect than complex 
and interdependent innovation (196). In our study, 90% of the respondents more 
often patent radical inventions which are novel, unique creations and which have an 
influence on future technology compared to incremental inventions, which are 
current inventions that are renewed, adjusted, modified and/or improved.  
D. Type of  patent  
Generally, three different types of health and life science patents exist: Composition 
of Matter; New Chemical Entity (NCE) and Platform Technology. The MN 
companies were asked to choose between these three patent choices or whether no 
distinction was made. Composition of matter patents relate to the nutritional 
composition of a product and include mixtures of ingredients (Fig. 4). 50% of the 
MN respondents selected composition of matter to be the most important factor 
involved in the decision to patent. A considerably lower number of respondents 
(10%) preferred to patent a platform technology, a generic technology that can be 
used in several applications. 

F igure  4 .  Impo r tance  o f  d i f f e ren t  t ypes  o f  pa ten t s  i n  t he  MN mar ke t   
 

 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
Composition of matter New entity / compound Platform Technology No distinction 
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6.3.5 .  IP  Dec is ion Framework 
By combining the results of the questionnaire sent to the MN companies, with 
Daizadeh’s IP decision framework, and rational argumentation, we designed the 
following MN IP decision framework (Fig. 5) (194). Choosing an IP method to 
protect MN inventions requires the consideration of multiple variables. The decision 
whether to apply for a patent, a trade secret, trade mark, defensive publication or 
patent lapse depends on various factors. These various factors have to be taken into 
account by the MN companies in their decision to patent, since a wrong choice can 
have a significant impact on a company’s market position. The factors that have been 
proven to be important in the companies’ decision to patent as a result from the 
questionnaire (3.4) are integrated in this MN specific IP decision framework. The 
framework consists of a 7-step approach (Fig. 5) based on Daizadeh (197). 
 
Step 1: Radical Invention. The first step that has to be taken into account is whether an 
invention is considered to be radical. Since radical inventions are rare and involve high 
development costs and have the possibility to change the industry a particular type of IP 
protection is necessary (196).   
 
Step 2: Easily Circumvented. In this step the companies ask the question whether or not a 
competitor can easily apply for a similar patent thereby circumventing the other patent in the 
process. Respondents stated that in the MN market granted claims are often very narrow and 
therefore circumvention can be quite easy. In addition, Allowed claims normally require 
specific formulations or disease states, it is easy for competitors to commercialize products 
without licensing patents. To avoid being circumvented, a thicket of similar patents can be 
built around a patented invention to block competition.  
 
Step 3: IP amenable to reverse engineering. The third step to be taken in the decision 
framework concerns the simplicity of reverse engineering the invention. If an invention 
product cannot be easily reverse engineered it may be valuable to forgo patenting and to 
choose a trade secret. However, if an MN product can be easily reversed then a defensive 
publication or a patent application followed by a patent lapse is advisable.  
 
Step 4: Costly clinical trials or high development costs. For the development of an MN 
product, clinical trials are important for validation and to prove efficacy. The development of 
an MN product may be very costly and the associated costs have to be taken into account 
when choosing a proper IP method. 
 
Step 5: expected return on investment. An important step in this framework is the expected 
return on investment. The return on investment concerns the amount of money invested in 
the development of the product against the expected revenue of the product. If the market 
revenues are low in comparison to the development costs, it is advisable to protect the 
product by a trade secret or defensive publication since the costs of a patent may be too high 
in comparison. When an invention cannot be protected by a trade secret than defensive 
publication is advisable. The advantage of defensive publication is that patents cannot be 
granted on this specific invention by competitors described in the publication. A respondent 
argued that especially in the MN industry the profit margins for products are slim, and thus 
with a low ROI and therefore not worth patenting in some cases. In these cases, a defensive 
publication may be the solution. 
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Step 6: Complicated platform technology. A complicated platform technology is a technology 
that can be used in several applications. It is the fundamental science behind a lot of 
products within the MN market and is therefore very important to patent. In addition, 
companies can also choose to opt for a trade secret, especially when it is difficult for 
competitors to unravel a platform technology.  
 
Step 7: Unique composition of matter. The composition of matter relates to chemical 
compositions and may include mixtures of ingredients. For MN products it is difficult to get a 
patent on a composition of matter, since MN products are often composed of naturally 
derived food substances and not a new chemical entity such as in the pharmaceutical 
industry. However, respondents stated that composition of matter provides the broadest 
protection and that it is most easily defended. Therefore, with a unique composition of matter 
a company is also advised to patent and/or to apply for a product trademark.  


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F igure  5 .  IP  dec i s i on  f r amework  
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6 .4 .  DISCUSSION & CONCLUSIONS 
In today’s R&D driven world, it is the IP portfolio that makes or breaks a company’s 
commercial success. In the newly emerging MN market, there is a pressing need for 
assessing the suitability of IP protection strategies. This paper not only provides 
insights into the relevance of various IP methods for MN companies, but also offers 
a method for assessing a suitable IP strategy. Our IP decision framework facilitates 
clear-cut decisions regarding the strategy of protecting IP. Furthermore, IP methods 
should be applied in a proactive way in the MN industry to protect MN innovations 
and in doing so maintain a competitive niche. As our findings acknowledge; 
applying different IP methods is perceived by the questionnaire respondents as 
essential to protect a MN innovation.  
 
Although patents are considered valuable instruments for protecting innovations in 
the health and life science industry, there are also many reasons to forgo patenting. 
The most important motive not to patent in the MN market is that certain MN 
products are simply unpatentable. This argument supports the choice by some MN 
companies to apply alternative IP protection strategies, such as trademark, trade 
secret and/or copyright. Especially trademarks are considered to be an indispensable 
IP method due to their ability to visually differentiate a company’s product from a 
competitor directly to the customer. Trade secrets also proved to be considered by 
questionnaire respondents as important in the MN market, however there are 
limitations. Trade secrets as a form of IP can only be applied if reverse engineering 
by competitors is considered close to impossible. It is therefore recommended that 
companies operating in the MN industry should always look beyond the boundary of 
the patent and carefully assess if any other relevant IP methods are applicable. 
 
Additionally, SMEs indicate that the cost for both filing and enforcing a patent, are 
important motives to consider alternative IP methods. Previous literature confirms 
this perceived cost-sensitivity of SME firms (179). The most logical explanation for 
this phenomenon is that SMEs have a lower budget available for the development of 
a product in comparison to large multinationals. However, SMEs should be aware 
that the presence of patents in the IP portfolio increases company value, which is 
favorable for both attracting investors and increasing the likelihood for acquisition or 
alliance with other/larger companies (169). 
 
When it comes to patenting, previous research has indicated that patenting behavior 
differs between companies within the MN industry (182). Even though there are 
many different strategic motives to apply for a patent in the MN market, the 
protective motive of preventing imitation proves to be most important. This confirms 
that the original rationale behind the patent system continues to fulfill its purpose 
within the MN market (198). This motive is closely followed by the motives for 
securing foreign markets and enhancing company reputation. Especially in the health 
and life sciences, a sector that revolves around high-tech state-of-the-art 
technologies, a company’s technological reputation is valuable. In other words; a 
company’s technological reputation can distinguish it from competition.  
 
The type of patent that has proven to be particularly relevant in the MN market is the 
composition of matter patent. Although the pharmaceutical and MN products are 
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both developed for patients with specific disease conditions, the products differ on 
many levels. The main difference revolves around the way the product is built-up; a 
pharmaceutical product is usually based on a new single-compound entity while a 
MN product usually describes a combination of existing nutrients. Since most 
patented inventions in the pharmaceutical industry are single-compound entities 
(199), we expected most MN patents to concern the nutritional compositions. This 
holds true for the MN market, where 50% of the MN companies stated to file for 
composition of matter patents, in which the nutritional composition of a MN product 
is patented. The disadvantage of this type of patent is that it does not always offer 
very broad protection.. This may explain why one of the most important motives not 
to patent is that companies are reluctant to publically disclose information about the 
invention. By providing this information, the fear exists that competitors may be able 
to incrementally adjust the originally patented invention, thereby circumventing the 
patent.  
 
Additional factors that are specifically associated with the patenting behavior of MN 
companies include; reimbursement granting, the use of a patent as a marketing tool, 
involvement of clinical trials, ROI, and invention radicalness. Since these factors 
proved to be important within this market, they were integrated in the IP decision 
framework. Reimbursement granting is perceived as a factor influencing the patent 
decision process, most likely due to regulatory demands.. Certain national competent 
authorities require a MN invention to be patented before it is eligible for 
reimbursement and market entry [interviews KOLs]. Patents may also be deployed as 
a marketing tool (192) by labeling MN products as a “proprietary product” or “patent 
pending” in product brochures, for example. In the view that MN products are 
directed towards healthcare professionals, who understand the significance of 
patents, such labels prove to be valuable in advertising campaigns. However, 
healthcare professionals should be aware that in some cases MN companies may 
already advertise with a “proprietary product” with only a pending patent 
application.  
 
In comparison to the pharmaceutical and biotechnology industry where clinical trials 
are mandatory, the R&D process of a MN product does not have to include clinical 
trials unless you want to assign a certain claim to your product or its effectiveness. 
Therefore the execution of clinical trials also affects the decision to patent since 
clinical trials are associated with higher development costs. If a MN company 
decides to perform clinical trials to determine the effectiveness of a MN product with 
the corresponding costs, they may do wise to also invest in the filing of a patent. This 
offers a temporary monopoly in order to ensure the protection and profitability of the 
high-investment invention from competition especially if the invention has a high 
expected ROI. ROI is therefore also an additional decision factor in the MN specific 
IP decision framework. The final characteristic that influences the patent decision 
process is the radicalness of the invention. Even though the chance of successfully 
developing a radical invention is distinctly lower than an incremental invention, the 
ROI of radical innovations are generally significantly higher (200). Since radical 
innovations are novel, unique creations that can influence future development, a 
company will set itself apart from competition and will be especially driven to 
protect such an innovation.  
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There are a few limitations to this study. First, a relatively small sample of MN 
companies participated in this study. However, since there are a limited number of 
MN companies, these represent a large share of the industry. In addition, it is a 
young and developing market and therefore representative for the MN industry. A 
drawback of the questionnaire analysis method is that it suffers from inter-
respondent variation. For example, a response of ‘very important’ for one respondent 
could be equal to a response of ‘important’ for another respondent (172). 
 
The above discussion shows that many complex factors determine the decision about 
whether or not to protect a particular MN invention and selecting the appropriate IP 
strategy. The data summarizes the most important factors affecting the decision of a 
MN company or academic institution seeking IP protection. In the IP decision 
framework, some of the factors affecting the decision in choosing the appropriate IP 
strategy are standard variables while others are specific to the MN market. Although 
the decision framework can be used as a general roadmap evaluating the appropriate 
protection; it cannot answer all in-depth business questions. Nevertheless, the 
decision on the type of protection is dependent on the nature of the innovation and 
the economics of commercialization. Each invention requires a careful assessment of 
whether the total benefits, either economic and/or intangible/societal, exceed the total 
cost of the protection. 
 
By using this MN decision framework, one can consider the different options 
available, whether to use the acquired knowledge themselves or to transfer the 
knowledge or invention (e.g. by means of out-licensing). Such an assessment is 
highly complex and unique for every invention.  
 
With this research we have made an attempt to simplify the complexity of the IP 
strategy decision by means of a MN specific IP decision framework. The framework 
serves as a tool to assist both industry and academic R&D departments in making 
clear-cut decisions on the most applicable IP method. The proposed IP decision 
framework can benefit further from additional research, by assessing its value in the 
practical setting. 
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CHAPTER 7  
PATIENT NEEDS AND RESEARCH PRIORITIES IN 
THE ENTERAL NUTRITION MARKET – A 
QUANTITATIVE PRIORITIZATION ANALYSIS 
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ABSTRACT  
 
A quantitative systematic identification and prioritization of unmet needs and 
research opportunities in relation to enteral nutrition was conducted by means of a 
tailor-made health research prioritization process.  
 
The research objectives were reached by conducting qualitative interviews followed 
by quantitative questionnaires targeting enteral nutrition key opinion leaders (KOLs). 
(1) Define disease areas that deserve more research attention; (2) Rank importance of 
product characteristics of tube feeding (TF) and oral nutritional supplements (ONS); 
(3) Assess involvement of KOLs in enteral nutrition R&D process. KOLs ranked 
three product characteristics and three disease areas that deserve additional research 
attention. From these, overall priority scores were calculated by multiplying ranks for 
both product characteristics and disease areas. 
 
17 qualitative interviews were conducted and 77 questionnaires (response rate 35%) 
were completed and returned. (1) Disease areas in ONS and TF with highest 
priorities are: ONS: general malnutrition & geriatrics, TF: intensive care. (2) TF 
product characteristics with highest priorities are: composition and clinical evidence 
from a KOL perspective; tolerance and ease of use from a patient perspective. ONS 
product characteristics with highest priorities are: composition, clinical evidence and 
taste from a KOL perspective; taste from a patient perspective. We find a high 
discrepancy between product characteristic prioritization from a KOL and patient 
perspective. (3) Although 62% of all KOLs give advice to enteral nutrition 
companies on patient needs, they under-influence the setting of research priorities by 
enteral nutrition companies.  
 
This study provides a systematic approach to achieve research prioritization in 
enteral nutrition. In addition to providing new directions for enteral nutrition research 
and development, this study highlights the relevance of involving KOLs in the 
identification of research priorities as they have the ability to provide a balanced 
view of the unmet patient needs. 
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7 .1.  INTRODUCTION 
The health and life science industry, which is an important driver of the health care 
sector, revolves around addressing unmet medical needs. A medical need is defined 
as the fundamentals required to sustain a healthy individual (201). To achieve 
optimal health services, policies and strategies from a public health perspective but 
also from a health care industry perspective, it is necessary to identify and prioritize 
medical needs, thereby functioning as the basis for research priorities. Unfortunately, 
there is limited knowledge of patient needs and priorities. As a result, there is often a 
mismatch between research driven by the interests of scientists, funders and powerful 
interest groups and the health needs of the population. 
 
The enteral nutrition (EN) market targets patients that require nutritional support to 
prevent or treat malnutrition or alleviate and manage symptoms of specific medical 
conditions. Through advancements in the fundamental knowledge of human bodily 
functions, a wide range of EN products are now available for several (previously 
unmet) medical needs/conditions. These products are prescribed by medical 
professionals for the nutritional support of patients in the dietary management of 
diseases. With 33 million people at risk of malnutrition throughout Europe, the 
development of specific and targeted EN products is crucial (153). Although 
awareness concerning the importance and effectiveness of EN is growing (33), there 
are still numerous unmet medical needs that need to be addressed, at the interface 
between pharma and food, by the EN industry. 
 
Unmet medical needs can be fulfilled through ‘market pull’ strategy, where the 
unmet medical need functions as the innovation opportunity input. The first step is to 
assess these unmet medical needs by means of a so-called needs assessment. This 
allows for the accurate evaluation of health related patient needs and may eventually 
function as innovation opportunity input for the EN industry (202, 203). The 
assessment of patient needs leads to the understanding of patient experiences and 
addresses which needs should be prioritized to improve the quality of care (204, 
205). The identification of patient needs is an essential success factor in the complex 
process of product development and innovation (206-208).  Products are more likely 
to be successful when built around customer needs as opposed to only addressing 
technological opportunities (206). Need assessment can be performed by means of 
health research prioritization (HRP) and may provide directions for future resource 
allocation and strategic planning at institutional, regional, national as well as 
international level (209).  
 
Although, during the past decades, an unprecedented number of innovations have 
had great clinical impact on the prevalence and treatment of disease-related 
malnutrition, an overview of unmet patient needs with priorities is lacking within the 
EN market. Considering the widespread prevalence and adverse consequences of 
malnutrition and the effectiveness of EN, such an overview would contribute to both 
fulfilling the unmet patient needs as well as the exploitation of commercial 
innovation opportunities (34). Therefore, the aim of this research was to assess 
unmet patient needs and research priorities in the EN market by means of 
quantitative questionnaires targeting EN key opinion leaders (KOLs). 
 104 
Heal th  Research Pr ior i t iza t ion  
HRP processes assist researchers, policymakers and industry in effectively targeting 
research that is needed most (210). In addition, HRP stimulates to evaluate health 
research and to identify its strengths, weaknesses, gaps and opportunities (211). 
Setting successful research priorities is complex, because choosing between priorities 
creates ethical equipoise (212). Nevertheless, the efficacy of setting prioritization has 
previously been demonstrated by various research groups (211, 213, 214). The aim 
of prioritization is to develop a relative ranking list rather than to define an absolute 
cut-off beyond which diseases are not considered important (215) . 
 
Several extensively tested and comprehensive approaches to HRP are available to 
guide researchers in setting their research priorities (210, 216). Nevertheless, it has 
proven impossible to set a golden standard/best practice in HRP since the context of 
priority setting varies per case (210).  Therefore, researchers develop their own 
unique research prioritization method based on an existing HRP method but adapted 
to their subject and research goal. A tailored prioritization was developed for this 
research to rank patient needs in the EN market in order to uncover research priority 
insights and innovation opportunities. EN patient needs exist at different levels. Our 
focus lies on assessing which disease areas require research attention but also which 
product characteristics require improvement. The research methodology was 
predominantly based on a prioritization research described by Balabanova et al. who 
developed a prioritization method to establish strategic priorities for the German 
national public health institute concerning infectious pathogens (209). Their research 
solely focused on the prioritization of infectious diseases in Germany. In our 
research, this method was extended by prioritizing both EN related disease areas but 
also the EN product characteristics. The aim of the research described here was to 
identify and prioritize unmet patient needs (disease areas and product characteristics) 
and research opportunities in the EN market by means of quantitative questionnaires 
targeting EN KOLs. This research also aimed to evaluate the opinions of the KOLs 
on their current involvement in EN research and research prioritization efforts. The 
objectives of this research are as follows: 
 
1. To determine the unmet needs and research priorities in the EN market by 
means of health research prioritization: 
1.1 To assess the disease areas that require more research attention in the EN 
market; 
1.2 To assess which product characteristics have the highest priority in EN 
development. 
2. To evaluate the degree of involvement of KOLs in the EN R&D process from a 
KOL perspective. 
  
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7 .2.  METHODOLOGY 
The prioritization process was based on previously used prioritization methods (209, 
210) and adapted to assess EN unmet patient needs and research priorities. The 
multi-staged prioritization process started with the compilation of a list of disease 
areas and product characteristics of EN by means of qualitative exploratory 
interviews. This was followed by the development of evaluation criteria, weighting 
of the criteria and ranking of the disease areas and product characteristics by means 
of an online questionnaire (209). This research also aimed to evaluate the opinions of 
the KOLs on their current involvement in EN research and research prioritization 
efforts.  

F igure  1 .  R esea rch  f r am ew ork   
 
 
 
7.2.1 .  Study sub ject   
Since patients do not have direct experience with more than a subset of innovations 
and generally only one disease area, KOLs were approached. Two-hundred-twenty 
KOLs with extensive EN knowledge (practicing MD, dieticians, nurses, researchers, 
professors, lecturers, and consultants) of the European Society for Clinical Nutrition 
(ESPEN) faculty were invited to participate in an email-survey. The aim of the 
survey was to investigate patient needs in the EN market. The anonymous online 
survey was created and distributed through the online web survey program 
SurveyMonkey. KOLs that did not respond to the initial survey received a follow up 
reminder e-mail 1.5 weeks later to increase response rates. 
 
7.2.2 .  Exploratory  in terv iews 
A set of questions was pretested by means of 17 exploratory pilot interviews with 
KOLs, in order to validate the survey tool as well as the possible answers to the 
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questions. By means of saturation curves all possible answers were ensured. 
Saturation was reached after 17 interviews. This procedure was intended to increase 
content validity of the survey.  
7.2.3 .  Survey des ign & analys is  
The survey consisted mainly of closed questions with a few open questions for 
gathering in-depth insights. The demographic information of the respondents was 
collected and included: title, profession, age, country of residence and department. 
Thirty-four questions were divided into two sections: unmet needs (disease areas & 
product characteristics; and current KOL involvement in research prioritization 
(Figure 1). Both tube feeding (TF) as well as oral nutritional supplements (ONS) 
were taken into account in this study. A copy of the survey is available on request.  
7.2.4 .  Unmet  need pr ior i t iza t ion –  Disease areas 
The KOLs were asked to answer 10 closed questions on the topic of unmet needs for 
TF and ONS. In the section concerning disease areas, respondents were presented 13 
disease areas and were asked to rank the 3 disease areas according to their 
assessment of whether these disease areas require or deserve to be investigated more 
thoroughly (1 being highest priority). The ranking is multiplied by the weight of the 
respective criterion, e.g. 1 being the highest ranking, receives a weight of 3. The 
higher the sum of these weighted scores reflects the higher unmet need prioritization. 
The total weighted scores were finally re-scaled to a range from 1-100 in order to 
facilitate final interpretation (209). Two cut-off points were applied to assign the re-
scaled weighted scores into three priority groups: 0-33 – low priority; 34-66 – 
medium priority; 67-100 – high priority (209). 
7.2.5 .  Unmet  need pr ior i t iza t ion –  Product  character is t ics  
In the category concerning product characteristic priorities the respondents were 
presented with 11 product characteristics and were asked to rank the 3 most 
important product characteristics ranging 1-3 (1 being highest priority). The KOLs 
were asked to rank the importance and improvement priority of the product 
characteristics. In addition, they were asked to rank the product characteristics from 
their perspective as well as from the patients’ perspective. This was done to measure 
a possible discrepancy in the ranking of the unmet product needs between the KOL 
and patient perspective. To ensure ranking validity in our research, a single response 
group prioritized the product characteristics both from a patient and KOL 
perspective. The rank 1 reflects the highest, and 3 the lowest level of importance of a 
criterion. The ranking methodology is identical to the one applied to the disease area 
prioritization (section 2.3.1). 
 
In the applied methodology, we followed the principles of good practice in health 
research priority setting (209, 210). We reached a proper level of objectivity and 
transparency by integrating the following components: (1) Involvement of a broad 
range of external experts with the extensive knowledge in the area of EN, (2) the 
compilation of a list of disease areas, product characteristics and content 
characteristics of EN by means of qualitative exploratory interviews, (3) weighting 
of the criteria and ranking of the disease areas and product characteristics.  
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7.2.6 .  KOL invo lvement  
Twelve questions were asked to assess current KOL involvement in patient need 
prioritization. It was assessed what percentage of KOLs are involved in the different 
stages of R&D by means of 4 closed dichotomous questions. Their opinion on the 
degree of their involvement was measured by means of a 5-item Likert scale (not at 
all, a little, a moderate amount, very much, an extreme amount). Each item on the 
Likert scale was appointed a value; the mean of these values represents the degree of 
KOL involvement. KOLs were asked to assess their involvement both in the R&D 
process of products in academic setting as well as their involvement in R&D process 
in industry setting. 
 
To assess the difference in KOL involvement in industry setting and academia 
setting, the Wilcoxon signed rank test of non-parametric data was applied. This test 
is used to compare matched samples, repeated measurements on a single sample, or 
in this case, two related samples to assess whether their population mean ranks differ. 
A P-value <0.05 was considered to be statistically significant. Statistical analyses 
were performed using a statistical package program (SPSS, Version 20.0). 
7.2.7 .  Stat is t ica l  ana lys is  between groups 
Total results were analyzed and differences between respondent groups according to 
demographic characteristics were analyzed. The respondents were grouped according 
to two demographic characteristics: age (25-55; and 55 and up); and geographic 
regions (Northern Europe; Southern Europe; Eastern Europe; and Outside Europe). 
To assess differences between groups in unmet need prioritization, the Mann-
Whitney U Test and Kruskal-Wallis analysis were applied (Table 1) In the KOL 
involvement section, the demographic groups were compared by means of the Chi-
squared test for the dichotomous questions and the T-test for the Likert scale 
questions (Table 1). A P-value <0.05 was considered to be statistically significant. 
Statistical analyses were performed using the statistical program SPSS, Version 20.0. 
 
Tab le  1 .  Sta t i s t i ca l  ana l ys i s  be tween  g roups   
 
Survey section 
 
Age groups Geographic 
characteristics 
Unmet needs: 
 
- Disease area ranking Mann-Whitney U Test 
(two samples) 
 
Kruskal-Wallis one-way 
analysis of variance by 
ranks (more than two 
samples) 
- Product 
characteristic ranking 
 
KOL involvement: 
 
- Dichotomous 
questions 
Chi-squared test Chi-squared test 
 
- Likert scale 
questions 
T-test T-test 
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7 .3.  RESULTS 
7.3.1 .  Demographic  character is t ics  o f  the sample 
A response rate of 35% was reached, seven cases failed to complete the 
questionnaires, leaving 77 respondents with valid data received from 27 different 
countries. The demographic characteristics of the respondents were as follows: 53% 
between 25-55yrs and 47% ≥55yrs. The majority of participants fulfilled a position 
as practicing MD (41%), followed by Professor (32%) and Consultant (11%). 
 
7.3.2 .  Disease area pr ior i t ies   
The 13 disease areas identified in prior exploratory interviews were presented to the 
participants. The respondents were asked to rank the three disease areas according to 
their assessment of these disease areas requiring or deserving to be investigated more 
thoroughly. The disease areas that received the highest research priority in ONS are 
(1) General malnutrition and (2) Geriatrics followed by (3) Non-surgical oncology 
and (4) Surgery & transplantation as medium priorities.  The disease area ranked as 
most important in TF is (1) Intensive care, followed by (2) General malnutrition and 
(3) Surgery & transplantation as medium priorities. Figure 2 presents the ranking of 
the diseases according to their weighted total score into three priority groups for 
ONS and TF. 








 
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F igure  2 .  D i sease  a rea  rank ing  acco rd i ng  t o  we igh ted  sco res  f o r  ONS 
and  TF .  Th ree  p r i o r i t y  g roups :  Low :  0 -33 ;  Med ium:  34 -66 ;  H i gh :  67 -100   



 
7.3.3 .  Product  character is t ic  pr ior i t ies  in  ONS and TF  
From a KOL perspective, the following TF product characteristics were ranked as 
most important: (1) Composition and (2) Clinical evidence, followed by (3) 
Tolerance. The TF product characteristics that need to be improved from a KOL 
perspective are: (1) Composition; (2) Clinical evidence; followed by (3) Tolerance; 
and (4) Price. The product characteristics, which from a patient perspective, were 
ranked as most important in TF, are: (1) Tolerance and (2) Ease of use, followed by 
(3) Price. Similarly, the TF product characteristics that need to be improved from a 
patient perspective are: (1) Tolerance; (2) Ease of use; followed by (3) Price. Table 2 
shows the TF product characteristic ranking results both from a KOL as well as 
patient perspective. 
 






ORAL NUTRITIONAL SUPPLEMENTS       TUBE FEEDING 
 
DISEASE AREA  RELATIVE RANKING  DISEASE AREA  RELATIVE RANKING 
General malnutrition  100    Intensive care   100 
Geriatrics    93.2      
 
Non-surgical oncology  54.7    General malnutrition  62.8 
Surgery & transplantation  34.2    Surgery & transplantation  61.2 
 
Gastroenterology   30.8    Gastroenterology   33.3 
Intensive care   15.4    Non-surgical oncology  27.9 
Renal failure   15.4    Geriatrics    27.1 
Pulmonary    12.8    Pulmonary    14.7 
Cardiology    10.3    Cognitive    10.9 
Hepatology    10.3    Cardiology     9.3 
Cognitive     7.7    Metabolic     4.7 
Metabolic     6.8    Hepatology     3.9 
Infectious diseases    3.4    Infectious diseases    1.6 
       Renal failure    0.8 
 
100 
 
 
 
 
 
 
66 
 
 
 
 
 
 
 
33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 
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Tab le  2 .  TF  p roduc t  cha rac te r i s t i c  we igh ted  rank ing  f r om a  KOL  and  
pa t i en t  pe rspec t i ve   
 
                                 TUBE FEEDING 
  KOL PERSPECTIVE PATIENT PERSPECTIVE 
  Important To be improved Important To be improved 
Composition 100 100 18,1 30 
Clinical evidence 69,5 96,6 16 31,7 
Tolerance 56,3 62,2 100 100 
Caloric density 24,5 25,2 3,5 9,2 
Ease of use 18,5 22,7 69,4 72,5 
Price 18,5 42,9 42,4 60,8 
Volume 9,3 11,8 24,3 22,5  
Taste 4,6 13,4 16,7 20 
Viscosity 4 7,6 4,9 6,7 
Shelf life 0,7 3,4 8,3 6,7 
Smell 0 2,5 17,4 25 

 

The product characteristic that is considered to be most important according to the 
KOLs in ONS is (1) Composition, followed by (2) Clinical evidence, (3) Taste, (4) 
Tolerance and (5) Price. The Dproduct characteristics that need to be improved 
according to the KOLs in ONS are (1) Clinical evidence and (2) Taste. From a 
patient perspective, the product characteristics that were ranked as most important in 
ONS were (1) Taste, followed by (2) Price and (3) Tolerance. Table 3 shows the TF 
product characteristic ranking results both from a KOL as well as patient perspective. 











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Tab le  3 .  ONS p roduc t  cha rac te r i s t i c  we igh ted  r ank i ng  f r om  a  KOL  and  
pa t i en t  pe rspec t i ve   
 
 ORAL NUTRITIONAL SUPPLEMENTS 
  KOL PERSPECTIVE  PATIENT PERSPECTIVE  
  Important To be improved Important To be improved 
Composition 100 61,9 6,8 7 
Clinical 
evidence 
65,9 100 2,5 12 
Tolerance 43,7 48,6 43,2 41,1 
Caloric 
density 
27 13,3 4,3 3,8 
Ease of use 11,9 21,9 28,4 19,6 
Price 34,9 59 47,5 46,2 
Volume 14,3 15,2 19,8 14,6 
Taste 57,1 92,4 100 100 
Viscosity 1,6 0 2,5 4,4 
Shelf life 0 4,8 1,9 3,8 
Smell 10,3 22,9 28,4 39,9 

 
 
7.3.4 .  Tube feed ing pr ior i ty  matr ices 
The TF product characteristic results were combined and visualized in the product 
characteristic priority matrices (Figure 3). The left matrix gives a representation of 
the TF prioritization from a KOL perspective, while the right matrix represents the 
patient perspective as ranked by the KOLs. The x-axis of the chart depicts the need 
for product characteristic improvement and the y-axis the importance of the specific 
product characteristic. The product characteristics situated in the upper right quadrant 
are those assigned to the high priority group (dark grey shading). The three 
surrounding quadrants represent the medium priority group (medium grey shading). 
The remaining five quadrants represent the low priority group (light grey shading). 
 






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F igure  3 .  TF  p roduc t  cha rac te r i s t i c  p r i o r i t y  m a t r i x  –  Le f t :  KOL  
pe rspec t i ve ;  R igh t :  Pa t i en t  pe rspec t i ve   
 
 
 
 
KOL perspect ive  
The TF priority matrix indicates composition and clinical evidence to be most 
important to be improved from a KOL perspective. Tolerance is assigned to the 
medium priority group.  The majority of the product characteristics is assigned to the 
low TF priority group. Those being: price; caloric density; ease of use; taste; 
viscosity; shelf life; and smell.   
 
Pat ient  perspect ive 
From a patient perspective, the product characteristics assigned to the high priority 
group are tolerance and ease of use.  Price is assigned to the medium priority group. 
Again, most product characteristics are assigned to the low TF priority group, in this 
case from a patient perspective. Those being: volume; composition; smell; taste; 
clinical evidence; shelf life; viscosity; and viscosity. 
 
KOL perspect ive versus Pat ient  perspect ive 
When focusing on the medium- and high-quadrants within the priority matrix, the 
results show that none of the TF product characteristics are ranked equivalently from 
the patient as well as from the KOL perspective. These results indicate a clear 
discrepancy between the prioritization of product characteristic from a KOL and 
patient perspective. 
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7.3.5 .  Oral  nut r i t iona l  supplement  pr ior i ty  matr ices 
Identical to the TF results, the ONS results were combined and visualized in the 
product characteristic improvement priority matrices (Figure 4). The left matrix gives 
a representation of the ONS prioritization from a KOL perspective, while the right 
matrix represents the patient perspective as ranked by the KOLs. The x-axis of the 
chart depicts the need for product characteristic improvement and the y-axis the 
importance of the specific product characteristic. The product characteristics situated 
in the upper right quadrant are those assigned to the high priority group (dark grey 
shading). The three surrounding quadrants represent the medium priority group 
(medium grey shading). The remaining five quadrants represent the low priority 
group (light grey shading). 
 

F igure  4 .  ONS p roduc t  cha rac te r i s t i c  p r i o r i t y  m a t r i x  –  Le f t :  KOL  
pe rspec t i ve ;  R igh t :  Pa t i en t  pe rspec t i ve   
 
 
 
 
KOL perspect ive  
Notable, none of the ONS product characteristics are assigned to the high priority 
group from a KOL perspective. The product characteristics allocated to the medium 
priority group are: composition; tolerance; price; clinical evidence; and taste. The 
majority of the disease areas is assigned to the low priority group. Those being: 
smell; caloric density; ease of use; volume; viscosity; and shelf life. 
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Pat ient  perspect ive 
The ONS priority matrix depicts Taste to be most important to be improved from a 
patient perspective. The product characteristics with a medium improvement priority 
are price and tolerance. Again, the majority of the disease areas is assigned to the 
low priority group. Those being: smell; ease of use; volume; clinical evidence; 
composition; caloric density; viscosity and shelf life.  
 
KOL perspect ive versus Pat ient  perspect ive 
When focusing on the medium- and high-quadrants within the priority matrix, the 
results show that only two - price and tolerance - for ONS are ranked equivalently 
from the patient as well as from the KOL perspective. These results indicate a clear 
discrepancy between the prioritization of product characteristic from a KOL and 
patient perspective. 
 
7.3.6 .  KOL invo lvement  in  the EN R&D process 
Results from the questionnaire indicate that unmet needs in EN are widely 
researched by 91% of the respondents. Unmet patient needs were investigated in 
most cases by direct contact with the patients (78%), followed by participating in 
research programs (61%) and questionnaires (40%). The majority of the respondents 
(62%) advise EN companies concerning patient needs, with personal interviews 
being the preferred route of communication between the KOLs and industry (Figure 
5).  

Figure 5. Majority (62%) of the KOLs advise EN companies on the topic of EN 
patient needs. Most KOLs give advice through personal interviews (65%), 
expert panels (49%), consults (47%) and advisory boards (45%). 

 
 

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The KOLs indicated to be involved “little” or “a moderate amount” in the academic 
R&D process of EN products with a total mean score of 2.45 (SD=1.06), and a range 
of 4.0 and a median of 2.0 (Figure 6). KOLs indicated to be even less involved in the 
EN R&D process in industry setting, total mean score: 1.9 (SD=0.96), with a range 
of 3.0 and a median of 2.0. The p-value for difference between involvement in the 
academic and industry R&D process based on Wilcoxon signed-rank test was 
significant (p<0.0001). This indicates that KOLs indicated to be involved to a greater 
extent in the academic R&D process compared to the industry R&D process of EN 
products. 

Figure 6. Comparison between the involvement of KOLs (n=77) in the industry 
and academic R&D process of EN products. Score (%) of involvement posed on 
the x-axis.(5-point Likert scale: 5: An extreme amount, 4: Very much, 3: A 
moderate amount, 2: A little, 1: Not at all). (p<0.0001). Academic: total mean 
score: 2.45 (SD=1.06), with a range of 4.0 and a median of 2.0. Industry: total 
mean score: 1.9 (SD=0.96), with a range of 3.0 and a median of 2.0 
 
 
 
 
 
Research relating to EN is done by most of the participating KOLs (n=52, 68%). 
Moreover, this research is in most cases (n=30, 58%) in collaboration with or 
research sponsored by EN companies. Influencing the research priorities set by EN 
companies by KOLs can only be done to a small extent, according to the respondents 
(fig 7). 
 




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F igure  7 .  Extent of influence by KOLs setting of research priorities by EN 
companies. (Likert scale: 5: An extreme amount, 4: Very much, 3: A moderate 
amount, 2: A little, 1: Not at all). Total mean score: 2.25 (SD=0.98), with a 
range of 3.0 and a median of 2.0. 
 
 
 
 
Although 62% of all KOLs give advice to EN companies on the topic of patient 
needs, they also experience their involvement with the industry R&D process is 
considerably less than in the academic R&D process (p<0.0001) (fig. 6). In addition, 
they feel they are only to a small extent able to influence the setting of research 
priorities by EN companies.  
Stat is t ica l  ana lys is  between groups 
No significant differences (p<0.05) were observed between the demographic groups 
in the disease area and product characteristic prioritization. Likewise, no significant 
differences (p<0.05) were observed between the demographic groups in the 
assessment of KOL involvement.  
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7 .4.  DISCUSSION 
This study provides a systematic approach to achieve research prioritization in EN. 
With disease related malnutrition as a major public health burden, EN has proven to 
be a cost-effective therapy. Faced with a decline in resources available for the 
development and reimbursement of EN products (31, 55, 217), this research proves 
EN to be of substantial societal value and therefore development should continue to 
be stimulated. Since the unmet patient need rather than commercial interest must 
guide the EN product development process, this strategic prioritization overview of 
disease areas and product characteristics could balance academic and industry 
viewpoints. In addition to providing new research directions for EN development, 
this research shows the perceived differences in KOL involvement between 
academia and industry. Although we have observed several efforts to stimulate 
communication (e.g. ESPEN and MNI) and the interaction between academia and the 
EN industry (151), communication has proven to remain a critical barrier inhibiting 
EN innovation (54).  
Unmet  needs –  Disease areas 
The results from this research show that factors other than the prevalence of 
malnutrition may and should affect the prioritization of the disease areas in EN. The 
disease areas in ONS and TF with the highest priorities according to the KOLs 
(ONS: general malnutrition & geriatrics, TF: intensive care) are in line with 
strategic goals set by interest groups such as ESPEN, the Medical Nutrition 
International Industry (MNI) and the European Nutrition for Health Alliance 
(ENHA) (153). The positioning of surgery and transplantation (ONS & TF), non-
surgical oncology (ONS) and general malnutrition (TF) in the medium priority group 
showed that these disease areas should also be given more EN research attention. 
The low priority group contains both disease areas with a low prevalence (e.g. renal 
failure, hepatology and pulmonary) as well as a high prevalence (e.g. infectious 
diseases, gastroenterology) of malnutrition. This shows that the importance of a 
disease area may be defined by multiple factors rather than by its prevalence alone. 
The allocation of metabolic diseases to the low priority group is noteworthy since 
most metabolic patients are completely dependant on the use of EN. It was therefore 
expected that the allocation of this disease area would be in a higher prioritization 
group. This is probably a result of a relatively low prevalence of patients with 
metabolic disorders in comparison to other disease areas. 
Unmet  needs-  product  character is t ics  
From a KOL perspective, clinical evidence is perceived as one of the priorities in 
both ONS as well as TF. Since EN is primarily prescribed by medical professionals, 
the need for clear and concise clinical evidence is evident. Nonetheless, obtaining 
clinical evidence for EN products remains a challenge due to several reasons (54). 
Literature shows that in most instances EN is an adjunct therapy and the effects may 
be confounded with the primary therapy; there is often a lack of specific biomarkers; 
it is difficult to design adequate control groups, “placebo nutrition” is neither 
technically feasible nor ethically acceptable; and patient stratification occurs 
according to the degree of the patient’s primary disease rather that their nutritional 
imbalance (218).  
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Since patients are often prescribed EN when they are unable to tolerate conventional 
foods, logically, tolerance of EN products is considered a priority, especially from 
the patient perspective. Numerous studies have demonstrated shortcomings of TF; 
the intolerance to this type of feeding may result in symptoms such as diarrhoea or 
delayed gastric emptying (219, 220). Nonetheless, this product characteristic is also 
ranked relatively high in ONS. Therefore, we propose that additional research 
attention should be paid to the improvement of the tolerance of TF and ONS. 
 
In addition to the importance of tolerance, it is well known that the sensory 
perception of ONS products is often experienced by the patients as distasteful. 
Patients may dislike the flavour, texture or smell (221). Moreover, due to disease or 
treatments, malnourished patients often suffer from reduced or altered taste, resulting 
in a decline in food intake (221, 222). It is therefore not surprising that KOLs have 
indicated that from a patient perspective, the taste of ONS has the highest priority. 
Especially since taste significantly affects ONS patient compliance which ultimately 
influences the effectiveness of the nutritional treatment.  
 
The ranking of taste in TF is particularly unusual. We expected this product 
characteristic to receive no ranking prioritization since TF does not pass through the 
patient’s oral cavity. Surprisingly, a KOL clarified that in specific countries, TF 
compositions may be administered as an ONS. The reason being that certain ONS 
and TF products have similar compositions, but that TF has significantly lower costs. 
 
The overall product characteristic prioritization shows that non-economic factors 
such as composition, taste and tolerance are valued highest. Nevertheless, costs are 
also considered important both from a KOL as well as a patient perspective. EN 
products are generally reimbursed within Europe, dependant on country-specific 
regulations (31, 32). However, the healthcare regulation landscape is affected by the 
economic downfall and EN reimbursement possibilities are continuously 
diminishing, whereby there is an increase pressure on the out-of-pocket expenses for 
the patient. Especially in the case of ONS, product reimbursement is likely to 
decline, forcing patients to pay out-of-pocket.  
KOL versus pat ient  perspect ive 
In the EN industry, the primary goal of technological innovation is to address unmet 
medical needs. One would assume that during this process of addressing unmet 
patient needs in EN, patients or patient groups/representatives are approached in 
order to express their needs. However, our results indicate that within the relatively 
small and growing EN industry, there is a clear discrepancy in the ranking of the 
unmet product needs between the KOL and patient perspective. To ensure ranking 
validity in our research, a single response group prioritized the product 
characteristics both from a patient and KOL perspective. When focusing on the 
medium- and high-quadrants within the priority matrix, the results show that only 
two out of eight - price and tolerance - for ONS are ranked equivalently from the 
patient as well as from the KOL perspective. This observation leads to a second 
question; which of the two opinions is most valuable in influencing the EN industry 
R&D decisions? Since the opinion of the KOLs is overall more knowledgeable on 
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both the perspectives and based on a set of arguments, we would rationally assume 
their input to be more influential when it comes to setting research priorities. On the 
other hand, the opinion of patients remains important, yet they lack the extensive 
knowledge to create a balanced set of research priorities. This emphasizes why the 
perspective of KOLs is more influential in the prioritization process of EN R&D.  
 
A second observation is the discrepancy between patient and KOL perspective 
regarding TF and ONS. It appears that the prioritization of ONS product 
characteristics from both perspectives is more alike than that for TF. Although ONS 
and TF are both perceived as EN, they seem to be two distinct markets. In China this 
difference is emphasized at regulatory level, where ONS is perceived as nutrition 
whilst TF as a pharmaceutical product. This difference is at present less defined in 
Europe. The reason for the differences between TF and ONS can be explained by the 
fact that the use TF is often the physician’s responsibility while the use and choice of 
ONS is often the patient’s responsibility. We therefore argue that in the case of ONS, 
the patient perspective may be more important than for TF. 
KOL invo lvement  
Innovation in the EN industry can be stimulated from both a pull/demand side, i.e. 
customer needs, and the push/supply perspective, i.e. progress in science/technology. 
Given the fact that our results indicate that KOLs are only marginally involved in 
influencing EN research priorities, the EN market seems to function as a 
science/technology-push market. We propose that although a science/technology-
push innovation system may seem profitable for EN companies, the identification of 
patient needs has proven to be an essential success factor in the complex process of 
product innovation (207, 208). Products are more likely to be successful when built 
around customer needs as opposed to only technological opportunities. At present, 
there appears to be a push and pull innovation system imbalance in the EN market. 
By readressing this imbalance, the EN market can move towards a more pull-
oriented market thereby revolving more around the unmet patient needs and realizing 
a societal benefit.  
Considerat ions 
The methodology of this research is partly based on a previously executed ranking 
exercise among communicable diseases in Germany (209). We adopted the same cut-
off points as in Balabanova et al. in our ranking methodology of disease areas and 
product characteristics. This resulted in the allocation of a high number of disease 
areas and product characteristics to the low priority groups. We therefore propose 
that in future studies, priority group cut-off points should be considered and if 
needed, re-calculated. 
 
Although, the ranking of health-related criteria is likely to correlate with societal 
values and reflect socio-economic, cultural and health system structures in a country 
(209), no differences (statistically tested) in ranking were observed between the 
different demographic profiles. Our results show that, irrespective of their age and 
geographic location, the KOLs represented in this research are fairly concordant in 
assessing EN priorities. Moreover, where in general a 35% response rate in online 
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surveying is considered relatively high, we only approached actively involved 
ESPEN faculty members and thus a higher response rate was expected. This, 
satisfactory, response rate may be attributable to the number of questions (n=34) in 
the survey, which may have been considered as too many by a number of KOLs. 
Nevertheless, we do not expect that this might have led to sampling bias since we 
observed a wide distribution of demographic characteristics among our KOL sample 
such as age, geographic location and area of expertise. Based on our saturation curve 
and statistical analyses of the demographic profiles, we therefore consider our KOL 
sample to be a representative group of EN KOLs. 
Future research 
This prioritization tool or its components can be applied across different disciplines 
in the health and life sciences to give balanced guidance on unmet needs that require 
additional research attention. Additionally, future prioritization analyses may focus 
on the prioritization of distinct disease areas within the EN market since the 
importance of EN product characteristics may differ between disease areas.  Another 
recommendation for future research is to involve patients and allow them to only 
rank the sensory perception of the EN products (smell/taste/intolerance) (in the case 
of altered sensory perception i.e. chemotherapy) or let KOLs experience (taste/smell) 
the EN products and prioritize the sensory product characteristics.   
 
In conclusion, to ensure the fulfillment of the unmet patient needs both at the level of 
disease areas and product characteristics, it is the joined responsibility for industry 
and academia/KOLs to create a network of collaboration and communication. This 
will be beneficial both from a societal as well as from a commercial perspective. This 
research provides the first systematic prioritization of unmet patient needs in the EN 
market and may function as a stepping-stone for future repeated EN unmet needs 
measurements.  
 
  
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CHAPTER 8  
FUTURE INDUSTRY DEVELOPMENT 
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8 .1.  CURRENT MEDICAL NUTRITION INDUSTRY DEVELOPMENT 
As an industry emerges its innovation activities correspondingly develop. It is 
therefore crucial for companies within emerging industries to manage innovation 
using appropriate strategies and business models. There is an extensive body of 
business oriented literature demonstrating that effective management of innovation 
works best when matched with the distinct stages of industry development (223). 
Examining these patterns is a crucial prerequisite for adopting the appropriate 
innovation strategies and business models for improving product development and 
enhancing value creating activities (223).  

F igure  1 .  Med i ca l  nu t r i t i on  i ndus t r y  deve lopmen t  1995 -2012 .  Upda ted  
f r om W eenen  e t  a l .  2013b .   
 
 
 

First, we identify the current stage of development in which the industry is in. In 
short, industry development is represented by an S-curve, delineating four key 
stages; emerging, growth, maturity and saturation (79, 224). The main method for 
evaluating the industry development phase is by analysing the tate-of-the-art via 
patent applications. These are a primary measure reflecting an industries’ 
technological development, which in turn illustrates on the industry’s development 
phase. We visualized a cumulative patent application timeline for the development of 
medical nutrition from 1995 to 2009 (10). Here we update, including 2012 (Fig. 2.).  
Since 2002, a steep increase in cumulative patenting activity is observed, which is 
considered to indicate that the technological development of the industry is currently 
in the growth stage. 
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Nevertheless, it is of importance to forecast the industry development curve, in order 
to infer future performance (Fig. 3). From a macro-perspective, four different future 
scenarios may exist for medical nutrition industry development, namely; classic S-
curve, steep S-curve, innovation cliff and jumping the S-curve. Here we will argue 
the possibility of each of the four scenarios, based on literature review and interviews 
with key opinion leaders in the field of medical nutrition (225). 

Figure 2. Medical nutrition industry development scenarios. Black line: Classic 
S-curved technology life cycle (10). Red line: Steep S-curved technology life 
cycle. Blue line: Innovation cliff. Green line: Jumping the S-curve. Adapted 
from: (79, 226-229)  
 
 
 
 
8.2.  FUTURE INDUSTRY DEVELOPMENT 
1. Classic S-curved technology life cycle  
The classic technology development S-curve was introduced in economics by 
Mansfield (1961) in a publication concerning the diffusion of new technologies. The 
S-curve has since been widely used in management and economic theory (227). The 
classical S-curve starts off with the emerging stage, which is characterized by a 
relatively low technological growth, followed by; the growth stage, in which the 
technological progress rises steeply, the maturity phase, where the growth slows and 
when it has reached saturation, reveals a plateau. During the saturation stage, the 
technology approaches its underlying natural limitation.  
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Based on the development stage an industry finds itself in, strategic R&D decisions 
can be made (79). The classic S curve of technology development is worth keeping 
in mind when considering the current status of the medical nutrition industry and 
where this industry may be headed. At present, the medical nutrition industry finds 
itself in the growth phase of the technology life cycle. Based on our data; if the 
industry performance continues to follow the classic curve, saturation could be 
reached by mid 2024.  
2. Accelerated S-curved technology life cycle  
For a very successful and fast-growing industry, the angle of the upward inflection in 
the emerging and growth phases may be less than 120° (229). The curve follows a 
similar pattern to the classical S-curve, and eventually levels off at a sustainable high 
level. One aspect that contributes to the steepness of the curve during the emerging 
and growth phases is the length of the product development timelines: the shorter 
this timeline, the steeper the curve. The product development timelines for medical 
nutrition are significantly shorter when compared to pharmaceutical new product 
development, yet longer when compared to other fast-moving consumer goods (e.g. 
conventional foods). Therefore we predict that the emerging and growth curve for 
medical nutritional products will fall in between the two other industry categories. 
Based on this knowledge, it is assumed to be highly unlikely that the medical 
nutrition industry performance will follow the steep S-curve. 
3. The innovation cliff 
An industry is, more often than not, perceived as durable and stable, capable of 
surviving many decades. Nevertheless; industries are fragile and prone to collapsing 
(43). This is represented by the green curve in Fig 3, which illustrates the so-called 
‘innovation cliff’ scenario. 
 
During this scenario a technology initially follows the performance characteristics of 
the classic S-curve in the emerging and growth phases and all seems well.  However, 
the curve is suddenly truncated 
(229) while the industry plunges 
off the metaphorical innovation 
cliff, and seizes to exist any 
longer. Many different factors can 
lead to the sudden demise of a 
technology. Two key factors 
contributing to this phenomenon 
include innovation barriers and/or 
reduced innovation adoption. 
Surprisingly; the majority of 
interviewed medical nutrition key 
opinion leaders predict that the 
medical nutrition industry is 
heading towards an innovation cliff within the coming 2-3 years. Based on 
theoretical models adopted from literature and results from our previous research 
(225) we propose two different explanations as to why the medical nutrition industry 
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might be headed towards this innovation cliff: 1- technology/innovation development 
and 2- technology adoption. 
 
Abernathy – Utterback technology development life cycle 
The technology development life cycle explores the roles of the manufacturing 
companies, as they respond to the forecasted unmet needs within the market. It 
describes a scissor-curve technology life cycle describing the evolutionary phases of 
technology development. Abernathy and Utterback‘s technology life cycle (Fig. 4.) 
consists of three phases: fluid, transitional and mature (230). The fluid phase is 
characterized by extreme diversities in new product designs. It is in this phase where 
competitors attempt to meet the various needs of the emerging customer, resulting in 
a high throughput of innovative product designs in order to grab the attention of the 
first-mover consumers. 
 
The fluid phase then gives way to a transitional phase, where product innovation 
decreases and process innovation is on the rise. During this phase a dominant design 
typically emerges, which has been accepted either by the market or selected as such 
by the regulatory authorities. Some technologies eventually transition to the mature 
phase, where product and process innovation lose momentum and the primary focus 
of the company is mainly set on reducing the manufacturing cost.  
 
When including the classical S-curve describing the industry life-cycle to the 
Abernathy-Utterback model, the mid-emerging phase of the industry life-cycle is 
manifested slightly before the crossing of product and process innovation in the fluid 
phase. This implies that not all of the customers’ needs have been fulfilled and the 
dominant design has not yet been adopted.  
 
This description typifies the current EU medical nutrition industry situation, which is 
supported by previous research into innovation barriers within the medical nutrition 
industry (225). As a result, the main obstacles include the regulatory ambiguity at 
both the clinical research as well as at the reimbursement level. Clinical research is 
perceived by the surveyed KOLs as the main innovation barrier, and it is intricately 
linked to other financial barriers. This includes the consideration of the chances for 
being granted reimbursement, which would ultimately stimulate the decision to 
perform clinical studies. This lack of clarity and standardization may prevent the 
adoption of a dominant design. Therefore a slippery slope is assumed, linking the 
clinical research barrier with the absence of establishing a dominant design, which in 
turn reduces the capacity for process innovation. All in all, this scenario would result 
in medical nutrition industry heading towards the innovation cliff.  
 






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F igure  4 .  Abernathy-Utterback technology development l i fe cycle -  adapted 
from (230, 231) 
 
 
 

The chasm of technology adoption  
The technology adoption life cycle is a model developed to understand the 
acceptance of innovation by the consumer market over time. Geoffrey Moore 
discovered that companies often fail to make the transition from the growth phase to 
maturity in the technology adoption life cycle (Fig. 5.) (232). This gap is known as 
the chasm, during which product sales drop (232). Crossing this chasm is often 
nearly impossible but progressing beyond it is considered crucial for the ability of an 
innovative industry to reach the stage of maturity and saturation.  
 
In the medical nutrition industry, innovation adoption is influenced by both 
healthcare professionals as well as by the patient. Generally, healthcare professionals 
prescribe medical nutrition and assess which type/nutrient content of medical 
nutrition is best. However, medical nutrition product characteristics such as taste, 
smell and tolerance are assessed by the patient. In the view that the medical nutrition 
industry is a relatively young industry (10) , innovation adoption is still at an early 
stage. The early adopters, in this case mainly the nutrition-oriented healthcare 
professionals have realized the potential of medical nutrition. Nevertheless, the 
awareness of available products is low (225) which may cause the medical nutrition 
industry to fall victim to the chasm.  
 
The challenge of crossing the chasm in this case is to raise awareness among all 
healthcare professionals concerning nutritional interventions through medical 
nutrition. Subsequently, if awareness among the medical professionals is heightened, 
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they will be able to educate their patients which in turn will stimulate innovation 
adoption.  
 

F igure  5 .  The  med i ca l  nu t r i t i on  chas m o f  t echno logy  adop t i on  adap ted  
f r om Moo re  (1991 )   
 
 

 
Based on sections 3a and 3b, the synergistic effects of technological development 
and market adoption pose a serious risk for the medical nutrition industry to face the 
innovation cliff. It is therefore, in any scenario, of utmost importance to address 
innovation barriers and increase general awareness on effectiveness of medical 
nutrition in order to prevent this negative scenario from happening in reality. 
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4. Jumping the S-curve 
As dark and gloomy as the previous scenario might seem, this scenario provides a 
more optimistic future for the medical nutrition industry. Generally, once the growth 
phase has been surpassed, the natural evolution of the industry is to reach the stage of 
saturation, where technological growth reaches homeostasis. Successful industries 
are those with companies that manage to jump the classical S-curve halfway through 
its growth phase to the next technology S-curve. Such a feat can only be 
accomplished when companies understand the dynamics of the S-curve, which 
implies the anticipation of market decline. One way of jumping the S-curve and 
taking advantage of this knowledge, is to radically innovate their way to a new S-
curve (233).  
 
Generally there are two types of innovations; incremental and radical. Incremental 
innovations consist of minor improvements or adjustments to existing inventions or 
technologies. Radical inventions exhibit key characteristics that are inherently 
different from existing inventions or technologies. The latter type is considered to 
form a crucial basis from which subsequent incremental development may evolve 
(163, 234). Most organizations are familiar with leveraging core products through 
incremental innovation. This approach is perceived as less risky. It assures positive 
revenue growth as opposed to the discontinuous and radical approach of 
breakthrough innovation. In prior research, we demonstrated that even though radical 
innovation is crucial for industry and company performance, only a few medical 
nutrition companies innovate radically (10).  
 
For an industry to jump the S-curve, companies are to strategically innovate towards 
the next S-Curve and jump at the optimal moment. Generally, the optimal time to 
start building the next S-curve is during the growth phase of the technology life 
cycle. Whilst in the technological growth phase, companies are still able to maximize 
their returns while starting to invest in a new radical technology (226, 233). One way 
for the medical nutrition companies to jump the S-curve is by identifying new 
opportunities, such as unmet needs. This can be in the form of addressing unmet 
patient needs, related to product characteristics, but also by responding to unmet 
medical needs  
 
As a rule of thumb; if one company successfully jumps the S-curve through radical 
innovation, the (incremental) others may follow. The radical innovator, will always 
benefit from first-mover advantages, and has a chance of establishing a dominant 
technology design. Furthermore, radical technology innovation is a strategy to 
overcome the innovation barriers as described in Weenen et al.  (225). 
 
  
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CHAPTER 9  
MAIN CONCLUSIONS, IMPLICATIONS & FUTURE 
RESEARCH 
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9 .1.  MAIN CONCLUSIONS 
To meet the aims of this research, the approach to studying the origin and 
development of medical nutrition is multidisciplinary, encompassing scientific, 
industrial, technical, economic and regulatory disciplines. This research evaluates 
both past and present trends from the various disciplines, from which future 
scenarios are forecasted. 
 
This dissertation describes the innovation dynamics within the European medical 
nutrition industry. We show that although the relatively new and emerging medical 
nutrition industry offers innovation potential, a lack of medical nutrition innovation 
may result in a gloomy future for the medical nutrition industry. We also aimed to 
increase theoretical understanding and empirical knowledge by analyzing the 
medical nutrition innovation system and the functioning thereof. To conclude, based 
on the research we propose different possible future scenarios for the medical 
nutrition market. 
Del ineat ing the medica l  nut r i t ion boundar ies  and the European 
medica l  nut r i t ion innovat ion system  
Medical nutrition innovation is understood as the whole process from the invention, 
protection and production of a novel nutritional composition, and finally to the 
innovation adoption: from prescription by healthcare professionals to patient 
acceptance. These medical nutrition innovations are developed along the value chain 
from basic research to innovation diffusion and adoption within the market (Figure 
1). Although the value chain represents all steps from invention to innovation, it does 
not take into account the complex network and feedback loops of stakeholder 
interaction. Understanding innovation dynamics and stakeholder interaction within 
an industry is best understood when applying the innovation system approach. This 
approach takes into account that innovation takes place within the context of a wider 
system where interaction between actors at different societal levels are needed in 
order to turn an idea into a successful innovation (40). It incorporates all actors and 
activities in value creation and diffusion that are necessary for innovation to take 
place, leading to economic development. 

F igure  1 .  The  med i ca l  nu t r i t i on  va lue  cha in   
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Before being able to understand an entire innovation system, setting clear boundaries 
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is essential. As it turns out, medical nutrition boundaries are not clearly defined. 
Chapter 1.1 describes the positioning of the medical nutrition industry at the food-
pharma industry. Since the concept of medical nutrition lacks universal coherence 
Chapter 2 set out to define the medical nutrition product category according to 
different features. The way an innovation system is structured and how it functions is 
dependent on the market and industry’s development phase (Chapters 2 and 5). 
Chapter 5. reveals by means of a cumulative patent application timeline that the 
medical nutrition is currently in the early growth phase of industry life-cycle. Patent 
analysis in Chapter 3 confirms that the medical nutrition market is still in the growth 
phase, being the epitome of food and pharma industry domain convergence. Chapter 
3 further reveals that although the medical nutrition industry’s core technology 
domain is food, technological development is mainly driven by pharmaceutical / 
pharmacological technologies.  
 
 In terms of the present medical nutrition innovation system, figure 2 provides an 
overview of the networks within which the medical nutrition stakeholders are 
embedded, and their subsequent inter-relationships. As shown, the main components 
of the framework are: Demand/Unmet need, Industry, Academia, Support/Funding 
and Policy/Regulations. Each chapter of this dissertation explores the dynamics of 
stakeholder innovation activities in the medical nutrition innovation system. 
 
Chapter 2 can be seen as an introduction to the topic of defining medical nutrition, 
and touching upon the very complex nature of the regulatory system. It briefly 
explains the Foods for Special Medical Purposes Directive, which sets out the 
European medical nutrition requirements intended as guidance for medical nutrition 
companies. Having explored the regulations and policy arena within which medical 
nutrition is found, it is the one all encompassing stakeholder that influences all others 
in the medical nutrition innovation system. 
 
Chapter 3 describes how technological development from different industry domains 
has caused industry convergence, resulting in the development of the medical 
nutrition industry. Quantitative patent industry domain analyses show that although 
medical nutrition is more “food” than “pharma”, technological development is 
mainly driven by pharmacological concepts. We therefore propose that it is 
important for medical nutrition companies to effectively monitor technological 
developments within as well as across the boundaries of the medical nutrition 
innovation system.  
 
Chapter 4 identifies the conditions that negatively impact the entire medical nutrition 
innovation system, as experienced by 77 key opinion leaders representing the 
medical nutrition industry. This research shows that although barriers impact all 
steps of the medical nutrition value chain, the most significant medical nutrition 
barriers are associated with financial aspects and clinical research, whereas the least 
significant are considered the product barriers. The chapter provides strategic 
recommendations to overcome barriers at the regulatory, demand, industry and 
academia levels. Moreover, Chapter 4 emphasizes how nutrition companies must 
realize that investment in innovation is and remains crucial for both economic and 
societal benefits. At the combined academia, industry, and policy level, adopting 
(orphan drug) clinical research with clear end-points and cost-effectiveness 
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methodologies may aid the reimbursement procedure and facilitate innovation 
adoption by healthcare professionals. Increasing awareness of medical nutrition 
effectiveness among medical staff and government may be achieved by initiating 
education programs and/or organizing conferences. Lastly, higher involvement of 
academic research institutions in the commercial medical nutrition innovation 
process can lead to higher patient acceptance and possible R&D investment 
reduction. Such involvement improvement would enhance the performance of the 
medical nutrition innovation system at industry; academia and unmet patient need 
levels.  
 
An important aspect of the innovation system both for industry and academia is the 
ability to protect valuable ideas. In the view that medical nutrition is a technological 
endeavor, it is necessary to research the most effective asset protection strategies. 
Chapter 5 endeavors to uncover the patenting strategies of the key players of the 
medical nutrition industry thereby proving that patenting behavior differs between 
the different companies. Between the five dominant European medical nutrition 
companies, the patent strategies range from few patent applications to excessive 
patent activity. Chapter 6 complements Chapter 5 by offering insights into 
applicable intellectual property strategies that can increase the protection of medical 
nutrition inventions. Chapter 6 adds to the existing body of knowledge on the 
importance of patenting and other intellectual property rights, by investigating 
strategies and motives for optimal protection of medical nutrition inventions. The 
intellectual property decision framework provides industry as well as academia with 
a decision framework to assess the best applicable intellectual property strategy. This 
strategy is usually dependent on the characteristics of the invention as well as the 
development process of the invention. Interaction between researchers working in 
private firms and those working in publicly financed institutions such as universities 
is seen as particularly important because it may provide unique competitive 
advantages for industry players and economical benefits for the public research 
domain (235). Properly aligned intellectual property strategies at academia level may 
stimulate technology-transfer opportunities from universities/research institutions to 
private firms, contributing to a more efficient and better-functioning medical 
nutrition innovation system.  
 
Fulfilling the unmet patient needs and increasing patient acceptance is the 
fundamental desired outcome of the medical nutrition innovation system. Chapter 7 
offers an overview of unmet patient needs relating to disease areas and product 
characteristics, uncovered by means of quantitative questionnaires targeting medical 
nutrition key opinion leaders. Mapping the unmet needs translates directly into 
research and innovation opportunities for both academia and industry. Innovation in 
any industry can be stimulated from both a pull/demand side, i.e. patient needs, and 
the push/supply perspective, i.e. progress in science/technology. This chapter 
demonstrates that medical nutrition key opinion leaders are marginally involved in 
influencing medical nutrition research priorities. It is therefore assumed that at 
present, innovation in the medical nutrition market functions mainly as a result of 
science/technology-push market. We propose that although a science/technology-
push innovation system may seem profitable for medical nutrition companies, the 
identification of patient needs has proven to be an essential success factor in the 
complex process of product innovation. Products are more likely to be successful 
 134 
when built around customer needs as opposed to only technological opportunities 
(206). At present, there appears to be an innovation system imbalance in the medical 
nutrition market, whereby push factors are dominant and the pull factors almost non-
existent. By readdressing this imbalance, the medical nutrition market can move 
towards a more pull-oriented market thereby revolving more around the unmet 
patient needs, realizing a societal benefit and increasing innovation adoption. 
 
The dynamics of the medical nutrition innovation system induces the realization that 
social well-being and economic growth are dependent on the participation and 
performance of all stakeholders in the innovation system. Since innovation systems 
co-evolve with the process of technological change, it is important to continue 
monitoring medical nutrition industry development. Chapter 8 explores four 
potential future scenarios for the medical nutrition industry: the classic S-curved 
technology life cycle; the accelerated S-curved technology life cycle; the innovation 
cliff and jumping the S-curve. We conclude this dissertation by exploring the 
implications of these scenarios for the medical nutrition innovation system.  
9.2.  IMPLICATIONS – BRIDGING THE MEDICAL NUTRITION  
INNOVATION CLIFF  
The health and life sciences are moving towards pharmanutrition oriented product 
development such as medical nutrition. Faced by innovation declines, pharma and 
nutrition industries are converging in order to fill the gap. On the one end the 
conventional food industries are converging with more health-oriented industries, 
while on the other hand the pharmaceutical industry is moving into the 
(pharma)nutrition space. It is estimated that in approximately 20 years, 50% of the 
pharmanutrition industry will be pharma owned (236). Enabled by a growing body of 
evidence, technology development and plenty of unmet needs to fulfill, the medical 
nutrition industry offers ample future potential. The industry development forecast 
analysis shows four possible future scenarios. These scenarios include both 
successful as well as more unfavorable possible outcomes. Currently the newly 
emerging medical nutrition industry is within the growth-phase of the industry life-
cycle yet all signs currently point in the pessimistic direction that the medical 
nutrition industry is heading towards an innovation cliff. In view of this diagnostic 
observation, the industry has the chance to pre-emptively jump the cliff by starting a 
new S-curve. The optimal time to start building the next S-curve is during the growth 
phase of the technological life cycle. Although the medical nutrition industry is 
currently encountering rapid growth in the growth phase of the technological life 
cycle, it is time to start thinking ahead. To prevent the dreaded industry saturation 
plateau, or even worse, the innovation cliff that may lie ahead, companies must 
realize that incremental innovation alone is insufficient. The solution for future 
success lies in the radical innovations. These radical innovations allow for jumping 
the S-curve, gain competitive advantage and start building the medical nutrition 
industry’s future. 
 
An illustrative case-in-point of a more mature industry which has been facing 
innovation decline since the early 1990s, is the pharmaceutical industry. In its early 
history, the productivity of the pharmaceutical industry and market approval of 
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innovative therapies was relatively easy, which is explained by some critics due to 
the selection of low-hanging-fruits (237). Currently, the pharmaceutical pipeline is 
drying up as patents on blockbuster products are expiring and the realization is 
setting in that incremental innovation is insufficient for sustaining business models 
(36, 238, 239). The perception of this innovation deficit has motivated large firms to 
exploit various other strategic options for capturing radical innovations. Since the 
early 1990s the pharmaceutical industry has been going through significant strategic 
consolidation of large pharma firms as well as the acquisition of small biotech 
(Appendix A). Solving this innovation deficit required that firms successfully 
combined or coordinated merger and acquisition (M&A) activities, strategic 
alliances, and licensing deals alongside conventional in-house R&D (240-242).  
 
Learning from the pharmaceutical industry, staying ahead of the medical nutrition 
innovation cliff requires radical innovation. Although the adoption of a clear generic 
competitive corporate strategy such as described by Porter (154) is essential, we 
focus on the implementation of internal development versus acquisition strategies. 
We propose two development strategies for the medical nutrition industry to achieve 
this and jump to the next S-curve: first by incorporating radical innovation strategies 
into their own corporate DNA (organic growth) and second through capturing radical 
innovation by acquiring smaller innovative medical nutrition start-ups (inorganic 
growth). The first can only be accomplished if companies adopt systematic processes 
for initiating, supporting, and rewarding radical innovation in-house activities (243, 
244). The challenge in this organic growth strategy lies in the fact that it is easier for 
existing companies to innovate incrementally since this only requires the leveraging 
of existing knowledge and resources. On the contrary, new entrants will have a 
considerable advantage in radical innovation since they do not have to change their 
knowledge background. Furthermore, large companies, such as the medical nutrition 
market leaders, may have a difficult time implementing radical innovation because 
they operate under a “managerial mindset/constraint”.  
 
The second strategy of inorganic growth through radical innovation acquisition only 
offers potential if medical nutrition start-ups continue to emerge and invest in the 
development of radical innovation. Entrepreneurial start-ups are a valuable source of 
knowledge necessary to develop radical innovation (245). Research has shown that 
active acquisition industries encourage radical innovation, particularly at the SME 
level (246).  
 
The medical nutrition industry, at present in the growth stage of the industry life-
cycle, may be considered as especially attractive to start-ups. When demand is 
growing in an industry, firms can achieve initial success without the intense 
competitive threat that firms face in mature and overregulated markets. In other 
words, there is more than sufficient market opportunity available for multiple 
entrants to achieve commercial successes (133).  
 
Since development and production costs are relatively high in the medical nutrition 
industry, it is highly unlikely that medical nutrition start-ups will develop into fully 
integrated nutrition companies [FINCOs]. Most likely, medical nutrition market 
leaders will view these small innovative firms as prey as opposed to competitors, and 
will incorporate them into their companies. Even if the SMEs are the source of new 
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ideas, commercialization and wide product diffusion will usually happen only after 
acquisition by the incumbent. Generally, being acquired is an attractive exit strategy 
for small firms. 
 
In a similar profile as the pharmaceutical industry but 15 years later, M&A activity 
within the medical nutrition industry has increased since 2004 (Figure 3.). A total of 
11 mergers and acquisitions and 3 joint ventures/ partnerships have occurred within 
this industry. In particular since 2010, acquisition has become more frequent. More 
start-ups may be realizing the potential of the medical nutrition industry in the last 
few years and are entering the playing field. In addition, large medical nutrition 
companies may already encounter difficulties in developing radical innovations and 
are shifting from organic to inorganic growth through acquisition. 
 
However, companies cannot solely rely on insourcing innovation since this is often 
only a quick-fix. Additionally, if entry barriers prove to be unscalable for medical 
nutrition start-ups, the flow of innovation will come at a halt and the acquisition 
opportunities for large medical nutrition companies will decline accordingly. The 
optimal innovation strategy is therefore a balanced integration of both organic and 
inorganic growth. Such a strategy will enable medical nutrition companies to jump 
the S-curve themselves when acquisition opportunity is low and stock up on radically 
innovative start-ups when it is an active acquisition industry.  
 
Here, we primarily focused on the process of radical innovation since this is 
considered the most challenging type of innovation. And although radical innovation 
has proven crucial, the importance of organizational ambidexterity must not be 
neglected. Organizational ambidexterity can be described as a company’s ability to 
align the development of both radical as well as incremental innovations (247). This 
holds particularly true for the medical nutrition market where incremental 
innovations have been proven valuable (Chapter 6). Incremental innovation can be 
achieved by enhancing and prolonging medical nutrition product life cycles (248). 
Examples for incremental medical nutrition innovation may include: more 
convenient packaging, taste improvement or increasing the tolerance of existing 
products. Therefore, to succeed in the medical nutrition industry, a company requires 
competences in both exploratory (radical) as well as exploitative (incremental) 
activities. 
 
 


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F igure  3 .  Med i ca l  nu t r i t i on  i ndus t r y  M&A   
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
F igure  4 .  Pha rmaceu t i ca l  M&A f r om 1990 -2013 .  
 
 
Johnson&Johnson 
Pfizer 
ALZA Corp. [$10.2 bn] 
Crucell [$2.4 bn] 
DePuy [$3.5 bn] 
Centocor [$4.9 bn] 
Scios [$2.4 bn] 
King Pharmaceuticals [$3.5 bn] 
Synthes (medical devices) [$3.5 bn] 
American Home Products              Wyeth  [$68 bn] 
Warner-Lambert [$90 bn] 
Pharmacia                                                  Pharmacia-Upjohn [$60 bn] 
Upjohn [$13 bn] 
Monsanto [$26,5 bn] Monsanto spun off as agricultural business 
Roche 
Syntex [$5.3 bn] 
Genentech (Roche already acquired 60% 1990) [$46.8 bn] 
Glaxo              GlaxoSmithKline 
Burroughs Wellcome [! bn] 
Smithkline Beecham [$76 bn] 
Human Genome Sciences [$2.9 bn] 
Sandoz                 Novartis 
Ciba-Geigy [$41 bn] 
Chiron [$5.1 bn] 
Alcon (Novartis already acquired 77% 2008) [$51.6 bn] 
Sanofi        Sanofi-Synthélaboo 
Synthélaboo [$26.3 bn] 
Rhone-Poulenc                         Aventis [$64.2 bn] 
Hoechst [$43 bn] 
Genzyme [$20.1 bn] 
Merial [$4.0 bn] 
Zeneca        AstraZeneca 
Astra AB [$36 bn] 
Medimmune [$15.6 bn] 
Abbott 
Merck & Co 
EMD Serono [$13.5 bn] 
Schering-Plough [$41.1 bn] 
Millipore Corp. [$6.1 bn] 
Bayer 
Eli Lilly 
Bristol-Myers    Bristol-Myers Squibb 
Squibb [$11.5 bn] 
Medarex Inc. [$2.2 bn] 
Inhibitex [$2.5 bn] 
Amylin Pharmaceuticals  (AstraZeneca participated for $3.4 bn and shares in BMS profits) [$7.2 bn] 
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American Cyanamid Comany [$9.5 bn] 
DuPont Pharmaceuticals [$7.8 bn] 
ICOS Corp [$2.3 bn] 
ImClone Systems Inc. [$6.5 bn] 
Knoll Pharmaceuticals  [$6.9 bn] 
Fisons plc [1.8 bn] 
Stiefel Laboratories [$2.9 bn] 
Ventana Medical Systems [$3.4 bn] 
Jones Pharma Inc. [$3.7 bn] 
Agouron [$2.1 bn] 
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9 .3.  SUGGESTIONS FOR FUTURE RESEARCH 
Although most aspects of the medical nutrition innovation system are thoroughly 
described in this dissertation, the funding aspect of the medical nutrition innovation 
system is only briefly explored in Chapter 3. Presently, medical nutrition start-ups 
are unlikely to start investing in innovation if governments are unwilling to support 
them financially. Vise versa, governments are not aware where financial support is 
necessary if the awareness concerning the public health benefit of medical nutrition 
is low, which is needed to legitimate policy support. Especially since one of the most 
important barriers according to medical nutrition key opinion leaders is related to the 
financial aspects of the medical nutrition innovation system further research into this 
aspect deems useful.  
 
The research in this dissertation focused on the European medical nutrition industry. 
As highlighted in Chapter 2, regulations, terms and definitions of medical nutrition 
differ tremendously between geographic regions. This implies that the medical 
nutrition innovation systems between these regions will also vary. A proposed 
research topic would be to improve the understanding of the idiosyncratic properties 
of particular geographic regions of the medical nutrition innovation systems (249). 
Such insights can contribute to the alignment of different innovation strategies for 
companies to operate in different geographic areas.  
 
Regulatory framework conditions have been identified as important factors 
influencing the performance of innovation systems (250). The regulatory landscape 
of the European medical nutrition market is currently changing which will most 
likely affect the dynamics of the entire European medical nutrition innovation 
system. Medical nutrition regulatory changes may be ambivalent; the primary goal to 
protect patients may also result in a higher (economic) burden for companies to 
fulfill specific regulations, thereby reducing innovation. Nevertheless, overall, 
policymakers are trying to limit the negative impacts of regulation on the innovative 
activities of industry, and have started to look more systematically for options to 
create ambidextrous regulations thereby protecting the consumer environment as 
well as promoting innovations (250). In the view of the changing medical nutrition 
regulatory landscape, regulatory impact assessments provide a critical area for 
further analysis. 
 
Finally, further research into the causes of heterogeneity in business performance 
within the medical nutrition industry would be interesting (251). Although value-
adding medical nutrition innovation strategies are proposed in this dissertation from 
a macro-level perspective, insights into managerial dynamic capabilities and mental 
maps of top managers at firm level would further complement this. The medical 
nutrition industry is defined as an oligopoly, where medical nutrition innovation is 
concentrated within five multinational companies. Comparison of these companies’ 
specific dominant logic, the mental maps developed by the top managers through 
innovation experience, presents possibilities for future research.  
 
While the findings in this thesis are specific to the present medical nutrition industry, 
we argue that the growing importance of this industry in the future deserves further 
academic attention. 
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SAMENVATTING 
Dankzij het vervagen van grenzen ontstaat convergentie tussen voorheen gescheiden 
industrieën en komen nieuwe industrieën tot stand. Ditzelfde geschiedt ook in de health & 
life science sector: de kloof tussen farma en voeding wordt steeds kleiner. Door 
combinatie en integratie van farmaceutische- en voedings-technologieën worden radicale 
innovaties gerealiseerd op de voedings-farma interface. Reden voor deze convergentie is 
onder andere het groeiende wetenschappelijke bewijs voor de rol van voeding in de 
preventie en/of behandeling van ziekten. Daarnaast verschuift de zorgvraag als gevolg 
van onder andere de vergrijzing naar meer chronische en ouderdomsziekten, wat vraagt 
om combinaties van therapieën, voeding en medicijnen. De medische voedingsmarkt 
biedt vandaag de dag belangrijke innovatie kansen van aanzienlijk maatschappelijk 
belang. Een van de industrieën die is ontstaan ten gevolge van voedings-farma 
convergentie is de medische voedingsindustrie. Medische voeding is specifiek 
samengestelde voeding die gebruikt wordt in de dieetbehandeling van verschillende 
ziektebeelden en ziekte gerelateerde ondervoeding. Medische voedingsproducten worden 
binnen Europa door medische specialisten zoals artsen en diëtisten voorgeschreven en 
zijn alleen in apotheken verkrijgbaar. Veelal worden de resultaten van klinische studies 
ingezet om deze medische specialisten te overtuigen van de effectiviteit van deze 
producten. Wettelijk zijn klinische studies niet verplicht tenzij het medische 
voedingsproduct een nieuw, nog niet onderzocht ingrediënt bevat. In dat geval moet de 
veiligheid van dat ingrediënt worden bewezen.  
 
De doelstelling van dit proefschrift is om een wetenschappelijke bijdrage te leveren aan 
het ontstaan en de ontwikkeling van de Europese medische voedingsmarkt. Het 
functioneren van deze markt is afhankelijk van de dynamiek van het gehele medische 
voedings-innovatiesysteem. Een dergelijk systeem beschrijft alle stappen van de 
medische voedingswaardeketen en alle betrokken partijen in een complex netwerk.  
 
De hoofdstukken in dit proefschrift tonen aan dat door een toename in wetenschappelijk 
bewijs, technologische ontwikkeling en onvervulde patiëntbehoeften, de medische 
voedingsmarkt uitgebreide kansen biedt voor de toekomst. Om een mogelijke 
toekomstige innovatiekloof de voorkomen is het noodzakelijk voor medische 
voedingsbedrijven om tijdig te realiseren dat zowel incrementele als radicale innovatie 
cruciaal is. Ook al bieden convergentie industrieën zoals de medische voedingsindustrie 
verhoogde radicale innovatie kansen, ze zijn niet zonder risico’s voor (startende) 
bedrijven. Om deze risico’s aanzienlijk te verkleinen kan de kennisbasis van bedrijven 
verbreed worden door middel van samenwerkingsverbanden met verschillende 
academische en commerciële partners en/of kennis acquisitie om zo de benodigde kennis 
te integreren en radicale innovaties succesvol in de markt te kunnen zetten.  
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SUMMARY 
As the boundaries between many once-distinct industries are blurring and 
consequently combine, this process gives rise to new industries. This also holds true 
for the health and life science sector. In the past few years the gap between pharma 
and nutrition science is closing. One reason is the increasing scientific evidence 
regarding the potential of nutrition and the role in the prevention or treatment of 
diseases and/or risk factors for disease. Furthermore, there is a transition in 
healthcare demand towards more chronic and age related diseases due to factors such 
as obsolescence. The medical nutrition industry, found in the pharmanutrition 
domain, offers ample innovation opportunities of high societal importance. Medical 
nutrition products are specially formulated nutritional compositions for the dietary 
management of patients with diseases, disorders or medical conditions that cause 
distinct nutritional requirements and are prescribed under healthcare professional 
supervision. Although clinical research is not mandatory, it is often executed to 
convince healthcare professionals on the product’s effectiveness.  
 
Since we are dealing with a relatively new industry, academic insights into medical 
nutrition innovation are lacking. Motivated by the multi-leveled societal importance 
of medical nutrition, this PhD dissertation aims to advance the understanding of the 
innovation dynamics of the European medical nutrition industry. It starts off by 
delineating the boundaries of medical nutrition; followed by an analysis of the 
medical nutrition innovation system and concludes by proposing possible medical 
nutrition industry future scenarios.  
 
The nine chapters in this dissertation show that the medical nutrition industry offers 
extensive future opportunities due to an increase in scientific evidence, technological 
development and unmet patient needs. To prevent a possible innovation cliff, 
medical nutrition companies must realize that both incremental and radical 
innovation is crucial. Even though convergent industries such as the medical 
nutrition industry offer innovation opportunities, they are not without risk. 
Expanding a company’s knowledge base by means of industry-academia 
collaborations and/or by means of inorganic growth (innovation acquisition) can 
significantly reduce these risks  
 
 
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promotietraject daadwerkelijk tot een mooi eind gekomen. Waar ik aan begon vier 
jaar geleden wist ik zelf ook nog niet, en het bleek een ware rollercoaster met de 
daarbij horende ups en downs. Bij de downs wilde ik de handdoek in de ring gooien, 
maar de voldoening van een gepubliceerd artikel maakte veel goed en deed het afzien 
vergeten.  
 
Met dit dankwoord wil ik me richten op iedereen die mij geholpen heeft bij het tot 
stand komen van dit proefschrift.  
 
Eric, jouw begeleiding heeft een grote rol gespeeld in zowel het tot stand komen van 
mijn promotie als wel mijn persoonlijke ontwikkeling. Zonder jou was ik überhaupt 
nooit begonnen aan een promotie, en de vrijheid die jij me gaf om mijn 
promotietraject zelf te vormen heeft geleid tot een resultaat waar ik megatrots op 
ben.   
 
Harry, dankzij jouw feedback als promotor heb ik mijn onderzoeksresultaten kunnen 
versterken door middel van sterke economische en bedrijfskundige inzichten. Jouw 
onuitputtelijke bron van kennis heeft mijn proefschrift naar een hoger niveau weten 
te tillen.  
 
De  leden  van  de  kleine commissie Prof. Dr. Enrico Pennings, Prof., Dr. Johan 
Garssen en Prof. Dr. Roy Thurik dank ik voor het kritisch lezen en beoordelen van 
mijn proefschrift. Prof. Dr. Wim van Gelder en Prof. Dr. Bert de Groot wil ik 
bedanken voor het voeren van oppositie tijdens de promotie ceremonie.  
 
Mijn collega’s Kenneth, Linda, & Tiberius, ik kan jullie gezelligheid en onze 
gezamenlijke brainstormsessies natuurlijk niet onbenoemd laten, dank daarvoor! 
Bahar, dank voor je inzet tijdens je stage en niet te vergeten: de gezellige dim-sum 
avondjes in Singapore. En natuurlijk dank aan Flore & Anne, jullie stage-resultaten 
hebben enorm bijgedragen aan mijn promotieonderzoek en hebben geleid tot mooie 
publicaties. David, dank voor jouw design hulp; en Elisa, jou wil ik bedanken voor 
het maken van de 3D-grafieken.  
 
Dik van Harte, Ceri Green, Wim van Gelder, Elsa Regan-Klapisz, Nils Kildemark, 
Johan Garssen, Pierre Singer and Yves Boirie – thank you all for your well-
appreciated help and feedback during the last four years. 
 
Esther, samen hebben wij het promotie-wiel opnieuw uitgevonden: van de Makro 
leegshoppen tot het schrijven van gestructureerde wetenschappelijke artikelen. Vorig 
jaar heb ik jou mogen zien promoveren en ik waardeer het dan ook dat jij mij als 
paranimf bij zal staan.  
 
Mijn andere paranimf Tinka, van het begin van onze vriendschap in de ghetto naar 
nu, tien jaar later. Jouw telefoonnummer staat bovenaan mijn lijst in tijden van stress 
en/of opluchting. Je nuchterheid zet me altijd weer met beide benen op de grond.  
 
 145 
Laura, Mireille, Yvonne, Mirte, Julia, Edwi, Heleen, Noor, Anne, Faye, Sabina, 
Jessey, Kim, Martijn, Andre, Thom, Annelieke, Merrel, Meertien en alle anderen: 
jullie gezelschap / koffietjes / etentjes / drankjes en dansjes hebben voor de nodige 
afleiding gezorgd gedurende de laatste 4 jaren. Ik prijs mezelf dan ook meer dan 
gelukkig met jullie om me heen! 
 
Lieve papa, mama en Floor. Pap, jouw altijddurende geduld en waardevolle input 
zijn van onschatbare waarde geweest gedurende deze 4 jaar. Dankzij jouw motivatie 
heb ik doorgezet, vooral in het begin toen ik niet wist hoe en waar te beginnen. 
Mama, ellenlange telefoontjes over onze gezamenlijke promotie-struggles. Wat ze 
zeggen is waar: gedeelde smart is halve smart. Ook jouw promotie zal dit jaar 
bezegeld worden, wat een accomplishment, mijn respect voor je doorzetvermogen! 
En Floor, het hebben van een zusje in dezelfde stad is zo fijn, onze gezellige 
kookavondjes hebben voor goede afleiding gezorgd. Dank jullie wel voor jullie 
eeuwige vertrouwen in mij! 
 
Rut, een speciaal woord van dank voor jou. Jouw onvoorwaardelijke steun en liefde 
hebben mij weten te kalmeren, motiveren en overtuigen van mijn eigen kunnen. 
Deze mijlpaal had ik niet kunnen bereiken zonder jou. 
 
 



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Product development in the health and life sciences is shifting from the development of
target-specific pharmaceutical products to multi-target therapies, including medical nutri -
tion. Medical nutrition consists of nutritional compositions, prescribed by medical profes -
sio nals for the nutritional support in the dietary management of diseases. The European
medical nutrition industry is rapidly maturing, driven by new knowledge on medical
nutrition effectiveness and increasing public awareness on its importance. Nevertheless,
there are still numerous unmet medical needs that can only be addressed through
innovation by the medical nutrition industry.
This dissertation describes the innovation dynamics within the European medical nutri -
tion industry, through exploring the origin and development of this industry and all
stakeholders involved. The research is multidisciplinary, encompassing scientific, industrial,
technological, economic and regulatory disciplines. Although the relatively new and
emerg ing medical nutrition industry offers innovation potential, the results show that a
lack of medical nutrition innovation may result in a gloomy future for the medical nutri -
tion industry. 
The dynamics of the medical nutrition innovation system induces the realization that
social well-being and economic growth is not only dependent on the innovation activity of
both the food and pharma industries but requires input from key opinion leaders in
academia; patients; regulatory and funding bodies.
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